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Abstract 
 
Post-translational modification of proteins via ubiquitination is mediated by three enzyme 
families; E1 activating enzymes, E2 conjugating enzymes and E3 ligases, all of which work 
in a hierarchical manner to facilitate different forms of protein ubiquitin ranging from mono-
ubiquitination to the formation of different forms of ubiquitin chains (Ciechanover et al., 
2000). Deubiquitinating enzymes (DUBs) act to remove ubiquitin from modified substrates. 
Apart from the classic interactions within the E1-E2-E3 enzymatic cascade, an unusual non-
hierarchical interaction has been observed between some E2 enzymes and a DUB called 
OTUB1 (Markson et al., 2009). This observation raises interesting questions concerning the 
molecular mechanisms and specificity of this unusual E2:DUB partnership. In this study, 
systematic yeast two-hybrid (Y2H) screens were performed between all human E2 and DUB 
proteins to analyse the extent of E2:DUB interactions. Putative partnerships between 
OTUB1 and UBE2D1, UBE2D2, UBE2D3, UBE2D4, UBE2E1, UBE2E2, UBE2E3 and 
UBE2N were identified. These data correlate well with data from other independent studies, 
including HTP Y2H screens (Markson et al., 2009) and mass spectrometry (Sowa et al., 
2009). An N-terminal truncated form of OTUB1 (
ΔN
OTUB1) was generated by removing a 
predicted 39aa N-terminal disordered region (Edelmann et al., 2009). Using this construct in 
combination with wild type (WT) OTUB1, complementary biophysical studies were 
performed to investigate the formation of complexes with UBE2D2 and UBE2E1 as these 
represented the strongest interactions detected in preliminary Y2H studies. Gel filtration 
chromatography showed convincing complex formation for both 
ΔN
OTUB1:UBE2D2 and 
ΔN
OTUB1:UBE2E1 in 1:1 stoichiometry. The thermodynamic profile of each complex was 
measured by ITC suggested a stronger affinity between 
ΔN
OTUB1:UBE2D2 (Kd 3.89 µM) 
than observed for the 
ΔN
OTUB1:UBE2E1 complex (Kd 16.55 µM). The n values for both 
complexes are 1.16±0.06 sites and 0.92±0.03 sites respectively, confirming that both 
complexes adopt a 1:1 stoichiometry. Observing the UBE2D2 (
1
H
15
N)-HSQC NMR spectral 
changes that occurred upon addition of unlabelled 
ΔN
OTUB1 allowed the identification of 
potential residues of contact between the two proteins. From this study, we were able to 
predict that the 1
st
 α-helix, the L1 loop of the 3rd and 4th β-sheet, the L2 loop connecting the 
4
th
 β-strand and the H2 α-helix within UBE2D2 were likely to be the binding surfaces for 
  iv 
OTUB1. Point mutants corresponding to predicted contact residues in UBE2D2 were 
generated and tested in Y2H studies to determine their role in facilitating the formation of 
both E2:OTUB1 and E2:E3-RING complexes. This data suggests that in some, but not all 
cases, OTUB1 and E3-RINGs bind competitively to the same interface on E2 proteins. 
Preliminary immunofluorescence studies show that partner proteins predominantly co-
localise in the cytoplasm, except UBE2E1 which is predominantly nuclear. Data from this 
study allowed us to propose a model of how OTUB1:UBE2D2 complex may forms and 
functions. Significantly, many of these predictions have now been verified by independent 
structural studies and subsequent live cell microscopy studies in our lab.  
(482 words) 
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1.1 Overview of the human ubiquitin system 
Many vital body functions such as temperature regulation and maintenance of blood pressure 
serve to maintain the state of homeostasis in our body. The same principle applies at the 
level of a single cell where control of protein homeostasis is essential for regulating cellular 
physiology or responding to adverse signals. One of the most important modes of post-
translational regulation is protein ubiquitination, a highly dynamic process that governs 
nearly every function in human cells (Hershko and Ciechanover, 1998). Over the past two 
decades, ubiquitination has been increasingly acknowledged as more than simply a signal for 
protein degradation, but also a main regulator of a diverse array of different biological 
processes (Weissman, 2001). It is a reversible post-translational modification of protein, 
almost as common as phosphorylation, which involves the addition of the ubiquitous small 
protein aptly named ubiquitin to the lysine residue of a target substrate (Hershko and 
Ciechanover, 1998). 
In general, ubiquitin attachment occurs through a sequential enzymatic cascade involving an 
E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin-
protein ligase, resulting in the modification of a specific protein  substrate (Pickart, 2001). In 
the classical view of ubiquitination, a polyubiquitin chain is synthesised by serial addition of 
ubiquitin moieties to the Lys48 residue of the previously conjugated ubiquitin (Hershko and 
Ciechanover, 1998). This particular polyubiquitinated substrate is recognised as a target for 
degradation by a multi-subunit ATP-dependent protease complex known as the 26S 
proteasome (Tashiro et al., 1997; Pickart, 2001). The reversibility of ubiquitination is 
provided by deubiquitinating enzymes (DUBs) which either prevent ubiquitin attachment to 
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the target substrate or remove ubiquitin from specific target proteins (Komander et al., 2009; 
Reyes-Turcu et al., 2009). 
 
1.2 Ubiquitin and ubiquitin like molecules 
Ubiquitin is a 76 amino acid globular protein with a molecular mass around 8.5 kDa and is 
highly conserved throughout eukaryotes (Weissman, 2001). Since its discovery over three 
decades ago, it has become abundantly clear that the ubiquitin system is an essential feature 
of all aspects of eukaryotic biology. Due to its pervasive action, ubiquitin does not seem to 
be produced in excess but the free pool of ubiquitin monomer is maintained at an adequate 
level to ubiquitinate the large number of its potential substrates in human cells (Kimura and 
Tanaka, 2010). In yeast as well as in higher eukaryotes, ubiquitin is initially expressed in the 
form of a precursor either as polyubiquitin, a linear fusion protein consisting of four or more 
ubiquitin copies in a head-to-tail configuration, or as fusion proteins between ubiquitin and 
large and small essential ribosomal polypeptides, L40 and S27, respectively (Finley et al., 
1989; Redman and Rechsteiner, 1989). These ubiquitin precursors are cleaved by DUBs to 
release identical functional monomeric ubiquitin units.  
In the ubiquitination process, ubiquitin covalently attaches to the lysine residues of target 
proteins via its carboxy-terminal glycine residue to form an isopeptide linkage in an ATP-
dependent fashion. Multiple ubiquitin can be covalently added to a substrate successively by 
E1, E2 and E3 enzymes, producing a substrate conjugated with polyubiquitin (Pickart, 2001; 
Dye and Schulman, 2007). The key feature of ubiquitin is the fact that it contains seven 
lysines, each of which can potentially mediate attachment to other ubiquitin molecules, 
allowing the formation of a range of structurally distinct polyubiquitin chains (Figure 1.1) 
(Komander, 2009). 
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Figure 1.1 Ribbon diagram representing the tertiary structure of ubiquitin and the 
functional implications of specific linkages: The structure of ubiquitin reveals that all 
seven lysine residues (red, with blue nitrogen atoms) and methionine (with a green sulphur 
atom) reside on different surfaces of the molecule. The percentage numbers refer to the 
relative abundance of the particular linkage in S. cerevisiae (Komander, 2009). Above is the 
amino acids sequence of ubiquitin with the seven lysine residues highlighted in red. 
 
In addition to ubiquitin itself, multiple polypeptides that are distinct from but related to 
ubiquitin are also enzymatically conjugated to target substrates via processes very similar to 
ubiquitination (Gill, 2004). These ubiquitin-like proteins (UBLs) participate in many 
biological processes including gene transcription, signal transduction, autophagy and cell-
cycle control (Welchman et al., 2005). So far, SUMO2/3 and NEDD8 are the only UBLs 
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known to participate in chain formation (Tatham et al., 2001; Xirodimas et al., 2008; Matic 
et al., 2008). Members of the UBL family are listed in the table below: 
 
Table 1.1 Known and putative UBLs in Saccharomyces cerevisiae: Reviewed in 
Hochstrasser (2009). ND = Not detectable by standard BLAST search.  
* = For each two ubiquitin-related domains.  
UBL 
Identity with 
ubiquitin (%) 
Known UBLs 
Rub1 (NEDD8) 55 
FUBI (also known as MNSF-β or FAU) 38 
FAT10 32 and 40* 
ISG15 32 and 37* 
Smt3 (SUMO1, SUMO2, SUMO3) 18 
Atg8 ND 
Atg12 ND 
Urm1 ND 
UFM1 ND 
Putative UBLs 
BUBL1, BUBL2 Variable (up to 80%) 
UBL-1 40 
SF3A120 30 
Oligoadenylate synthetase 30 and 42* 
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1.3 Roles of ubiquitination 
1.3.1 Intracellular protein degradation by ubiquitin-proteasome pathway: The classical 
ubiquitin role 
Protein degradation in eukaryotic cells is carried out either by lysosomal or proteasomal 
degradation (Cooper, 2000). Lysosomes are membrane-enclosed organelles that contain a 
large variety of hydrolytic enzymes which digest extracellular proteins taken up 
by endocytosis. Most of the proteolysis of cytosolic proteins that occurs in lysosomes is non-
specific (Knopp et al., 1993). In contrast, the Ubiquitin-Proteasome System (UPS) uses 
ubiquitin as a marker which can target cytosolic and nuclear proteins for selective 
destruction by proteasomes (Pickart, 2001). It is the responsibility of the UPS to identify and 
exterminate damaged and faulty proteins or those simply surplus for requirement to maintain 
the right amount of proteins within cells. The UPS can malfunction in two ways: it can either 
become overzealous and destroy useful protein inappropriately, or it can be restrained in 
some way resulting in the build up of potentially harmful proteins, which can then reach 
toxic levels. An imbalance in the UPS is thought to occur in common diseases especially 
cancer (Scheffner et al., 1990; Loda et al., 1997; Joazeiro et al., 1999; Maxwell et al., 1999; 
Waterman et al., 1999; Bignell et al., 2000). The UPS marks a target protein for destruction 
by the addition of a specific form of ubiquitin modification, in essence, proteins tagged with 
polyubiquitin chains of more than four ubiquitin residues (Thrower et al., 2000). There is a 
lot of ubiquitin present in cells but it cannot attach itself to protein at random due to its 
highly regulated and controlled process which has evolved ways of avoiding any unwanted 
protein degradation. 
The multi-stage ubiquitination process occurs by the sequential action of three different 
enzymes (Pickart, 2001; Weissman, 2001; Markson et al., 2009). As can be seen in Figure 
1.2, ubiquitination is initiated by the formation of high energy thioester intermediates, E1-
Cys~ubiquitin generated upon binding between the cysteine active site of E1 ubiquitin-
activating enzyme with the C-terminal glycine (G76) of ubiquitin in an ATP-dependent 
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process (Groettrup et al., 2008). The activated ubiquitin moiety is then transferred from the 
E1 to the E2 ubiquitin-conjugation enzyme by transthiolation, again involving the carboxyl 
terminus of ubiquitin to generate an E2-Cys~ubiquitin intermediate (Michelle et al., 2009). 
The E2 protein acts as an escort for ubiquitin to its next destination, which is either an E3 
HECT (homologous to E6-AP terminus) ligase or directly to a specific substrate protein via 
E3 RING (Really Interesting New Gene). Unlike the situation with HECT type which really 
involves in accepting and delivering the ubiquitin molecule to the substrate, E3-RINGs 
primarily act as a platform on which the active E2-ubiquitin complex and target protein 
substrate can meet and interact. The E3 proteins represent a pivotal part of ubiquitin cascade 
processes as they define both substrate specificity and the recruitment of selective E2 
enzymes. In each case, an E2 enzyme loaded with activated ubiquitin interacts with one of a 
specific subset of E3 proteins in order to transfer ubiquitin to the target protein by the 
formation of an isopeptide bond between ubiquitin's C-terminal glycine and the ε-amino 
group of a lysine residue within the protein substrate or a selective lysine residue in 
previously added ubiquitin, thereby forming polymeric chains of selective structure and 
function (Deshaies and Joazeiro, 2009). The Lys48 polymeric chains target proteins to the 
cell’s waste disposal unit, the proteasome (Hersko and Ciechanover, 1998). The proteasome 
binds and removes the polyubiquitin chain and unfolds the protein. The protein is then 
threaded through the proteasome chamber before being chopped up into component building 
blocks, which are reused for the synthesis of new proteins while the ubiquitin is recycled 
(reviewed in Hochstrasser (1996)). 
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Figure 1.2 Protein degradation through the UPS: (A) ATP-dependent ubiquitin 
activation by E1 followed by ubiquitin delivery to E2. (B) Complex formation by E2-
Cys~Ub, E3 and the substrate, involving formation of thioesters between the active-site 
cysteines of E1 and E2 enzymes and the carboxy-terminal carboxylate of ubiquitin. (C) 
Transfer of ubiquitin(s) to the substrate lysine(s) to earmark the substrate with a 
polyubiquitin chain. (D) Polyubiquitinated substrates are released from the E3. Proteasome 
recognises the polyubiquitin chain as a signal for deubiquitination and subsequent 
degradation. (E) The proteasome unfolds the substrate in an ATP-dependent manner, 
removing the ubiquitin chain through a proteasome-associated ubiquitin hydrolase activity 
before threading the unfolded protein into the proteasome. Here, the protein is degraded and 
released as peptides together with the ubiquitin molecules. 
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1.3.2 The diversity of ubiquitin chain configurations 
Protein ubiquitination is essential to the process of protein homeostasis. However, different 
forms of protein ubiquitination confer different affects other than proteasome mediated 
degradation (Weissman, 2001). Proteins can be modified through the conjugation of 
monoubiquitin or polyubiquitin chains of variable length on any of the seven ubiquitin Lys 
residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 or Lys63) or the amino-terminal Met 
(Met1) of the ubiquitin monomer. Ubiquitin chains can thus be connected by at least eight 
different homotypic linkages, as well as by a range of atypical chains such as heterologous, 
forked or mixed chains (Ikeda and Dikic, 2008; Iwai and Tokunaga, 2009; Ye and Rape, 
2009). The various conformations of ubiquitin chain create a range of molecular signals in 
cells (Table 1.2). 
Among these examples are non-canonical polyubiquitination through the Lys63 residues, 
which are involved in DNA damage response (Nakada et al., 2010), stress response 
(Arnason and Ellison, 1994), mitochondrial DNA inheritance (Fisk and Yaffe, 1999) and 
ribosomal function (Spence et al., 2000). Another mode of conjugation is exemplified by 
linking ubiquitin molecules via Lys29 of ubiquitin, which may also act as a signal for 
degradation. However, Lys29-ubiquitinated Deltex, a regulator of Notch signalling was 
found to be degraded by lysosomal rather than proteasomal degradation pathways 
(Chastagner et al., 2006). Meanwhile, Lys11-linked chains have been implicated in ERAD 
(endoplasmic-reticulum-associated degradation) where Lys11-linked ubiquitin chains were 
co-purified with UBA/UBX family proteins (Alexandru et al., 2008) in which, the UBX 
domains interact with the AAA (ATPase associated with various cellular activities) protein 
Cdc48/p97, an important regulator of ERAD (Ye et al., 2001; Schuberth and Buchberger, 
2008). On the other hand, monoubiquitination (or multi-monoubiquitination) of surface 
receptors acts as a signal for internalisation mediated by ESCRT (endosomal sorting 
complex required for transport) (Haglund et al., 2003; Raiborg and Stenmark, 2009). This 
could also be observed in yeast in which a monoubiquitin conjugate attached to membrane 
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proteins or associated transport modifiers serves as a signal for internalisation into the 
endocytotic pathway, ultimately resulting in lysosomal proteolysis (Hicke and Dunn, 2003). 
 
Table 1.2 Functions of various ubiquitin chains: The variety of biological functions 
of ubiquitination inside the human cells resulting from different types of ubiquitin chain 
formation. 
Type of ubiquitin chains Biological function References 
 
Monoubiquitination 
Trafficking, endocytosis, 
virus budding, nuclear 
export, DNA repair, gene 
expression 
(Haglund et al., 2003) 
 
Linear ubiquitin Signalling (Rahighi et al., 2009) 
 
Lys6 chain Proteasomal degradation 
(Baboshina and Haas, 1996; 
Xu et al., 2009) 
 
Lys11 chain 
Proteasomal degradation, 
protein stability 
(Baboshina and Haas, 1996; 
Nishikawa et al., 2004; Xu et 
al., 2009) 
 
Lys27 chain Proteasomal degradation (Xu et al., 2009) 
 
Lys29 chain 
Lysosomal degradation, 
proteasomal degradation, 
regulation of kinase 
activity, protein stability 
(Nishikawa et al., 2004; 
Chastagner et al.,2006; 
Al-Hakim et al., 2008; 
Xu et al., 2009) 
 
Lys33 chain 
Proteasomal degradation, 
regulation of kinase 
activity 
(Al-Hakim et al., 2008; 
Xu et al., 2009) 
 
Lys48 chain Proteasomal degradation (Chau et al., 1989) 
 
Lys63 chain 
Trafficking, kinase 
activation, proteolytic 
degradation of misfolded 
proteins 
(Olzmann et al., 2007; 
Tan et al., 2008; 
Wooten et al., 2008) 
 
Forked chain 
Negative effect on 
proteasomal degradation 
(Kim et al., 2007; 
Kim et al., 2009) 
   Chapter One | INTRODUCTION  
 
Page | 10  
 
1.4 Ubiquitin conjugation components 
1.4.1 Human E1 ubiquitin-activating enzyme 
The ubiquitin activating enzyme (UBE1) stands on the top of the ubiquitin hierarchy, being 
responsible for activating ubiquitin and preparing it for one of a large number of distinct E2 
ubiquitin-conjugating enzymes. Before the formation of the thioester bond between the C-
terminus of ubiquitin and E1, the ubiquitin was activated by adenylation via binding with 
MgATP, leading to the formation of a ubiquitin adenylate intermediate that serves as the 
donor of ubiquitin to a cysteine in the E1 active site (Haas et al., 1982; Groettrup et al., 
2008). Each charged E1 molecule carries two molecules of activated ubiquitin: one as a 
thioester, and one as an adenylate. Only the thiol-linked ubiquitin is transferred to the E2 by 
transthiolation. E1 is an efficient enzyme, justified by its maximum turnover number of 
ATP-AMP exchange (1-2 s
-1
) involving all steps from ATP binding through thioester 
formation (Haas et al., 1982) when compared to the catalytic rate (kcat) of substrate 
ubiquitination which is 10- to 100-fold slower (Mastrandrea et al., 1999). This allows the 
production of sufficient activated ubiquitin for all cellular ubiquitination reactions, even 
though the concentration of the E1 protein is thought to be lower than the total concentration 
of E2 proteins (Pickart, 2001). 
The human genome encodes only two E1 genes: A1S9T (Zacksenhaus and Sheinin, 1990; 
Zacksenhaus et al., 1990), which appeared to be an ubiquitin-activating enzyme and 
designated later as UBE1, and UBA6 which was recently identified by homology searches 
using one of the two ThiF-homology motifs that compose the adenylation domain (Pickett, 
2007).  
 
1.4.2 Human E2 ubiquitin-conjugating enzyme 
The second component in the ubiquitin cascade are the E2 enzymes, which are the key 
enzymes in a ubiquitin pathway. In contrast with E1 enzymes, E2 proteins will not forge 
thioester linkages with ubiquitin in the absence of E1. Instead, the charged E1 will bind to 
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the E2 conjugating enzyme through its ubiquitin fold domain to bring the catalytic cysteine 
on the E2 into close enough proximity to the E1 active site, thereby allowing transfer of the 
thioester bound from ubiquitin from the E1 to the E2 (Pickart, 2001). Once loaded with 
ubiquitin, E2 proteins can donate the thioester linked ubiquitin to the active cysteine of a 
HECT domain E3 ubiquitin ligase (E3) which then transfers ubiquitin to a protein substrate. 
Alternatively, E2 proteins can transfer ubiquitin directly onto a lysine residue of a target 
substrate protein. In this case, an E3 RING protein may assist the E2 protein in recognising 
the appropriate protein target (Ptak et al., 2001).  
The importance of E2 proteins lies in their role of determining the lysine preferences in 
ubiquitination, hence dictates the topology of polyubiquitination (David et al., 2010). This 
can be seen in BRCA/BARD, an E3 ligase which acts with UBE2K to generate Lys48-
conjugated chains, whereas with the UBE2N-UBE2V1 combination of E2 proteins, these 
catalyse the formation of polyubiquitin chains conjugated through Lys63 (Christensen et al., 
2007). Also, the Pellino1 E3 protein acts with UBE2N-UBE2V1 to generate lysine 
Lys63 chains, but when acting with UBE2R1, it actually catalyses the formation of 
Lys48 chains. However, when this E3 functions with members of the UBE2D family 
(Ubc4/5), it promotes the formation of Lys11 and Lys48 chains (Ordureau et al., 2008).  
 
1.4.2.1 E2 structure 
E2 proteins are distinguished by the presence of a UBC (ubiquitin conjugating) domain that 
is approximately 35% conserved throughout eukaryotes. This domain consists of about 150 
amino acids (Pickart, 2001), which is organised into four standard alpha helices (α1-4), a 
short 310 helix, and four-stranded (S1-4) antiparallel β-sheets as demonstrated in Figure 1.3 
(Pickart, 2001; Özkan et al., 2005). The β-sheets and α2 form a central region that is 
bordered by the α1 region at one end and α3/α4 regions at the other. The cysteine residue of 
the active site lies in a long loop that connects S4 to α2, and sits in a shallow groove formed 
by upstream residues of the same loop on one side, and residues of the α2-α3 on the other 
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(Pickart, 2001). A large proportion of the most highly conserved E2 residues are found 
around the active site. Some of these residues interact with ubiquitin, and others are 
presumed to interact with the E1 protein (Pickart, 2001). In contrast, the region of the E2 
protein that faces the active site contains some of the most poorly conserved residues found 
within the protein, perhaps to make the structural region easier to define. It is suggested that 
a proportion of these residues may have diverged under low selective pressure due to a lack 
of essential function. However, it is also possible that these differences may actually 
facilitate specific partner interactions (Pickart, 2001). Support for the theory that the region 
opposite the active site may be involved in specific E2 interactions is provided by the 
analysis of the UbcH10 (UBE2C) protein, which shows that many residues in this region are 
conserved among orthologues of UBE2C. However, these residues are not conserved among 
different E2 enzymes within the same species, thus implying that these residues are specific 
to the function of UBE2C (Pickart, 2001). 
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Figure 1.3 Conservation of E2 structures between species: (A) Yeast Ubc4 
(UBE2D1 homologue). The active site cysteine (C86) is highlighted black, along with side 
chains corresponding to F63 (green) and P97 (red) of UBE2C. (B) Clam E2-C (UBE2C 
homologue). Relative to (A), the molecule was rotated ~180° along the y axis. The side 
chains of R129 (purple) and L133 (brown), corresponding to the first and fourth residues of a 
destruction box located in α2, are highlighted. Picture from Pickart (2001). 
 
The structures of UbcH7 (UBE2L3) bound to RING E3 c-Cbl and of UbcH5B (UBE2D2) 
bound to CNOT E3 RING have been solved (Zheng et al., 2000; Dominguez et al., 2004) 
and would therefore provide a general explanation of E2 specificity. The CNOT4 RING 
finger interacts specifically with UBE2D2 and not with UBE2L3 despite the fact that in both 
complexes the same regions of the E2s are involved (helix α1, loops L1 and L2) in the 
interaction with the RING (Winkler et al., 2004). This suggests that although the three 
regions of UBE2D2 and UBE2L3 involved in the binding are similar, the binding properties 
must be different. For example, several contacts between the H1 helix of UBE2D2:CNOT4 
are not present in the UBE2L3:c-Cbl complex (Figure 1.4). Furthermore, UBE2L3:c-Cbl 
involved mainly hydrophobic or uncharged residues while UBE2D2:CNOT4 governs the 
binding by charged residues. 
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(A) 
  
(B) 
  
 UBE2D2:CNOT4 UBE2L3:c-Cbl 
 
Figure 1.4 Comparison between the UBE2D2:CNOT4 docking model and the 
UBE2L3:c-Cbl crystal structure: (A) The orientation of the RING domain compared to the 
E2 enzyme is similar in both complexes. UBE2D2 and UBE2L3 are coloured blue, CNOT4 
and c-Cbl RING domains are coloured red, and the other domains of c-Cbl are coloured 
brown. (B) The helix α1 of UBE2D2 makes many contacts with the CNOT4 RING domain, 
whereas the helix α1 of UBE2L3 interact mainly with the linker region of c-Cbl. Residues 1, 
4, 5, and 8 of UBE2D2 and 5, 9, 12, and 16 of UBE2L3 are labelled in blue. Residues 13, 16, 
18, and 19 of CNOT4 and 385 of c-Cbl RING are labelled in red. Residues 366, 369, 370, 
and 373 corresponding to the linker region of c-Cbl are labelled in brown. Picture from 
Dominguez et al. (2004).  
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1.4.2.2   E2 family diversity 
The existence of at least 37 E2 enzymes suggest some degree of specificity in ubiquitination 
events with regards to partners, substrates, and functions. Generally, the E2 family are 
classified based on the existence of additional extensions to the UBC catalytic core (Figure 
1.5). E2 class I consist of the catalytic domain only, while others with additional N- or C- 
terminal extensions are classified as Class II and Class III, respectively. E2s that have 
extension in both termini are categorised Class IV. These extensions are involved in 
functional differences between E2s, which involve differences in subcellular localisation, 
stabilisation of the interaction with E1 enzymes, or modulation of the activity of the 
interacting E3s (van Wijk and Timmers, 2010). 
While the majority of E2 enzymes contain predominantly the UBC domain alone along with 
N- or C-terminal flanking regions, there are also a few examples of domains outside of the 
UBC region, which are required for functions, both within and external to the ubiquitin 
cascade. For example, it has been hypothesised that the ubiquitin binding UBA domain C-
terminal of the UBC domain in UBE2K may be involved in ubiquitin chain formation based 
on a similar domain in the yeast Ubc1 protein (Merkley and Shaw, 2004). The massive 
atypical E2 BIRC6 is annotated for an anti-apoptotic BIR domain distal to the C-terminal 
UBC domain. At almost 5 000 amino acids in length it is likely however that BIRC6 
contains many ordered domains. It is thought to be the sole chimeric E2:E3 ligase that 
utilises the BIR domain to bind and mediate ubiquitination of SMAC and caspase-9 (Bartke 
et al., 2004). 
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Figure 1.5 The family of human E2 ubiquitin-conjugating enzymes: Schematic 
overview of the superfamily of active, human E2 enzymes. The UBC fold is indicated as a 
dark-blue thick line, the N- and/or C- termini  are represented by the light blue line, UBA 
domain of UBE2K is indicated as a red line and the BIR domain of BIRC6 as a green line. 
Different classes of E2 enzymes are indicated in different colours. Scale bar indicates protein 
lengths (aa). Picture from van Wijk and Timmers (2010). 
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1.4.3 Human E3 ubiquitin-protein ligases 
Human E3 ligases perform the final step in the ubiquitin pathway, having a vital role in the 
recognition of specific protein substrates and mediating ubiquitin transfer from E2 enzymes 
to specific protein substrates. Among all of the components of the ubiquitin cascade, they are 
the most numerous and display the greatest diversity. Even though E3s are heterogeneous, 
they can nevertheless be classified into two primary classes according to domain homology 
and mechanism of action: HECT domain and RING finger-containing E3s (Glickman and 
Ciechanover, 2002). 
 
1.4.3.1 HECT domain E3s 
HECT domain proteins harbour a 350aa sequence homologous to the E6-AP carboxyl-
terminal domain. This domain contains a conserved catalytic Cys residue that transfers the 
activated ubiquitin from an E2 to an internal Cys residue within the E3 before conjugation of 
ubiquitin to an NH2 group in the substrate (Glickman and Ciechanover, 2002). Indeed the 
HECT domain has at least four biochemical activities: (1) it binds specific E2s; (2) it accepts 
ubiquitin from the E2, forming a ubiquitin-thioester intermediate with its active-site cysteine; 
(3) it transfers ubiquitin to the ɛ-amino groups of lysine side chains on the substrate by 
catalysing the formation of an isopeptide bond; and (4) it transfers additional ubiquitin 
molecules to the growing end of the multi-ubiquitin chain (Wang et al., 1999).  
 
1.4.3.2 RING domain E3s 
RING finger proteins were first thought to play a role in the dimerisation of proteins. It was 
only in the late nineties that RING finger domains were identified as ubiquitin ligases 
(Lorick et al., 1999). The RING finger proteins have been defined by a pattern of conserved 
Cys and His residues that form a cross-brace structure allowing the binding of Zinc cations. 
The conserved RING finger consensus is CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-
48)CX2C (Borden and Freemont, 1996; Joazeiro and Weissman, 2000). RING finger 
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domains fall into three categories: RING-HC, RING-H2 and RING-CH depending on 
whether a Cys or His occupies the fifth coordination site respectively. While RING fingers 
are structurally diverse, all contain two interleaved Zinc-binding sites (Glickman and 
Ciechanover, 2002). Unlike HECT E3s, RING E3s do not have recognisable catalytic active 
sites that define classical enzymes. Instead, these E3s have large binding interfaces and act 
as scaffold proteins that bring together the participant E2 and substrate proteins.  
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1.5 Hierarchical structure and specificity of the ubiquitin system 
The structure of the ubiquitin system appears to be hierarchical. In human cells, only two 
main E1 proteins carry out the activation of ubiquitin required for all modifications. These 
enzymes are responsible for transferring ubiquitin to different E2 enzymes. Subsequently, 
each E2 acts in conjunction with either one or more different E3 enzymes. Beside the two 
main E1 activating enzymes and approximately 40 types of E2 conjugating enzymes, there 
are about 600-800 E3 ligases in human cells, in other word there are nearly 50 000 different 
potential combinations might operate in ubiquitin cascades, making the ubiquitin pathway 
both versatile and highly complex (illustrated in Figure 1.6). The diversity of ubiquitin, 
besides being contributed by more than 600 E3 ligases, is further expanded by the generation 
of different forms of ubiquitin chains. Even though the type of ubiquitin chain formation is 
depend on the E2 enzyme, it is still possible that the E3 ligase determines which substrate to 
bind ubiquitin to (Nakada et al., 2010). 
 
 
 
 
      
Figure 1.6 Illustration of the hierarchical structure and specificity within the 
ubiquitin system: One E1 (coloured orange) interacts with several different E2s (labelled 
E2a, E2b, E2c and coloured red), in which each of them may interact with multiple different 
E3s (labelled E3a to E3f and coloured green). Each E3 may target several different substrates 
(labelled Sa to Sl, coloured black). 
  
   Chapter One | INTRODUCTION  
 
Page | 20  
 
1.6 The deubiquitinating enzyme 
1.6.1 Classification of deubiquitinating enzyme 
Deubiquitinating enzymes (DUBs) belong to the superfamily of proteases and they function 
to remove covalently attached ubiquitin from proteins, either from the polyubiquitin chain or 
from the substrate (Wilkinson, 1997). Among all ubiquitin machineries, the functions, targets 
and regulation of DUBs are the most poorly understood due to their non-uniform structure 
and function, though it is becoming increasingly apparent that DUBs regulate various 
cellular processes (Ventii and Wilkinson, 2008). The human genome encodes approximately 
95 DUBs, which fall into five major classes (Nijman et al., 2005) namely ubiquitin specific 
proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases 
(OTUs), Josephins and the Jab1/MPN/MOV34 metalloenzymes (JAMMs, also known as 
MPN
+
). The USP, UCH, OTU and Josephin families are cysteine proteases, whereas the 
JAMM/MPN
+
 family members are zinc metalloproteases. Figure 1.7 show the structures of 
the catalytic domains of all five subclasses of the DUBs. For the cysteine proteases, the 
enzymatic activity relies on the thiol group of a cysteine in the active site. The adjacent 
histidine, which is polarised by an aspartate residue helps in cysteine deprononation hence 
these three make up the catalytic triad. During catalysis, the cysteine performs a nucleophilic 
attack at the peptide bond between the target and the ubiquitin resulting in the release of the 
target protein and formation of a covalent intermediate with the ubiquitin moiety. Upon 
reaction of this intermediate with a water molecule, free enzyme and ubiquitin are released 
(Nijman et al., 2005). On the other hand, metalloproteases generally use a Zn
2+
 bound 
polarised water molecule to generate a non-covalent intermediate with the substrate. The 
metal atom is stabilised by an aspartate and two histidine residues (Ambroggio et al., 2003). 
The intermediate is further broken down by proton transfer from a water molecule causing 
the release of the DUB (Nijman et al., 2005). 
In spite of what appears to be a hierarchical system, an interaction between a DUB called 
OTUB1 and E2 enzymes was observed (Markson et al., 2009). This is really against the 
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conventional hierarchy and therefore much attention should be paid to elucidate the purposes 
of such interaction. 
 
1.6.1.1 USP domain 
The largest and most diverse cysteine protease, the domain contains well-conserved Cys and 
His boxes, which include all the catalytic triad residues as well as other residues in the active 
site pocket (Amerik and Hochstrasser, 2004). 
 
1.6.1.2 UCH domain 
Generally small proteins and were originally identified by their ability to hydrolyse small 
amides and esters at the C-terminus of ubiquitin (Amerik and Hochstrasser,  2004). 
 
1.6.1.3 OTU domain 
A novel family of cysteine proteases which display structural similarity in a presumed 
catalytic core domain containing conserved Cys, His and Asp residues thought to comprise 
the proteolytic/catalytic triad. OTU has been proven to have DUB activity by the ability of 
its prominent members, Otubain 1 and 2, to cleave ubiquitin from either a ubiquitin–GFP 
fusion protein or a tetraubiquitin fusion (Balakirev et al., 2003).  
 
1.6.1.4 Josephin domain 
Its representing member, Ataxin-3 has the typical properties of DUBs: the enzyme 
disassembles ubiquitin–lysozyme conjugates, cleaves ubiquitin-7-amido-4-methylcoumarin 
(ubiquitin-AMC), and binds to the DUB inhibitor ubiquitin aldehyde (Ubal) (Burnett et al., 
2003). The Josephin domain, which is found in over 30 predicted proteins, most of unknown 
function, includes segments that show weak similarity to the His and Cys boxes of UBPs and 
UCHs, suggesting that this region of Ataxin-3 and its relatives will also assume the papain-
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like protease fold that characterises the other cysteine proteases (Amerik and Hochstrasser, 
2004). 
 
1.6.1.5 JAMM domain  
The MPN
+
/JAMM motif DUB called AMSH (associated molecule with the SH3 domain of 
STAM) was found to have deubiquitinating activity as well (McCullough et al., 2004). This 
metalloprotease motif includes two absolutely conserved His residues and an Asp residue 
that together coordinate a zinc ion important for proteolytic activity.  
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Figure 1.7 Structures of the catalytic domains of the five subclasses of DUBs (yellow) with ubiquitin (blue): Structures show the remarkable 
variability in secondary structure between the DUB classes. Catalytic centers are shown as Van der Waals spheres (carbon, grey; nitrogen, blue; oxygen, red; 
sulphur, orange; zinc, purple) and have been aligned for easy comparison. The OTU domain of OTUB2 lacks the conserved Asp in the catalytic centre and the 
Asn/Glu/Gln that is normally used to stabilise the oxyanion hole in these proteases. Picture from Nijman et al. (2005).  
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1.6.2 General function of DUB 
Generally, DUBs activity can be divided into three major functional categories. Firstly, the 
DUBs are responsible for processing linear ubiquitin precursor proteins into single ubiquitin 
molecules. As explained earlier, ubiquitin is encoded as a polyubiquitin gene or ribosomal 
fusion gene. Upon expression of ubiquitin protein, DUBs play a vital role in separating the 
polyubiquitin and cleave the ribosomal protein to generate a free ubiquitin (Komander et al., 
2009a). Mutations in several DUBs have been shown to cause ubiquitin reduction and 
therefore resulting in various serious defect in living cells. In yeast, deletion of DUB 
encoding genes, including DOA4 and UBP6 were shown to reduce the amount of 
monomeric ubiquitin (Swaminathan et al., 1999). 
DUBs also functioned to remove ubiquitin chains from post-translationally modified 
proteins, leading to the reversal of the ubiquitin signal hence rescuing the protein from either 
proteasomal or lysosomal degradation. However, if a commitment to these degradative 
machines has been made, DUBs act to recycle the ubiquitin released from the protesome (or 
lysosome), thereby maintaining the free ubiquitin pool. Any ubiquitin that is released as an 
oligomer could also be disassembled by DUBs (Komander et al., 2009a). Thirdly, DUBs can 
also be used to edit the form of ubiquitin modification by trimming ubiquitin chains from the 
distal end of the chain (Komander et al., 2009a). 
The knowledge about cellular functions of DUB has increased significantly in recent years. 
Due to the diversity in DUBs structure and functions, the prediction of DUBs main role in 
cellular regulation has proved to be quite tricky. Nevertheless, essential progress that largely 
focuses in elucidating the role of DUBs in the area of membrane trafficking, cell signalling 
and regulation of nuclear events has been observed in recent years (Clague et al., 2012). 
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1.7 Protein-protein interactions 
Upon completion of Human Genome Project in 2003, approximately 23 000 genes of the 
human genome were identified and mapped. However, this knowledge about the entire 
human genome could not provide an understanding even of the basic principles in human 
cellular systems. Entering the post-genomic era, the importance of protein-protein 
interactions is becoming even more apparent in order to explain how the genetic information 
in the form of DNA manage to generate functions. In order to tackle this question, we need 
to understand how the gene products, particularly proteins, interact with each other to 
perform many biological functions that build a living organism. Protein-protein interactions 
(PPI) are fundamental to all biological processes. Determination of the PPI that take place 
within an organism provides a framework for understanding the links between molecular and 
cellular biology. Alteration of PPI are thought to be involved in the development in many 
diseases for example neurodegenerative disorders, cancers and infectious diseases. Hence, 
examination of when and how they are controlled is essential for understanding diverse 
biological processes and elucidating the molecular basis of disease as well as identifying 
potential targets for therapeutic interventions. 
Various methodologies can be used to detect PPI. Each has its own strengths and weaknesses 
with regard to the sensitivity and specificity of the method. Generally methods for 
identifying interacting proteins can be divided into two types: (1) biology/biochemical 
methods for example co-immunoprecipitation and genetic manipulation yeast two-hybrid 
methods; (2) biophysical methods such as NMR, ITC and crystallography. 
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1.7.1 Genetic in vivo methods 
1.7.1.1 Yeast two-hybrid screen 
Since its description in 1989 (Fields and Song, 1989), yeast two-hybrid (Y2H) analysis has 
become widely used to detect binary protein-protein interaction. In this system, a protein of 
interest (the bait) is fused to the DNA binding domain (BD) of a transcription factor (such as 
GAL4) as can be seen in Figure 1.8. The bait’s potential interacting partner (the prey protein) 
is fused to the transcription factor’s activation domain (AD). These fusions are carried out by 
DNA cloning methods, allowing expression of the subsequent bait and prey fusion proteins 
in the nucleus of the yeast host. The yeast strain used in this system carries a set of reporter 
constructs which are under the control of an upstream sequence containing the binding sites 
for the BD. If the bait-BD and prey-AD fusions interact, then a functional transcription 
factor is reconstituted and expression of the reporter gene is activated (Fields and Song, 
1989). The reporter genes produce a scorable phenotype such as growth on selective media 
or colour change. For example, activation of the reporter genes ADE2 and HIS3, enables 
growth on media lacking adenine and histidine respectively, and the activation of the lacZ 
reporter gene produces a blue colour in an X-gal assay. 
The first genome-wide Y2H interaction map was generated for bacteriophage T7, and large-
scale yeast two-hybrid screens have been conducted for several viruses, H. pylori, S. 
cerevisae, P. falciparum, C. elegans, Drosophila and human (Flajolet et al., 2000; McCraith 
et al., 2000; Uetz et al., 2000; Guo et al., 2001; Ito et al., 2001; Giot et al., 2003; Li et al., 
2004; Stanyon et al., 2004; Formstecher et al., 2005; LaCount et al., 2005; Rual et al., 2005; 
Stelzl et al., 2005; Uetz et al., 2006). The data generated from these screens will be useful 
for individual studies and for system wide studies (Parrish et al., 2006). For example the 
human pathogen interaction maps have generated lead proteins that may interact during 
pathogenesis and identified potential drug targets (Parrish et al., 2006). The potential for 
proteome-wide interactome mapping in humans has been demonstrated by two major 
studies. Rual et al. (2005) screened approximately 7 200 human full-length ORFs, randomly 
   Chapter One | INTRODUCTION  
 
Page | 27  
 
chosen on the basis of clone availability, and identified 2 754 protein interactions. Stelzl et 
al. (2005) screened two-hybrid arrays generated from a human foetal brain cDNA library 
and a collection of full-length ORFs, identifying 3 156 interactions. Combined, these two 
datasets identified over 5 900 protein interactions, a large proportion of which are novel.  
Our lab has used the Y2H system to perform both library screen and targeted matrix 
experiments. A library screen allows the identification of novel interactive partners, whereas 
a matrix approach enables the detection of an interaction between two specific proteins. A 
library screen is applied as a tool for the discovery of binding partners for a specific bait, by 
screening it against an AD-cDNA library (which contains potential cDNA prey clones fused 
to the GAL4 AD). Direct yeast colony PCR of the diploid yeast colonies using prey specific 
primers permits identification of the preys via sequencing. Meanwhile, the matrix method 
involves pairs of proteins which are systematically tested for a binary two-hybrid interaction. 
Here, arrays of yeast of one mating type containing bait clones are mated with arrays of yeast 
of the opposing mating type containing individual prey clones. The advantage of the matrix 
method is that there is no need to identify the interacting protein, as the clone is already 
defined by its position in the array.  
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(A) 
 
  
(B) 
 
  
(C) 
 
Figure 1.8 The Y2H system: The yeast GAL4 transcription factor can be divided into 
two domains, the DNA binding domain (in purple, labelled BD), and the transcription 
activating domain (in green, labelled AD). (A) The unmodified GAL4 transcription factor 
can activate the expression of a reporter gene by binding a GAL4-specific promoter (in pink) 
and confer a survival phenotype to yeast growing on selective media. (B) Expression of 
either the DNA binding domain or the transcription activating domains in isolation cannot 
activate reporter gene expression and therefore yeast cells growing on selective media cannot 
survive. (C) To assess the interactions between a protein X and a protein Y, fusion constructs 
can be co-expressed in yeast cells to produce BD-X and AD-Y chimeras. If protein X and 
protein Y interact the survival phenotype is restored. 
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1.7.2 Biophysical and theoretical methods 
1.7.2.1 Isothermal titration calorimetry (ITC) 
ITC has been extensively used to study protein-ligand binding and its application in protein-
protein binding are growing rapidly (Leavitt and Freire, 2001). It is the only technique that 
determines directly the thermodynamic parameters of a given reaction which are the   ,    
and   . Theoretically, the binding of two proteins cause a change in the thermodynamic 
potentials (  ,    and   ) and these are measured directly by highly sensitive calorimetry 
(Velazquez-Campoy et al., 2004). ITC uses stepwise injections of one protein into a 
calorimetric cell containing the second protein to measure the heat of the reaction for both 
exothermic and endothermic processes (Figure 1.9). The underlying principles of ITC lies on 
the chemical scheme based on a reversible association equilibrium: 
               
where    and    are the interacting macromolecules. The strength of the interaction is 
described by the association constant    or the dissociation constant    : 
                     and         
where      and       are the concentrations of the free reactants and        is the 
concentration of the complex. These constants are related to the Gibbs energy of association 
    and dissociation     and can be expressed in terms of the enthalpy,    and 
entropy,   , change in the process: 
                           
                           
where   is the gas constant (1.9872 cal/Kmol) and   is the absolute temperature (kelvins). 
Among the information available by doing ITC are simultaneous determination of the 
association constant, the enthalpy of binding and the stoichiometry.  
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An ITC composed of two identical cells made of a highly efficient thermal conducting and 
chemically inert material, surrounded by an adiabatic jacket (O’Brien et al., 2000). Sensitive 
thermocouple circuits are used to detect temperature differences between the reference cell 
filled with buffer and the sample cell filled with the first protein. Before the addition of 
second protein, a constant power is applied to the reference cell. This directs a feedback 
circuit, activating a heater located on the sample cell (MicroCal ITC manual). During the 
experiment, ligand is titrated into the sample cell in known amount, causing heat to be either 
taken up or evolved, depending on the nature of the reaction.  
 
 
       
Figure 1.9 Illustration of the configuration of an ITC reaction cell: (A) The cell is 
filled with the protein 1 (red) while the injection syringe is filled with protein 2 (blue). At 
specified time intervals (see B) a small volume of protein 2 is injected into the cells 
triggering the binding reaction and producing a characteristic peak sequence in the recorded 
signal. (B) After integration of the area under each peak, the individual heats are plotted 
against the molar ratio from which, through non-linear regression, is possible to estimate the 
thermodynamic parameters such as the stoichiometry of the interaction ( ),    and   . 
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1.7.2.2 Nuclear magnetic resonance (NMR) 
The fundamental questions in protein-protein interaction are the location of binding 
interface. A lot of biochemical or biophysical techniques are currently available to address 
this question but among the most widely used is NMR chemical shift perturbation due to its 
sensitivity to subtle changes in the chemical environment of proteins. NMR can provides 
both specific and qualitative information for examples: (1) give specific information on 
physical properties of individual functional groups such as ionisation states, pKa, and 
hydrogen bonds; (2) provide site-specific information on backbone and side-chain dynamic 
motions in solution; (3) be used to identify contacts between individual atoms of a protein 
and its binding partners, as well as to study the kinetics of ligand binding (Gao et al., 2004). 
Table 1.3 below shows the comparison between ITC and NMR. 
 
Table 1.3 The comparison between ITC and NMR: Pros and cons of ITC and NMR. 
NMR, however, has an extra advantage since it can provides binding site information. 
 ITC NMR 
Measure ΔH Δδ 
Concentration P1 >1 μM >10 μM 
Concentration P2 >10*[P] Any (>10*[P] opt) 
Volume 0.3 ml 0.5 ml 
Titration time ~30 min ~1 day 
Binding parameter ΔH, Kd, TΔS Kd 
 
 
Chemical shift arises from anisotropies in the electronic environment surrounding magnetic 
nuclei. Some nuclei like 
1
H, 
13
C, 
19
F, 
31
P have nuclear spin that can create a magnetic 
moment. By placing these nuclei in a magnetic field, they absorb electromagnetic radiation 
at particular frequencies governed by their chemical environment and give an electronic 
signal displayed as a peak (Figure 1.10). Their chemical environment is influenced by 
various factors such as chemical bonds, molecular conformations and dynamic processes. So 
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even the nuclei of the same element give rise to distinct spectral lines. The relative positions 
of these spectral lines are therefore called chemical shifts. In other words, upon addition of 
ligand or protein partner, shifting peaks, line width, and/or intensity changes indicate which 
residues experience a change in their environment, and this in turn allow the identification of 
the binding interface. In practice, this can be achieved by simply titrating the unlabelled 
protein into an isotopically enriched (
15
N or 
13
C) protein sample and monitoring peak 
perturbations in spectra of the labelled protein (Gao et al., 2004). 
 
 
          
Figure 1.10 Schematic operation of basic NMR spectrometer: Data is usually 
collected from 300-600 μl protein in concentration range of 0.1-0.3 mM. The sample is 
placed in a thin glass tube between the poles of a strong magnet and irradiated with rf 
energy. A sensitive detector monitors the absorption of rf energy, and the electronic signal is 
then amplified and displayed as a peak.  
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1.7.2.3 X-ray crystallography 
X-ray crystallography is the oldest technique in determining protein structure with a vast 
number of Nobel prize medals and contribution to majority of PDB depositions. It is a 
method of determining the atom arrangement within a crystal, in which a beam of X-
rays strikes a crystal and causes the beam of light to scatter into many specific directions. A 
3D picture of the electron density within the crystal can be determined from the angles and 
intensities of these diffracted beams. From this electron density, the mean positions of the 
atoms in the crystal can be determined, as well as their chemical bonds, their disorder and 
various other information. In the past decade, biological crystallography has experienced an 
improvement in data collection and structure and has deposited more than 58 000 
crystal structures into the PDB (Ennifar, 2012). 
Proteins can be prompted to form crystals when placed in the appropriate conditions. In 
order to crystallise a protein, the purified protein undergoes slow precipitation from an 
aqueous solution. As a result, individual protein molecules align themselves in a repeating 
series of unit cells by adopting a consistent orientation. The crystal that forms is held 
together by non-covalent interactions (Rhodes, 1993). The complete step-by-step method of 
protein crystallography is illustrated in Figure 1.11. 
Protein in solution needs to be incubated with precipitants in order to form crystal. The 
general function of precipitants in protein crystallisation experiments is to decrease the 
solubility of the protein. In theory, the precipitants compete with the protein solutes for 
water, thus leading to supersaturation of the proteins (McPherson, 2001). Salts, polymers, 
and organic solvents are the most popular precipitants. 
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Figure 1.11 Steps of protein X-ray crystallography: (A) and (B) Proteins in solution 
are set up with precipitant(s) to obtain a good-diffraction crystal. (C) The electrons 
surrounding the molecule diffract as the X-rays hit them and (D) forms a pattern called the 
‘X-ray diffraction pattern’ as the electrons leave. (E) The diffraction data is then processed 
by Fourier transform and the structure of the atom or molecule is deduced and visualised. 
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1.8 Thesis overview and aims 
Research advancement in the ubiquitin field has developed rapidly since its inception. 
Having its major role protein degradation extensively explored, the current interest is now 
focused on elucidating the non-degradative functions covering every cellular process 
governed by ubiquitination. The expansion of ubiquitin research has also revealed the non-
classical partnership among the ubiquitin enzymes for example the interaction between E2 
and DUB. In this thesis, I aim to investigate and discuss the behaviour of interactions 
between the E2, particularly UBE2D2 and the DUB represent by OTUB1 in the human 
ubiquitination system. In the first results chapter, I will concentrate on a Y2H assay between 
E2 and DUB clones that has been established in our lab. The next chapter will focus on 
validation of the Y2H data by means of biophysical analysis and the discussion of my 
unfortunate attempt to have the structure of OTUB1:E2 complex solved. Following this, the 
third results chapter will discuss on Y2H targeted analysis on selective binding residue 
mutants UBE2D2 and co-localisation experiment in order to get a better understanding about 
the characteristics of the OTUB1:E2 partnership. Finally, in the last chapter, I will put 
emphasis on the discussion of OTUB1:UBE2D2 complex structure which has been solved in 
recent literature and how our Y2H targeted analysis matched this finding. 
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2.1 Introduction 
This project employed a range of experimental methods including: molecular biology, yeast 
two-hybrid, protein biochemistry, biophysical analysis of purified proteins and protein 
complexes, cell biology and bioinformatic analysis of protein interaction networks and 
pathway prediction methods. For ease of presentation, these methods have been divided into 
six general areas: Y2H methods, molecular biology, protein expression methods, biophysical 
procedures, cell biology methods and bioinformatic methods. Experimental procedures are 
depicted in detail in this chapter while explanation about the principle or limitations of 
particular methods or reagents are addressed more comprehensively in succeeding chapters. 
 
2.2 Preparation of clones for Y2H screening 
2.2.1 Reagents 
Human KOD Hot Start DNA Polymerase was obtained from Novagen (distributed by Merck 
Chemicals Ltd., Nottingham, UK). DNA HyperLadder, agarose and BIOTaq DNA 
polymerase were obtained from Bioline (London, UK). Sets of dNTPs (100 mM solutions) 
were obtained from GE Healthcare (Buckhinghamshire, UK). SYBR® Safe DNA gel stain 
was from Invitrogen (Paisley, UK). TBE buffer was obtained from VWR International Ltd 
(Lutterworth, UK). Gel extraction purification kit was from Qiagen (Crawley, UK). Peptone, 
yeast nitrogen base w/o amino acids and glucose were from Formedium (Norfolk, UK). 
Yeast extract and BioAgar were from BioGene (Cambridge, UK). Salmon testes DNA and 
primers were from Invitrogen (Paisley, UK). Polyethylene glycol (PEG), all amino acids and 
other chemicals were from Sigma-Aldrich (Poole, UK) unless otherwise stated. The yeast 
two-hybrid host strain used for bait clones in conventional yeast two-hybrid experiments was 
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PJ69-4A (MATa trp1-901, leu2-3, 112 ura3-52, his3-200 gal4Δ gal80Δ LYS2::GAL1-HIS3 
GAL2-ADE2 met2::GAL7-lacZ), while prey clones were constructed using the 
complementary PJ69-4α strain. Both strains were kindly provided by Phil James, (University 
of Wisconsin, USA). 
 
2.2.2 Proofreading PCR-amplification of protein coding inserts from pDONR223 entry 
clones 
A selected of pDONR223 entry clones containing specific DUB expression clones were 
PCR-amplified using primers flanking with Gateway®- and yeast- sequence to allow in vivo 
gap repair cloning into BamHI linearised pACTBE-B or pGBAE-B vectors as described by 
Markson et al. (2009). Primers were typically designed to be 18-22 bp long with melting 
temperatures (Tm) around 60°C. PCR mastermix was prepared on ice by mixing the PCR 
reaction in sterile 1.5 ml Eppendorf tubes. The mastermix was vortexed at full speed for 2 
second before aliquoting into thin-walled PCR plates or PCR tubes. pDONR223 constructs 
containing ORFs of interest were pipetted separately into each aliquot and PCR cycle was 
performed on thermocycler (Table 2.1). The PCR conditions were occasionally optimised to 
increase product yield by increasing cycle number or adjusting the annealing temperature 
when using different primer combinations. Typically the annealing temperature is about 3-
5°C below the Tm of the primers used. All PCR products were evaluated by agarose gel 
electrophoresis to ascertain correct band size. 
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Table 2.1 Reaction mixture and cycling parameters used for typical KOD Hot 
Start PCR reactions: Components for a single PCR reaction are shown in (A). For multiple 
samples, mastermix was prepared by multiplying the volume (excluding DNA template) 
with total number of reactions. Typical PCR reaction parameters are shown in (B). 
 
(A)  Ingredient Volume Final conc. 
 1 DNA template 1.0 μl 1-5 ng/μl 
 2 Forward primer (10 mM) 0.5 μl 0.5 mM 
 3 Reverse primer (10 mM) 0.5 μl 0.5 mM 
 4 dNTPs (32 mM total) 2.5 μl 0.96 mM 
 5 KOD Hot Start buffer 2.5 μl 1x 
 6 MgSO4 (50 mM) 1.5 μl 2.5 mM 
 7 KOD Hot Start DNA pol. 0.5 μl - 
 8 dH2O 15.0 μl - 
  Total 24.0 μl - 
 
(B) Segment Cycles Temperatures Duration 
 1 1 94°C 2 min 
  
2 
 
 
30 
 
94°C 30 s 
 60°C 30 s 
 70°C 1 min 
 3 1 70°C 5 min 
 
 
2.2.3 Agarose gel electrophoresis 
0.8% to 1.2% (w/v) agarose gels were prepared by adding appropriate amount of agarose 
into 0.5x TBE buffer before heating in a microwave until completely dissolved. Gel mixtures 
were allowed to cool before adding 5 μl of SYBR® Safe DNA gel stain to per 100 ml agar. 
Gels were then left to set at RT before being submerged in 0.5x TBE buffer in an 
electrophoresis tank (BioLine, UK). 5 μl of PCR product were mixed with 2 μl Orange G 
(5% (w/v) sucrose, 0.05% (w/v) orange G) sample buffer before loading into each well. 5 μl 
of HyperLadder marker was loaded into the first lane on each gel and electrophoresis was 
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performed at 100 V for 30 minutes to 1 hour to resolve PCR products before visualising 
DNA bands on an ultraviolet light (UV) source. 
 
2.2.4 Purification of PCR products by gel extraction 
DNA fragments were excised from agarose gels using a clean scalpel and the gel slices were 
trimmed to minimise gel volume before being transferred into 1.5 ml Eppendorf tubes. After 
weighing, three volume of QG neutralisation buffer (5.5 M guanidine thiocyanate, 20 mM 
Tris-HCl pH 6.6) was added to one volume of gel (100 mg≈100 μl) and gel slices were 
dissolved by heating at 50°C for 10 minutes. Tubes were vortexed every 2-3 minutes during 
the incubation period in order to speed up gel solubilisation. The resulting sample was then 
loaded onto a spin column with a 2 ml collection tube before being centrifuged for 1 minute 
to bind the DNA and remove excess buffer. The column was washed twice with 750 μl of PE 
wash buffer (20 mM NaCl, 2 mM Tris-HCl pH 7.5, 80% (v/v) ethanol) to remove excess 
salt. 50 μl of dH2O was added to elute bound DNA by spinning for 1 minute at 13 500 rpm 
in a bench top centrifuge. Purified PCR products were either used directly for yeast 
transformation or stored at -20°C for future use. 
 
2.2.5 Yeast media preparation 
Media required for yeast transformation and Y2H screening protocols were prepared in-
house from individual components. The list below provides a brief description of  the 
constituents of all types of media used in these studies: 
 
Table 2.2 List of Y2H medium and their uses. 
 Name Description Used for: 
1 YPAD 
Nutrient rich Yeast Extract-
Peptone-Adenine-Dextrose 
Routine growth of yeast strains and 
mating of haploid bait and prey clones 
2 SD-W 
Synthetic Defined medium, 
deficient in tryptophan 
Bait (pGBAE-B) selection and growth 
3 SD-U Deficient in uracil 
Bait (pGBDU-GW) selection and 
growth 
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4 SD-L Deficient in leucine Prey pACTBE-B selection and growth 
5 
SD-W, low 
adenine 
Deficient in tryptophan, 
insufficient amount of 
adenine hemisulphate 
Selection and growth of  Mat-a (bait) 
clones 
6 
SD-L, low 
adenine 
Deficient in leucine, 
insufficient amount of 
adenine hemisulphate 
Selection and growth of  Mat- (prey) 
clones 
7 
SD-WH 
(3-AT) 
Deficient in tryptophan and 
histidine, supplemented with 
3-aminotriazole (3-AT) 
Testing for HIS3 autoactivation when 
using pGBAE-B (bait) constructs 
8 
SD-LH 
(3-AT) 
Deficient in leucine and 
histidine, supplemented with 
3-AT 
Testing for HIS3 autoactivation when 
using pACTBE-B (prey) constructs 
9 SD-WA 
Deficient in tryptophan and 
adenine 
Testing for ADE2 autoactivation in 
bait pGBAE-B construct 
10 SD-LA 
Deficient in leucine and 
adenine 
Testing for ADE2 autoactivation when 
using pACTBE-B prey constructs 
11 SD-WL 
Deficient in tryptophan and 
leucine 
Select of diploid clones containing 
pGBAE-B (bait) and pACTBE-B 
(prey) constructs  
12 SD-UL Deficient in uracil and leucine 
Select of diploid clones containing 
pGBDU-GW (bait) and pACTBE-B 
(prey) constructs  
13 
SD-WLH 
(3-AT) 
Deficient in tryptophan, 
leucine and histidine, 
supplemented with 3-AT 
Less stringent triple selection media, 
used to select positive interactions 
between pGBAE-B (bait) and 
pACTBE-B (prey) clones 
14 SD-WLA 
Deficient in tryptophan, 
leucine and adenine 
More stringent triple selection media, 
used to select positive interaction 
between pGBAE-B (bait) and 
pACTBE-B (prey) clones 
15 
SD-ULH 
(3-AT) 
Deficient in uracil, leucine 
and histidine, supplemented 
with 3-AT 
Less stringent triple selection, used to 
select positive interaction between 
pGBDU-GW (bait) and pACTBE-B 
(prey) clones 
16 SD-ULA 
Deficient in uracil, leucine 
and adenine 
More stringent triple selection, used to 
select positive interaction between 
pGBDU-GW (bait) and pACTBE-B 
(prey) clones 
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Table 2.3 Recipes for basic yeast media: (A) YPAD and (B) SD-X, all media were 
made up with 500 ml dH2O and autoclaved. Media were allowed to cool before pouring into 
50 or 90 mm petri dishes which were left at room temperature to set. 
(A) YPAD (B) SD-X 
10 g D-glucose 10 g D-glucose 
10 g Peptone 3.35 g Yeast Nitrogen Base 
5 g Yeast extract Appropriate amount of amino acid 
mix (Table 2.4A and 2.4B) 0.1 g Adenine hemisulphate 
10 g BioAgar (for solid medium) 10 g BioAgar (for solid medium) 
 
Table 2.4 SD-X amino acids supplement mixes: (A) Media for yeast transformation 
and autoactivation test. (B) Media for double and triple selection on Y2H screening. 
A/H/L/W/U DO is listed in Table 2.5. 
(A)  SD-X mix (Grams/10 L) 
  -W -W* -U -L -L* -WA -WH -LA -LH 
 Adenine 0.6 0.06 0.6 0.6 0.06 - 0.6 - 0.6 
 Histidine 0.2 0.2 0.2 0.2 0.2 0.2 - 0.2 - 
 Leucine 1.0 1.0 1.0 - - 1.0 1.0 - - 
 Uracil 0.2 0.2 - 0.2 0.2 0.2 0.2 0.2 0.2 
 Tryptophan - - ** ** ** - - ** ** 
 A/H/L/W/U DO 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 5.3 
 Total g/L 0.73 0.73 0.71 0.63 0.63 0.67 0.71 0.57 0.61 
*Low adenine media for selecting positive transformants. 
**20 mg/l filter-sterilised Trp was added after autoclaving the media to avoid Trp 
degradation by high heat.  
 
(B)  SD-X mix (Grams/10 L) 
  -WL -UL -WLA -WLH -ULA -ULH 
 Adenine 0.6 0.6 - 0.6 - 0.6 
 Histidine 0.2 0.2 0.2 - 0.2 - 
 Leucine - - - - - - 
 Uracil 0.2 - 0.2 0.2 - - 
 Tryptophan - ** - - ** ** 
 A/H/L/W/U DO 5.3 5.3 5.3 5.3 5.3 5.3 
 Total g/L 0.63 0.61 0.57 0.61 0.55 0.59 
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Table 2.5 Dropout (DO) amino acid mixture: DO mix was added to all SD-X media 
with the appropriate amino acids as stated above (Table 2.4A and 2.4B). 
A/H/L/W/U DO 
Amino acid Grams/100 L 
Arginine 2 g 
Isoleucine 3 g 
Lysine 3 g 
Methionine 2 g 
Phenylalanine 5 g 
Threonine 20 g 
Tyrosine 3 g 
Valine 15 g 
Total (g/L) 0.53 
 
 
2.2.6 Yeast transformation / gap repair 
2 ml of YPAD broth was inoculated with fresh Mat-a or Mat-α yeast and grown overnight in 
a shaking incubator at 30°C, 220 rpm. An additional 8 ml of YPAD was added next morning 
and the cells were incubated for a further 5 hours at 30°C, 220 rpm. Cells were then 
harvested by centrifugation at 2 300 rpm for 5 minutes in a bench top centrifuge and the 
supernatant was discarded. Cell pellets were resuspended in 5 ml 100 mM LiOAc and 1.5 ml 
of each was transferred to a 1.5 ml Eppendorf tube. Cells were again harvested by 
centrifugation at 2 300 rpm for 5 minutes before being resuspended in 320 μl transformation 
mixture containing 230 μl 50% (w/v) PEG 3350, 35 μl 1 M LiOAc, 45 μl dH2O, 9 μl of 10.5 
mg/ml denatured salmon testes DNA and 20 ng/μl BamHI-linearised yeast vector. The 
mixture was vortexed and transferred into 10 individual PCR tubes (32 μl per tube) and 4 μl 
of purified target DNA was added to each tube before mixing. Samples were then incubated 
in a thermal cycler at 30ºC for 30 minutes, 42ºC for 25 minutes and 30ºC for 1 minute. 
Transformation reactions were then plated onto appropriate SD-X selection medium (see 
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Table 2.2) containing low adenine before being incubated for three to five days at 30°C to 
allow the growth of red and white colonies (Semple et al., 2005). 
 
2.2.7 Diagnostic yeast colony PCR (YC-PCR) 
Red colonies indicating positive gap repaired reactions were picked for analysis by YC-PCR 
in order to confirm correct insert size. For each reaction, 30 μl dH2O and 3 μl 0.02 M NaOH 
were prepared in separate PCR tubes/wells. PCR mastermix was set up on ice and mixed by 
vortexing at full speed for 2 seconds. Red/pink yeast colonies were then picked with sterile 
toothpicks, dipped three times into 30 μl dH2O before being resuspended in 3 μl 0.02 M 
NaOH at RT in order to the lyse yeast cells. After 10-15 minutes, 12 μl of PCR mastermix 
was aliquoted into each tube containing lysed cells, giving a final reaction volume of 15 μl. 
YC-PCR reactions were then cycled in thermocycler as described below in the table 2.6B: 
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Table 2.6 Reaction mixture and cycling parameters for a typical YC-PCR: (A) 
Ingredients for YC-PCR reaction mixture for one sample. (B) The typical cycling parameters 
conditions were occasionally altered to suit with the primers Tm.  
(A)  Ingredient Volume Final conc. 
 1 Forward primer (10 mM) 0.75 μl 0.5 mM 
 2 Reverse primer (10 mM) 0.75 μl 0.5 mM 
 3 dNTPs (32 mM total) 0.45 μl 0.96 mM 
 4 Taq pol. buffer 1.5 μl 1x 
 5 MgCl2 (50 mM) 0.75 μl 2.5 mM 
 6 Taq pol. 0.15 μl - 
 7 DMSO 0.3 μl - 
 8 dH2O 7.35 μl - 
 9 NaOH yeast suspension 3.0 μl - 
  Total 15.0 μl - 
 
(B) Segment Cycles Temperatures Duration 
 1 1 95°C 5 min 
  
2 
 
 
35 
 
95°C 1 min 
 68°C 1 min 
 72°C 3 min 30 s 
 3 1 72°C 5 min 
 
 
2.2.8 Autoactivation assay 
Following verification by YC-PCR, 5 μl of the corresponding inoculated dH2O sample (see 
section 2.2.6) were spotted onto appropriate SD-X plates: single dropout (e.g. SD-L) for 
colony growth and double dropout plates lacking interaction reporter (e.g. SD-LA, SD-
LH(3-AT)) for autoactivation testing. Plates were then incubated at 30°C for up to 14 days. 
Any growth of haploid yeast on double dropout plates is indicative of autoactivation, hence 
these clones were discarded from further Y2H experiments. Non-autoactivating clones were 
maintained on appropriate media and archived as glycerol stock for future use. 
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2.2.9 Glycerol stocks 
Fresh colonies were picked and inoculated into 200 µl SD-X broth medium in a 1.5 ml 
Eppendorf tube. They were grown with shaking at 30°C, 220 rpm for 24 hours before adding 
80 µl of 80% (v/v) autoclaved glycerol to each culture, which was then thoroughly mixed 
before storing at -80°C. 
 
2.2.10 Y2H matrix mating 
Yeast clones from glycerol stocks were spotted onto appropriate SD-X agar and allowed to 
grow for three days at 30°C. Alternatively yeast colonies were picked from fresh single 
dropout autoactivation plates. After three days (or directly after autoactivation test), healthy 
yeast colonies were picked using sterile toothpicks and resuspended in 200 μl dH2O (until 
dH2O turned cloudy, similar opacity in every experiment assessed by eyes) in 1.5 ml 
Eppendorf tube. 2 μl was then spotted onto a YPAD plate in a 8x12 grid format (96 x 2 μl = 
192 μl, hence 200 μl suspension needed for each prey clones). The step is repeated for every 
Mat-α (prey) or Mat-a (bait) clone using a different YPAD plate. In the meantime, each 
transfected Mat-a bait yeast colonies were resuspended in X μl of dH2O in 96-well Y2H 
mating plate to similar opacity so each well representing different bait clones. 2 μl from each 
96 well were transferred on YPAD on top of the prey spots plate using multichannel pipette. 
(X = 2 μl x total amount of YPAD plates with prey spots x 2; for example if there were 10 
YPAD plates, X wil be 2 μl x 10 x 2 = 40 μl). All the YPAD plates were allowed to dry at 
RT before being incubated at 30°C for 24 hours. On the following day, yeast grown on the 
YPAD plates were replica-plated onto double selection SD-X plates using a sterilised velvet 
cloth in order to select for diploid cells. Double selection plates were incubated at 30°C for 
another two days and then transferred by velvet replication onto triple selection SD-X plates 
to select growth reporter activators. Yeast colonies were allowed to grow on triple selection 
SD-X plates at 30°C for 7-10 days before growth was scored as will be discussed 
comprehensively in Chapter 3. 
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2.3 Molecular biology 
2.3.1 Reagents 
α-select silver efficiency cells (F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk
-
, 
mk
+
) supE44 thi-1 phoA Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ-) were from BioLine 
(London, UK). Gateway® BP and LR Reaction Kits, Champion™ pET151 Directional 
TOPO® Expression Kit and DH5α subcloning efficiency (F- endA1 recA1  relA1 gyrA96 
hsdR17(rk
-
,mk
+
) supE44 thi-1 phoA Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ-) were from 
Invitrogen (Paisley, UK). Antarctic phosphatase, all restriction endonucleases and T4 DNA 
ligase were obtained from New England Biolabs (Hertfordshire, UK). QuikChange® II Site-
Directed Mutagenesis Kits were from Agilent Technologies (Berkshire, UK). Miniprep kits 
were from Promega (Southampton, UK). Midi and maxiprep purification kits were from 
Qiagen (Crawley, UK). Tryptone was from Fisher (Loughborough, UK). Primers were 
purchased from either Invitrogen (Paisley, UK) or Sigma Aldrich (Poole, UK) and all 
chemicals were obtained from Sigma-Aldrich (Poole, UK) unless otherwise stated. 
 
2.3.2 Cloning 
2.3.2.1 Gateway® LR reaction to generate expression vector 
LR reactions were performed to transfer E2 and OTUB1 ORFs and mutant constructs from 
pDONR207 and pDONR223 entry vectors into required destination vectors including pc-
Myc, pDEST27, pEGFP-N2 and pG-cherry-mGR. For each reaction, approximately 200 ng 
of entry clone and destination vector were combined with 2 µl of LR clonase, 2 µl of clonase 
buffer and dH2O to bring the total volume to 10 µl. The LR reaction mixture was then briefly 
centrifuged and incubated at 25°C for 16 hours. On the following day, 0.5 µl of proteinase K 
was added to the reaction mixture before incubating at 37°C for 10 minutes. 2 µl of the 
reaction mix was then used transform chemically competent α-select cells.  
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2.3.2.2 Conventional cloning into the pETM-11vector 
2.3.2.2.1Target DNA amplification and restriction digest 
ORFs of interests were cloned into the pETM-11 expression vector in order to generate His-
tag proteins in bacterial cells. The selected E2s and OTUB1 ORFs were amplified by KOD 
PCR from sequence-verified pDONR207 or pDONR223 entry clones using gene-specific 
primers containing NcoI/HindIII restriction sites. 5 µl of PCR products were analysed by 
agarose gel electrophoresis and the DNA bands with the correct size were purified by PCR 
purification kit. Meanwhile, the initial aliquot of His-tag vector pETM-11 (kindly provided 
by Paul Elliott, University of Liverpool) was transformed and amplified in α-select 
chemically competent cells and purified by maxiprep. Purified PCR products (‘inserts’) and 
the pETM-11 vector were both  double digested with 2 µl NcoI and 2 µl HindIII in 1x 
NEBuffer 2 with 1x BSA at 37°C for 10 hours. The linearised vector were then treated with 
2 µl antarctic phosphatase and 1x antarctic phosphatase reaction buffer for 45 minutes at 
37°C to remove phosphate groups from DNA overhangs and prevent vector reannealing 
without an insert. Finally the reactions were heated at 65°C for 20 minutes to inactivate the 
restriction enzymes. 
 
2.3.2.2.2Ligations of double digested DNA inserts and pETM-11 
Double digested inserts and vectors were mixed in 1.5 ml Eppendorf tubes with a molar ratio 
of insert to vector of 0.5:1 in 1x ligase buffer containing 0.5 μl T4 DNA ligase. They were 
then incubated in a thermocycler for 16 hours at 25°C followed by heat inactivation at 65°C 
for 10 minutes. After incubation, approximately 1-5 μl ligation product were transformed 
into 25 µl of α-select chemically competent cells. The insert:vector ratio (and to some extent 
the DNA ligase concentration) were sometimes adjusted to 2:1 to increase the number of 
positive colonies as the ligation reaction for some ORFs proved to be problematic.  
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2.3.2.3 Directional TOPO® cloning 
TOPO® cloning was performed as an alternative method to conventional pETM-11 cloning. 
Targeted ORFs were amplified by proofreading KOD PCR from pDONR entry vectors with 
forward primers flanked with an over-hanging CACC sequence at the 5’ end. PCR products 
were resolved by agarose gel electrophoresis and correct sized DNA products were purified 
by gel extraction method. Approximately 5 ng of purified PCR products were then incubated 
with 1 µl of salt (1.2 M NaCl, 0.06 M MgCl2), 1 µl 15 ng/µl pET151/D TOPO® vector (both 
provided in the TOPO® kit) and dH2O was added to make the total volume up to 6 µl. Tubes 
were then mixed gently and incubated at 25°C for 15 minutes before transferring 3 µl of the 
reaction mix into 50 µl of ready to use OneShot® TOP10 chemically competent cells (F
-
mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 
galU galKrpsL (StrR) endA1 nupG). 
 
2.3.3 QuikChange® site-directed mutagenesis 
PCR reactions were set up using pDONR207 entry clones containing the sequence-verified 
UBE2D2 ORF and two complementary primers designed to include the required base 
substitutions in the centre of each primer. Following thermal cycling (see Table 2.7), 
reactions were transferred into 1.5 ml Eppendorf tube and 1 μl DpnI was added to the 
reactions before incubating at 37°C for 1 hour. Immediately after 1 hour, 2 μl of the DpnI-
digested reaction were transformed into 45 μl XL-10-Gold Ultracompetent cells (Tetr 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F´ proAB lacI
q
ZDM15 Tn10(Tet
r
) Amy Cam
r
) containing 2 μl β-mercaptoethanol.  
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Table 2.7 Typical QuikChange® mutagenesis reaction setup: (A) Reactions 
indicated in the table were set up on ice. Negative controls were set up without polymerase 
to control for incomplete digestion of the template DNA by DpnI. (B) Reactions were cycled 
as indicated. Cycling parameters were occasionally altered to suit primers Tm values. 
(A)  Ingredient Volume Final conc. 
 1 DNA template x 50 ng 
 2 Forward primer (10 mM) 2.5 μl 0.5 mM 
 3 Reverse primer (10 mM) 2.5 μl 0.5 mM 
 4 dNTPs (32 mM total) 1.0 μl 0.96 mM 
 6 Pfu Ultra buffer 5.0 μl 1x 
 7 Pfu Ultra DNA pol. 1.0 μl - 
 8 dH2O (38-x) μl - 
  Total 50 μl - 
 
(B) Segment Cycles Temperatures Duration 
  
1 
 
1 
 
95°C 30 s 
 95°C 30 s 
 50°C 1 min 
 2 15 68°C 2 min per kb 
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2.3.4 Transformation of cloning reactions into chemically competent cells  
Products from mutagenesis reactions were mixed with appropriate chemically competent 
cells by gentle pipetting. Cells were then incubated on ice for 30 minutes before heat-
shocking at 42°C for 45 seconds and subsequent incubation on ice for 2 minutes. 250 µl of 
SOC (2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 8.56 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2 and 20 mM glucose) media was added to the transformation reaction before 
incubating the tubes horizontally at 37°C, 220 rpm for 1 hour. After incubation, 200-250 µl 
of the mixture was plated onto 2xTY* agar plates containing the appropriate antibiotic as 
stated in Table 2.8. Plates were then incubated at 37°C for 16 hours to allow colony growth.  
* 2xTY recipe: 16 g tryptone, 10 g yeast extract, 5 g NaCl made up with 1 L dH2O and 
autoclaved. Media were allowed to cool before adding antibiotic. 
 
Table 2.8 Description of bacterial plasmid and E. coli strains: When plasmids were 
transformed into E. coli strains carrying their own antibiotic selection, both antibiotics were 
included in 2xTY agar plates. 
 Plasmid name Selection Conc. Description 
1 pDONR207 Gentamicin 10 µg/ml Entry vector 
2 pDONR223 Spectinomycin 50 µg/ml Entry vector 
3 pEGFP-N2 Kanamycin 50 µg/ml N-terminal GFP-tag  
4 pG-cherry-mGR Kanamycin 50 µg/ml mCherry-tag vector 
5 pETM-11 Kanamycin 50 µg/ml His-tag vector 
6 pET151/D TOPO® Ampicillin 100 µg/ml His-tag vector 
 Bacterial strain Selection Conc. Description 
1 α-select cells -  Routine propagation 
2 OneShot® TOP10 - 
 High-copy plasmid 
propagation 
3 
XL-10-Gold 
Ultracompetent cells 
Chloramphenicol 25 µg/ml 
For extremely demanding 
cloning 
4 OneShot® ccdB -  ccdB vector propagation 
5 BL21 Star™ (DE3) -  Expression host 
6 Rosetta™  Chloramphenicol 25 µg/ml Expression host 
7 B834 cells -  Expression host 
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2.3.5 Diagnostic bacterial colony PCR (BC-PCR) 
BC-PCR was performed using vector-specific primers on colonies from the transformation 
plates to confirm the presence of required inserts. A mastermix (Table 2.9) was prepared and 
briefly vortexed. Then, two sets of PCR plates/tubes were prepared; one with 20 µl of dH2O 
and the other with 10 µl of PCR mastermix. Selected colonies on the transformation plates 
were picked with sterile toothpicks and dipped into 10 µl of PCR mastermix and then 
resuspended in 20 µl of dH2O. Reactions were then cycled in a thermocycler as described  in 
the Table 2.9B. PCR products were then run on a 1% (w/v) agarose gel for size verification.  
 
Table 2.9 Reaction mixture and cycling parameters for BC-PCR: Reagents listed 
(A) were set up on ice and PCR reactions were cycled as indicated (B). Cycling parameters 
conditions were occasionally altered to suit primer Tm values. 
(A) 
 Ingredient 
Volume (per 
sample) 
Final conc. 
 1 Forward primer (10 mM) 0.7 μl 0.7 mM 
 2 Reverse primer (10 mM) 0.7 μl 0.7 mM 
 3 dNTPs (32 mM total) 0.25 μl 0.8 mM 
 4 10 x Taq pol. Buffer 1 μl 1x 
 5 MgCl2 (50 mM) 0.4 μl 2 mM 
 6 Taq pol. 0.05 μl - 
 7 dH2O 6.9 μl - 
  Total 10 μl - 
 
(B) Segment Cycles Temperatures Duration 
 1 1 95°C 5 min 
  
2 
 
35 
 
95°C 1 min 
 55°C 1 min 
 72°C 1 min per kb 
 3 1 72°C 5 min 
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2.3.6 DNA amplification, purification and glycerol stocks 
Following size verification, inoculated dH2O solutions corresponding to the correct DNA 
band size were transferred into 10 ml 2xTY broth containing the appropriate antibiotic and 
incubated at 37°C, 200 rpm for 16 hours. After incubation, 200 µl of the cultures were 
aliquoted into 1.5 ml Eppendorf tubes and 80 µl of 80% (v/v) glycerol were added to make a 
glycerol stock which was then stored at -80°C for future used. Meanwhile, the rest of the 
culture were spun at top speed in a bench top microfuge for 20 minutes at 4°C, the 
supernatant discarded and the pellet was used for plasmid isolation by mini-, midi- or 
maxiprep kits. 
 
2.3.6.1 Miniprep 
250 µl of cell resuspension solution (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 100 µg/ml 
RNase A) was added to the cell pellet and mixed by vortexing. The suspension was then 
transferred to a sterile 1.5 ml Eppendorf tube and 250 µl of cell lysis solution (0.2 M NaOH, 
1% SDS) was added. Tubes were incubated at RT for 5 minutes. 10 µl of alkaline protease 
solution was added to the suspension and they were then incubated for another 5 minutes. 
Upon addition of 350 µl of neutralisation solution (1.32 M potassium acetate pH 4.8), the 
reaction was spun at 13 500 rpm for 10 minutes at 20°C. The pellet was discarded and lysate 
was transferred into a spin column attached with a 2 ml collection tube. They were 
centrifuged for 1 minute to bind the DNA to the spin column membrane before washing 
twice with 750 µl of column wash solution (80 mM potassium acetate, 8.3 mM Tris-HCl pH 
7.5, 40 µM EDTA) containing ethanol. Finally 50 µl of nuclease free water was added and 
the DNA was eluted by centrifugation at 13 500 rpm for 5 minutes. 
 
2.3.6.2 Midi- and maxiprep 
Plasmid isolation was performed in a large scale for low copy plasmids or when high 
concentrations of cleaner plasmid were required. To perform midi- or maxiprep, larger 
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culture volume was required. 25-100 ml culture should be sufficient for midiprep while for 
maxiprep, around 100-500 ml culture was required. To prepare the large-scale culture, starter 
culture was prepared by picking a single colony on 2xTY agar (freshly streaked from 
glycerol stock) or from the inoculated dH2O (from BC-PCR section 2.3.5) into 2.0 ml 2xTY 
containing appropriate antibiotic and grown at 37°C, 200 rpm for 5-8 hours. 25 µl from the 
starter culture were diluted into 25 ml fresh 2xTY with antibiotic and incubated for a further 
12-16 hours (overnight) at 37°C, 220 rpm. For maxiprep, up to 500 ml fresh culture could be 
inoculated from a 500 µl starter culture.  
On the following day, the overnight cultures were centrifuged at 4 300 rpm for 20 minutes at 
4°C, the supernatant discarded and pellet was resuspended with 4 ml buffer P1 (50 mM Tris-
Cl  8.0, 10 mM EDTA, 100 µg/ml RNase A). 4 ml of buffer P2 (200 mM NaOH, 1% SDS) 
was then added and gently mixed to lyse the cells and were left at RT for 5 minutes before 4 
ml of chilled buffer P3 (3 M potassium acetate pH 5.5) was added. If doing maxiprep, 10 ml 
of buffer P1, P2 and P3 were used instead of 4 ml. The suspension were mixed gently before 
poured into QIAfilter cartridges and incubated for further 10 minutes. Meanwhile, QIAGEN-
tips (midiprep: QIAGEN-tip 100, maxiprep: QIAGEN-tip 500) were equilibrated with 4 ml 
(10 ml if doing maxiprep) of buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) 
isopropanol, 0.15% (v/v) Triton® X-100). After 10 minutes incubation, the lysed suspension 
in QIAfilter cartridges were injected into the equilibrated QIAGEN-tips to bind the DNA to 
the tips’ resin while the buffer passed through the resin by gravity flow. QIAGEN-tips were 
then washed twice with 10 ml (30 ml if doing maxiprep) buffer QC (1 M NaCl, 50 mM 
MOPS pH 7.0, 15% (v/v) isopropanol) and DNA was eluted in 50 ml Falcon tubes with 5 ml 
(15 ml if doing maxiprep) buffer QF (1.25 M NaCl, 50 mM Tris-Cl pH 8.5, 15% (v/v) 
isopropanol). The eluted DNA was precipitated with 3.5 ml isopropanol (10.5 ml if doing 
maxiprep) and then centrifuged at 4°C, 4 300 rpm for 1 hour. The supernatant was carefully 
decanted and the pellet was washed with 2 ml 70% (v/v) ethanol (5 ml if doing maxiprep) 
before spun at 4°C, 13 500 rpm for 30 minutes. After discarding the ethanol, the pellet was 
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left to air-dry and finally resuspended in 100 µl dH2O. The DNA was transferred to a new 
1.5 ml Eppendorf tube and quantified with UV spectrophotometer at 260 nm. PCR (Table 
2.10) and agarose gel electrophoresis can be performed to confirm correct product size 
before sending them for sequencing. 
 
Table 2.10 Reaction mixture and cycling parameters for mini-, midi- or maxiprep-
PCR: Reagents were set up in thin-walled PCR tubes on ice as indicated in  (A) and were 
cycled as in (B). Cycling conditions were altered to suit primers Tm. 
(A)  Ingredient Volume Final conc. 
 1 
Mini-/midi-/maxiprep DNA 
(diluted to 10 ng/μl) 
0.4 μl 40 pg/μl 
 2 Forward primer (10 mM) 0.7 μl 0.7 mM 
 3 Reverse primer (10 mM) 0.7 μl 0.7 mM 
 4 dNTPs (32 mM total) 0.25 μl 0.8 mM 
 5 10 x Taq pol. buffer 1 μl 1x 
 6 MgCl2 (50 mM) 0.4 μl 2 mM 
 7 BIOTaq pol. 0.05 μl - 
 8 dH2O 6.5 μl - 
  Total 10 μl - 
 
(B) Segment Cycles Temperatures Duration 
 1 1 95°C 5 min 
  
2 
 
 
30 
 
95°C 1 min 
 55°C 1 min 
 72°C 1 min per kb 
 3 1 72°C 3 min 
 
 
2.3.7 Sequencing 
All sequencing of DNA constructs was performed by automated fluorescent DNA 
sequencing by GATC BioTech (London, UK) to ascertain the correct ORF insert. 
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2.4 Protein expression methods 
2.4.1 Reagents 
β-mercaptoethanol, N,N,N’,N’-Tetramethylethylenediamine (TEMED), ammonium 
persulphate (APS) and mammalian protease inhibitor cocktail were from Sigma Aldrich 
(Poole, UK). BenchMark Prestained Protein Ladder was from Invitrogen (Paisley, UK). 
Protogel electrophoresis buffers (ProtoGel® 30% Acrylamide/Bisacrylamide solution 
(37.5:1 w/v ratio), ProtoGel resolving buffer and ProtoGel stacking buffer were from 
GeneFlow (Staffordshire, UK). Glycine and Tris-Base were from Fisher (Loughborough, 
UK). Rosetta™2(DE3)pLysS Single™ Competent Cells (F-ompT hsdSB(rB
-
 mB
-
) gal 
dcm (DE3) pLysSRARE2 (Cam
R
) were from Merck Chemicals Ltd. (Nottingham, UK). 
Isopropyl-β-D-thio-galactopyranoside (IPTG) was from Melford Laboratories Ltd. (Ipswich, 
UK). Ni-NTA agarose was from Qiagen (Crawley, UK). All chromatography columns were 
from GE Healthcare (Buckhinghamshire, UK) and chromatography studies were performed 
using the ÄKTA™ purification platform of GE Healthcare (Buckhinghamshire, UK). 
 
2.4.2 Protein expression and purification 
2.4.2.1 Small-scale expression test 
Rosetta cells were transformed with clones containing genes of interest as in Section 2.3.4. A 
single colony from the transformation plate was picked and incubated in 1.5 ml 2xTY 
containing appropriate antibiotic at 37°C, 200 rpm for 16 hours. On the following day, 500 
μl of the culture was diluted into 10 ml media in 50 ml Falcon tubes and grown until the 
OD600 reached 0.8 at which point the incubator was cooled down to 18°C. 0.2 mM IPTG was 
added to the culture to induce protein expression (uninduced cultures without IPTG were 
also prepared as a negative control). The culture was incubated at 18°C, 200 rpm overnight. 
The next day, bacterial cells were sedimented by centrifugation at 4 300 rpm and 4°C for 15 
minutes and resuspended in 1 ml lysis buffer A (all buffer recipes were listed in Table 2.11). 
After addition of protease inhibitors (10 μl 1.0 M PMSF, 1 μl pepstatin and 1 μl leupeptin), 
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cells were disrupted by incubating the sample with 1 mg/ml lysozyme for 30 minutes. 1 
μg/ml DNase was sometimes added at this stage if lysates were too viscous. Lysates were 
centrifuged at 13 500 rpm for 30 minutes and the supernatant was transferred to a fresh 1.5 
ml Eppendorf. 10 μl of 50% (w/v) slurry Ni-NTA resin was added to the supernatant which 
was gently mixed on ice for 15 minutes. The resin was pelleted by centrifugation at 3 000 
rpm for 1 minute, the supernatant was decanted off and the resin were washed several times 
with lysis buffer A to remove loosely-bound proteins. Finally 1 ml of lysis buffer B was 
added to collect the protein tagged by Ni-NTA resin by centrifuging in the same manner as 
in washing step. Elution was repeated two times and tagged proteins were analysed by 1D 
SDS-PAGE. 
 
2.4.2.2 Large-scale protein production 
Single colonies were picked from transformation plate and grown overnight in 10 ml 2xTY 
with antibiotics at 37°C, 200 rpm. 1 L of 2xTY was then inoculated with the overnight 
cultures and left at 30°C, 200 rpm until the OD600 reached 0.6. Protein expression was 
performed by incubating the culture with 0.2 mM IPTG at 18°C, 200 rpm overnight. Pellet 
was collected by centrifugation at 8 000 rpm, 4°C for 15 minutes before resuspended in lysis 
buffer A and stored at -80°C for at least 2 hours. Cells were then lysed by French press in the 
presence of DNAse and a protease inhibitor cocktail. Soluble and insoluble components were 
separated by centrifugation at 18 000 rpm, 4°C for 30 minutes. The soluble solution was 
loaded directly into the Ni
2+
 affinity column to bind the His-tagged proteins. The His-tag was 
then cleaved by overnight incubation with TEV protease (5 μg protease for 1 mg target 
protein) at RT. To remove the His-tag, uncleaved proteins, TEV protease and other 
contaminants, the sample was again injected to the Ni
2+ 
column in which the His-tag, 
uncleaved proteins and contaminants bound to the column while the tag-free protein eluted. 
This eluted proteins from Ni
2+ 
column were then loaded into ion exchange chromatography 
(IEC) in order to separate the proteins according to their pI hence any contaminants that were 
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not distinguished by Ni
2+ 
column can be removed. IEC eluates were buffer-exchanged into 
storage buffer using PD10 desalting column equilibrated with the storage buffer and 
concentrated to a final concentration of approximately 0.1 mM to 0.5 mM using a vivaspin 
concentrator (MWCO 5 000 kDa). Finally, the concentrated protein was aliquoted into 1.5 
ml Eppendorf tubes (500 μl per tube) before being flash-frozen in liquid nitrogen and stored 
at -80°C 
 
Table 2.11 Buffer recipes: All buffers were made up to 1 L with dH2O before being 
filter-sterilised and degassed prior to use.  
 Buffer Ingredients pH 
1 Lysis buffer A 
20 mM Na2HPO4, 500 mM NaCl, 25 mM 
imidazole 
7.4 
2 Lysis buffer B 
20 mM Na2HPO4, 500 mM NaCl, 500 mM 
imidazole 
7.4 
3 Q buffer A 20 mM Tris-base, 20 mM NaCl, 2 mM DTT 8.0 
4 Q buffer B 20 mM Tris-base, 1 M NaCl, 2 mM DTT 8.0 
5 SP buffer A 20 mM MES, 10 mM NaCl, 2 mM DTT 6.5 
6 SP buffer B 20 mM MES, 1 M NaCl, 2 mM DTT 6.5 
7 
NMR buffer 
(storage buffer) 
20 mM Tris-base, 50 mM NaCl, 2 mM DTT 7.4 
8 
Gel filtration 
buffer 
20 mM Tris-base, 150 mM NaCl, 2mM DTT 7.4 
9 ITC buffer 
20 mM Tris-base, 20 mM NaCl, 1 mM TCEP, 
0.02% (w/v) NaN3 
7.4 
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2.4.2.3 (
1
H
15
N) labelled protein expression 
Overexpression of (
1
H
15
N) labelled protein was accomplished by growing a single colony 
from Rosetta transformants for 6-8 hours in 500 μl 2xTY with appropriate antibiotics at 
37°C, 200 rpm. 10 ml 2M9 minimal media (Table 2.12) was then inoculated with 100 µl of 
2xTY preculture and grown overnight at 37°C, 200 rpm. Overnight cultures were then 
transferred into 1 L of 2M9 minimal media and incubated at 30°C, 200 rpm until the OD600 = 
0.6 at which stage proteins were expressed and purified using the same protocol as described 
for unlabelled proteins. 
 
2.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel plates from the Mini-Protean® electrophoresis system (Bio-Rad) were assembled. 
Resolving gel (see Table 2.13 for acrylamide concentration) were prepared and a 4% (w/v) 
acrylamide stacking gel was added once the resolving gel was polymerised. The gel was then 
submerged in 1x electrophoresis running buffer (50 mM Tris-HCl, 0.1% (w/v) SDS and 380 
mM glycine). Meanwhile, protein sample were diluted in 1x sample buffer (0.04 mM Tris 
pH 6.8, 2% (w/v) SDS, 5% (v/v) glycerol, 2 mM β-mercaptoethanol, 0.01% (w/v) 
bromophenol blue) and heated at 95°C in a heat block for 5 minutes to denature the protein. 
Using a Hamilton syringe, proteins were loaded into wells and run at 200 V for 38 minutes 
alongside a protein molecular weight ladder. Gels were then removed and soaked in the 
Coomassie-Blue stain (50% (v/v) methanol, 7% (v/v) acetic acid, 0.1% (w/v) Coomasie Blue 
R250) on a rocker for at least 1 hour at RT. The dye was removed using de-stain solvent (5% 
(v/v) methanol, 85% (v/v) dH2O, 10% (v/v) acetic acid) to visualise and evaluate the protein 
band. 
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Table 2.12 Recipe for 2M9 minimal media: Solution A was made up with 975 ml 
dH2O, adjusted to pH 7.2-7.4 and autoclaved. It was allowed to cool before addition of 
Solution B. Meanwhile, Solution B was made up in 25 ml dH2O, filter-sterilised and added 
to autoclaved Solution A to make up 1 L 2M9 media. 
2M9 minimal media 
Ingredients Amount per L 
A 
Na2HPO4 14.6 g 
KH2PO4 5.4 g 
15
NH4Cl 1.0 g 
B 
Glucose 4.0 g 
Thiamine hydrochloride 20 mg 
5 g/L MnSO4 0.5 ml 
37.5 g/L CaCl2 0.5 ml 
1 g/L FeCl2 0.5 ml 
 
 
Table 2.13 Recipe for SDS-PAGE resolving and stacking gel: Table shows the 
differing acrylamide concentration used for resolving gels depending on the expected band 
sizes and the fixed 4% (w/v) acrylamide for stacking gels. 
Reagent  
Resolving gel (ml) 
8% 10% 12% 
Protogel acrylamide solution 2.67 3.33 4.0 
Resolving buffer 2.6 2.6 2.6 
dH2O 4.62 3.96 3.29 
TEMED 0.01 0.01 0.01 
10% APS 0.1 0.1 0.1 
Total Volume 10.0 10.0 10.0 
Reagent 
Stacking gel (ml) 
4% 
Protogel acrylamide solution 0.65 
Stacking buffer 1.25 
dH2O 3.05 
TEMED 0.005 
10% APS 0.025 
Total Volume 4.98 
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2.5 Biophysical procedures 
2.5.1 Reagents 
PD10 desalting column was from Amersham (Buckinghamshire, UK). Wizard: Cryo™ and 
Wizard™ Screens I and II were from Emerald BioSystems (Washington, USA), ProPlex™ 
was from Molecular Dimensions (Suffolk, UK), Crystal Screen was from Hampton Research 
(California, USA). ITC system was from MircoCal Inc. (Buckinghamshire, UK). 
 
2.5.2 Gel filtration chromatography 
The protein eluted from the ion exchange column (Section 2.4.2.2) or from -80°C freezer 
was passed through a PD10 column which had been equilibrated with gel filtration buffer 
(Table 2.11). 500 μl of individual proteins were injected onto the gel filtration column 
(Superdex 75 10/300 GL) which was run at 1 ml/min. The step was repeated to the premix of 
both proteins in 1:1 followed by varying ratio to assess complex formation.  
 
2.5.3 Isothermal titration calorimetry 
All proteins were buffer-exchanged into ITC buffer (Table 2.11) using a PD10 column 
which had been equilibrated with ITC buffer and concentrated to 0.1 mM (protein A) and 2.1 
mM (protein B). All protein samples and buffers used in this experiment were degassed for 5 
minutes. ITC cell chamber was washed three times with the degassed buffer before pipetting 
300 μl of 0.1 mM protein A into the chamber. Meanwhile, 80 μl of 2.1 mM protein B (or at 
least ten-fold from the concentration of protein A) was loaded to the syringe. The injection 
of sample from the syringe to the cell was performed at 180s time intervals, 3 μl per injection 
and the cell temperature was set at 25°C. 
 
2.5.4 Nuclear magnetic resonance 
Protein in NMR buffer was diluted or concentrated to 0.1-0.5 mM. The sample was prepared 
for NMR by adding 5% (v/v) D2O to 600 μl of protein sample. Then, the sample was placed 
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in a clean standard NMR tube (5 mm diameter) by a long Pasteur pipette. Care was taken not 
to introduce any air into the NMR tube. All NMR spectra were collected at 25°C using a 
Bruker Avance 600 or 800 MHz solution-state spectrometer. For the chemical shift 
perturbation experiments, (
1
H
15
N)-HSQC 2D spectra were recorded on 
15
N-labelled protein 
alone and titration with different ratios of its unlabelled partners (1:0.25, 1:0.5, 1:0.75, 1:1, 
1:1.5, 1:2). For all (
1
H
15
N)-HSQC spectra, 2 048 points with a spectral width of 8 012 Hz in 
the direct dimension and 512 points with a spectral width of 2 200 Hz in the indirect 
dimension were recorded. The number of scans varied between 16 and 64 during the titration 
and the relaxation delays were set to 1s. All NMR spectra were processed and analysed using 
Bruker TopSpin 3.1.  
 
2.5.5 Crystallisation trial 
Two sets of 500 μl of OTUB1:UBE2D2 complex were prepared in 10 mg/ml and 20 mg/ml 
alongside 10 mg/ml free protein. 80 μl of each condition (Wizard, ProPlex, Crystal and 
Cryo) were pipetted into the reservoir of the MRC 96-well sitting drop vapour diffusion 
crystallisation plate (Molecular Dimensions). 0.5 μl of each protein samples were pipetted 
into drop reservoir followed by 0.5 μl from each condition. Plates were sealed with crystal 
sealing film and incubated at RT and the other set at 4°C for about two weeks. 
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2.6 Cell biology 
2.6.1 Reagents 
All cell culture reagents were obtained from Invitrogen unless otherwise stated. Plasticware 
was obtained from Corning Inc. (New York, USA) and chemicals were from Sigma unless 
otherwise stated. 
 
2.6.2 Cell culture 
HeLa cells were cultured in a humidified 5% (w/v) CO2 atmosphere at 37°C in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) foetal bovine serum, 1% 
(v/v) non-essential amino acids (NEAA), and 1% (v/v) penicillin/streptomycin sulphate. 
Cells were maintained by growing in 75 cm flasks.  Every three to four days when the cells 
reach ~80% confluency, the media was removed and cells were washed with 30°C PBS 
before being trypsinised with 2 ml trypsin for 2 minutes in 37°C (5% (w/v) CO2) incubator. 
Cells were then split into 1:5 to 1:10 dilution into a new flask with fresh DMEM. 
 
2.6.3 Cell transfection and fixation 
80% confluent cells were trypsinised as above and 0.5x10
5
 cells (counted by 
hemocytometer) were seeded onto coverslips in 12-well plate containing 1 ml of DMEM. 
They were incubated at 37°C (5% (w/v) CO2) for 24 hours until cells reached 50%-80% 
confluency. On the next day, 1.5 µl Genejuice was added to 50 µl DMEM media with no 
additional supplements and mixtures were vortexed gently and mixed at RT for 5 minutes 
before adding 0.5 µg of DNA. They were mixed by gentle pipetting and incubated at RT for 
15 minutes before being pipetted into 12-well plates in a drop-wise manner to ensure the 
whole coverslip was covered. They were then mixed by gently rocking at 37°C (5% (w/v) 
CO2) for 24 hours. Optionally, transfection mixture was removed after 4 hours incubation 
and replaced with complete DMEM. On the next day, the DMEM was removed and cells 
were rinsed twice with 1 ml of 30°C PBS before fixing with 300 µl of 4% (v/v) 
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paraformaldehyde. The 12-well plates were then placed on a rocker for 15 minutes to gently 
mix. Coverslips were then rinsed twice with PBS and dH2O and the edges of coverslips were 
blotted. 10 µl of Vectashield® HardSet™ mounting reagent containing DAPI for nuclear 
staining was put onto slides and the coverslips were mounted immediately with the cells 
facing downwards to the Vectashield®. They were left to air-dry for 1 hour before storing in 
the dark at 4°C. Cells were visualised using an Olympus Model IX81 microscope system. 
All images were taken with a Hamamatsu C4742-80 camera. 
 
 2.7 Bioinformatic method 
Four public databases namely the Human Protein Reference Database (HPRD) (Keshava 
Prasad et al., 2009), Molecular Interaction database (MINT) (Chatr-aryamontri et al., 2007), 
IntAct (Aranda et al., 2010) and BioGRID (Breitkreutz et al., 2008) were mined by Russell 
Hyde (University of Liverpool) to provide overlapping yet complementary datasets to detail 
as many literature-reported interactions as possible. The data were integrated to produce 
human ‘interactome’ network containing both binary protein-protein interactions observed 
and more ambiguous protein interactions derived from co-complexes detection techniques. 
To analyse or predict an interaction data, computational filters written by Jonathan 
Woodsmith (University of Liverpool) were utilised. Visualisation of protein-protein 
interaction data were generated using the open source bioinformatics software platform 
Cytoscape. All cytoscape figures were generated using Cytoscape version 2.8.2. 
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3.1 Introduction 
To provide a better understanding of the order and specificity within the human 
ubiquitination process, it is crucial to perform a detailed analysis of protein interaction 
preferences within this system. Previous large-scale Y2H screens performed in our lab 
generated a high-density map of human E2:E3 RING interactions and identified a surprising 
interaction involving a specific subset of E2 proteins (UBE2Ds and UBE2Es) and a 
deubiquitinating enzyme (DUB) called OTUB1 (Figure 3.1A) (Markson et al., 2009). This 
data raised an interesting question as to why OTUB1 should associate with specific E2 
proteins. Classically, DUB proteins are well-known for cleaving or trimming ubiquitin 
chains from the substrates and although DUB proteins had been found to interact with some 
E3-RING proteins, no association with E2-ubiquitin conjugating enzymes had been 
observed. 
During the course of this project, a large-scale systematic mass-spectrometry analysis of 
human DUB proteins was performed in which interactions between OTUB1 and UBE2D2 
and UBE2N proteins were observed (Figure 3.1B) (Sowa et al., 2009). Functional 
investigation of these non-canonical DUB:E2 complexes revealed a role in DNA damage 
response and p53 signalling (Nakada et al., 2010; Sun et al., 2012). Although these reports 
have addressed two functional roles of E2:OTUB1 complexes, little attention was given to 
define the molecular mechanism of E2:OTUB1 interactions. 
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Therefore three key aims of this project were: 
1) To establish if OTUB1 was unique among DUB enzymes in being able to bind E2 
proteins; 
2) To verify that OTUB1 binds E2 proteins via direct binary interactions and finally; 
3) To provide insight into the molecular mechanism or specificity of interactions within 
OTUB1:E2 complexes. 
 
 
 
 
 
         (A)                                                          (B) 
 
Figure 3.1 Known E2:DUB interaction: (A) Library screen shows OTUB1 interacted 
with E2 from D and E subfamilies (Markson et al., 2009). (B) Mass spectrometry analysis 
defined that UBE2D2 and UBE2N are among OTUB1 interactors (Sowa et al., 2009). 
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3.2 Yeast strains and vectors 
The Y2H method has been extensively used to study protein-protein interactions as it can be 
performed in a high-throughput format and is known to be able to detect even transient or 
weak binary protein interactions. In these experiments, PJ69-4A (MATa trp1-901 leu2-3, 112 
ura3-52, his3-200 gal4∆ gal80∆ LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) was 
used as the bait strain and PJ69-4α, a suitable mating partner with identical genotype to 
PJ69-4A was used as the prey strain (James et al., 1996). All Y2H assays performed in this 
study employed a mating strategy to generate diploid yeast containing both bait and prey 
constructs as this procedure has been shown to be more efficient than co-transfection 
protocols which tend to be affected by variability in transfection efficiency (Garcia-Cuellar 
et al., 2009).  
The PJ69-4A contains three promoters: GAL1, GAL2 and GAL7 that are all induced by the 
GAL4 transcription activator (Bram et al., 1986). The three reporter genes controlled by 
these promoters are HIS3 (GAL1), ADE2 (GAL2) and lacZ (GAL7). The HIS3 gene in this 
strain was initially reported to be “leaky” as some growth was observed on media lacking 
histidine (James et al., 1996). Therefore to increase selection stringency, the HIS3 product is 
inactivated by the competitive inhibitor 3-aminotriazole (3-AT). The concentration of this 
competitive inhibitor can be varied to increase screen stringency as required, providing a 
form of ‘tunable rheostat’ that can be used to eliminate non-specific background interactions 
(James et al., 1996) or to order relative strength of interactions between different partners 
(Lehner and Sanderson, 2004). Previous experiments in our laboratory (Lehner et al., 2004; 
Lehner and Sanderson, 2004) has shown that 2.5 mM 3-AT can effectively eliminate false 
positive interactions, so this concentration was used for all further experiments described in 
this study. In contrast, the ADE2 reporter gene is a more stringent reporter than the HIS3 
reporter (James et al., 1996) showing very low background or non-specific interactions. The 
lacZ reporter gene encodes β-galactosidase, an enzyme that cleaves the disaccharide lactose 
into glucose and galactose (Lederberg, 1948). Yeast colonies can be assayed for β-
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galactosidase expression by using a chemical called X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) that is cleaved into galactose and a blue insoluble product. In our 
experience the lacZ reporter in the PJ69-4 strains is less reliable than the two growth 
reporters. As such, in this study we independently monitored growth on -HIS (+3AT) or -
ADE conditions. Although growth on both independent reporters is considered ideal, 
previous studies from the Sanderson lab show that reproducible positive interactions 
observed on -HIS selection alone were sufficient to allow the reliable prediction of 
interactions which are confirmed by subsequent in vitro assays and mutagenesis studies 
(Markson et al., 2009). 
In this study, the pGBAD-B and pACTBD-B vectors were used to construct sets of bait and 
prey E2 clones respectively. For DUB proteins, baits were inserted in pGBDU-GW and 
preys were expressed in the pACTBE-B vector. Meanwhile for generating bait and prey 
ΔN
OTUB1 clones, pGBAE-B and pACTBE-B were used. The pGBAD-B/pACTBD-B 
vectors were designed for cloning DNA sequences that incorporate an in-frame termination 
codon at the end of an ORF while pGBAE-B/pACTBE-B vectors have a one base pair 
insertion at the recombination site separated by the attB flanking regions to allow frame-shift 
and stop codon insertion after homologous recombination (Semple et al., 2005). Unlike 
conventional Y2H vectors which encode either BD or AD domains, the pGBAD-
B/pACTBD-B and pACTBE-B vectors encode both BD and AD domains separated by an in-
frame linker containing the attB1 and attB2 Gateway® recombination sequences flanking a 
BamHI restriction site which are vital in selection of positive transformants following in vivo 
homologous recombination (Figure 3.2). In contrast, pGBDU-GW was generated by 
insertion of a Gateway® Rf-conversion cassette into the pGBDU-C1 vector (James et al., 
1996). This vector contains only the BD domain hence serves as a bait plasmid and attR1 
and attR2 recombination sites downstream the BD domain that make it possible to insert any 
ORF with attL1 and attL2 sites by LR recombination cloning. The principle behind the 
Gateway® cloning system is discussed in detail in Section 3.3.2.1. 
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pACTBD/E-B 
 
 
 
 
 
 
(A) 
 
 
 
(B) 
   
 
 
 
(C) 
 
 
 
 
 
Figure 3.2 Y2H vectors used in this study: (A) pACTBD/E-B prey vectors based on 
pACT2 carrying LEU2 gene to allow selection on media lacking leucine. (B) pGBAD/E-B 
bait vectors based on pGBD-C1 depends on TRP1 as selection marker for colony growth on 
SD-W plate. (C) pGBDU-GW vector based on pGBT9 conferred with URA3 gene to allow 
selection on media lacking uracil. 
  
pGBADB/E-B 
pGBDU-GW 
                                                                        Chapter Three | YEAST TWO-HYBRID SCREENING  
 
Page | 69  
 
3.3 Construction of Y2H bait and prey clones 
3.3.1 Existing constructs 
3.3.1.1 E2 bait and prey 
Y2H binary interactions involving human E2:E3-RING, E3-RING:E3-RING and E3-
RING:DUB  proteins have been systematically conducted in large-scale Y2H studies in our 
lab. Therefore, enormous resources of Y2H constructs were already available at the start of 
this study. Previously, a collection of 39 human E2 clones (Table 3.1) were obtained from 
Mammalian Gene Collection (Collins et al., 2002) or from Matchmaker cDNA libraries 
(Clontech). These ORFs were PCR-amplified with primers designed in accordance with 
RefSeq annotations for the full-length protein-coding region, including the endogenous stop 
codon. Each primer contained forward or reverse flanking sequences to facilitate transfer of 
the PCR products into the Y2H pGBAD-B bait and pACTBD-B prey vectors by in vivo gap 
repair reactions. Positively transfected Mat-a bait and Mat-α prey yeast cells were selected 
for growth on media lacking tryptophan (SD-W) and leucine (SD-L) respectively, as the 
pGBAD-B and pACTBD-B vectors contain the TRP1 and LEU2 gene that allows for growth 
on this medium. From 39 unique human genes encoding E2 proteins, a complete set 
consisted of 44 bait clones (including duplicate UBE2L3, UBE2W, UEVLD and UBE2Z 
clones and a splice variant of UBE2I) were successfully generated, although only 35 prey 
clones (excluding UBE2J2, UBE2Q2, UBE2DNL and TSG101) were available for use in 
this study (Table 3.1).  
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Table 3.1 The ubiquitin conjugating enzyme (E2s): The names and ID of the 39 
human E2 and ubiquitin E2 variant (UEV) proteins involved in this experiment. Some of the 
construct are only available in bait as can be seen by legend: =bait;=prey. 
 GeneID Gene Name Alternate name 
Bait () 
Prey () 
1 7319 UBE2A UBC2; HHR6A; RAD6A  
2 7320 UBE2B HR6B; UBC2; HHR6B; RAD6B; E2-17kDa  
3 11065 UBE2C UBCH10; dJ447F3.2  
4 7321 UBE2D1 SFT; UBCH5; UBC4/5; UBCH5A; E2(17)KB1  
5 7322 UBE2D2 
UBC4; PUBC1; UBC4/5; UBCH5B; 
E2(17)KB2 
 
6 7323 UBE2D3 
UBC4/5; UBCH5C; MGC5416; MGC43926; 
E2(17)KB3 
 
7 51619 UBE2D4 HBUCE1; FLJ32004  
8 7324 UBE2E1 UBCH6  
9 7325 UBE2E2 UBCH8; FLJ25157  
10 10477 UBE2E3 UBCH9; UbcM2  
11 140739 UBE2F NCE2; MGC18120  
12 7326 UBE2G1 UBC7; E217K; UBE2G  
13 7327 UBE2G2 UBC7  
14 7328 UBE2H UBC8; UBCH; UBCH2; E2-20K  
15 7329 UBE2I P18; UBC9; C358B7.1  
16 51465 UBE2J1 
UBC6; Ubc6p; CGI-76; NCUBE1; HSPC153; 
HSPC205; NCUBE-1; HSU93243; MGC12555 
 
17 118424 UBE2J2 NCUBE2; NCUBE-2; PRO2121BAIT  
18 3093 UBE2K 
LIG; HIP2; HYPG; UBC1; E2-25K; 
DKFZp564C1216; DKFZp686J24237 
 
19 7332 UBE2L3 E2-F1; L-UBC; UBCH7; UbcM4  
20 9246 UBE2L6 RIG-B; UBCH8; MGC40331  
21 9040 UBE2M UBC12; hUbc12; UBC-RS2  
22 7334 UBE2N UBC13; MGC8489; UbcH-ben; MGC131857  
23 63893 UBE2O E2-230K; FLJ12878; KIAA1734  
24 55585 UBE2Q1 GTAP; UBE2Q; NICE-5; PRO3094  
25 92912 UBE2Q2 DKFZp762C143  
26 997 UBE2R1 UBC3; UBCH3; CDC34; E2-CDC34 
27 54926 UBE2R2 UBC3B; CDC34B; FLJ20419; MGC10481  
28 27338 UBE2S EPF5; E2EPF; E2-EPF  
29 29089 UBE2T PIG50; HSPC150  
30 148581 UBE2U MGC35130; RP4-636O23.1  
31 7335 UBE2V1 
CIR1; UEV1; CROC1; UBE2V; UEV-1; 
UEV1A; CROC-1 
 
32 7336 UBE2V2 
MMS2; UEV2; EDPF1; UEV-2; DDVIT1; 
EDAF-1; EDPF-1; DDVit-1 
 
33 55284 UBE2W hUBC-16; FLJ11011  
34 65264 UBE2Z USE1; HOYS7; FLJ13855  
35 
10013181
6 
UBE2DNL MGC42638  
36 55293 UEVLD ATTP; UEV3; FLJ11068  
37 64400 AKTIP FT1; FTS  
38 57448 BIRC6 
BRUCE; APOLLON; FLJ13726; FLJ13786; 
KIAA1289 
 
39 7251 TSG101 TSG10; VPS23  
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3.3.1.2 DUB bait 
The DUB bait set was generated in the Sanderson lab by Sebastian Hayes (Hayes, 2009). 
The ORFs were collected from various sources mainly via Human ORFeome v1.1 (Rual et 
al., 2004), IMAGE clones, and from the lab of Mike Clague and Sylvie Urbe (University of 
Liverpool) and cDNA libraries (Clontech). Only the ORFeome cDNA clones were already in 
Gateway® format, while other clones were PCR-amplified using Gateway® primers and put 
through BP reactions to create pDONR223 constructs with attL sites. All the ORFs were 
cloned by LR reaction into pGBDU-GW bait vectors and then transfected into Mat-a bait 
yeast cells. Positive clones were selected by growing the cells on media lacking uracil (SD-
U). From the original list of 92 putative human DUBs, seven were excluded either because 
they were thought to be pseudogenes, or because they contained massively large ORFs with 
incomplete sequence information. Some clones were also eliminated at different stages of 
clone generation, resulting in a final collection of 65 human DUB proteins which were 
successfully cloned into the pGBDU-GW vector. Five were disqualified for Y2H screening 
for being autoactivated in diploid. The final collection of DUB baits tested in this study 
included 69 ORFs representing a total of 60 unique DUBs and nine duplicates including 
additional clones for the USP5, BAP1, USP15, USP20, USP25, USP30, STAMBP and 
STAMBPL1 proteins. These are listed in Table 3.2. 
 
3.3.2 Generation of a new Y2H DUB prey clone set 
3.3.2.1 Application of the Gateway® cloning strategy to create DUBs in pDONR223 
The Gateway® system (Invitrogen) was used to generate clone libraries in our lab because of 
its effective one-step cloning method which facilitates easy shuttling of ORFs from entry 
vectors into a wide range of expression plasmids (illustrated in Figure 3.3) (Landy, 1989; 
Hartley et al., 2000). DUB ORFs were PCR-amplified with primers specifically designed to 
contain the appropriate Gateway® recombination sequences. Forward primers were designed 
to contain 18-25 bases of ORF-specific sequence with an additional 5’ sequence containing 
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the attB1 recombination sequence (ACA AGT TTG TAC AAA AAA GCA GGC T). 
Reverse primers were similarly designed to contain 18-25 bases of ORF-specific sequence 
with a 3’ extension containing the attB2 sequence (AC CAC TTT GTA CAA GAA AGC 
TGG GT). All primers were designed to contain ORF specific start and stop codons. Once a 
PCR product has been generated, it can be incubated in vitro with the pDONR223 donor 
vector containing the attP1 and attP2 sites flanking the ccdB gene and BP clonase mix 
containing the integrase and integration host factor (IHF) proteins. The BP recombination 
reaction results in the ccdB gene getting flipped out of the pDONR223 vector and being 
replaced by the DUB ORF, which is now flanked by the newly recombined attL1 and attL2 
sequences. It is important to note that the attB1 site only recombines with the attP1 site 
(similarly for attB2 and attP2) and therefore the correct 5’ to 3’ orientation is maintained. 
DH5α strain E. coli were transformed with the BP reaction mixture and only pDONR223 
vectors that had successfully undergone recombination were able to grow while pDONR223 
with ccdB gene will not grow. The ccdB protein interferes with the E. coli DNA gyrase 
(Bernard and Couturier, 1992), thereby inhibiting growth of most E. coli strains carrying this 
gene. Positive colonies were selected on spectinomycin selective agar as pDONR223 confers 
resistance to this antibiotic (Rual et al., 2004). 
From these pDONR223 entry clones, ORFs can be shuttled to other expression vectors 
known as destination vectors by a similar recombination reaction. Entry clones (containing 
attL1-ORF-attL2) were incubated with a destination vector (attR1-ccdB-attR2) with a 
different antibiotic selection to the entry vector, and an LR clonase containing Int, IHF and 
bacteriophage excisionase. E. coli were transformed with the reaction mixture and 
transformants were selected for growth on appropriate antibiotic media. Subsequently, the 
product of LR reaction (termed ‘expression clones’) can be used for expression studies in a 
range of biological systems.  
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Figure 3.3 The Gateway® system: (A) ORFs are initially amplified with Gateway® 
primers with 5’ and 3’ overhangs. (B) The amplified ORF now flanked with attB1 and attB2 
sites can be recombined with the attP1 and attP2 sites on a donor vector (pDONR223) to 
produce an entry clone flanked by attL1 and attL2 sites in what is called a BP reaction. (C) 
Generation of Gateway®-compatible destination vector by insertion of Gateway® 
conversion cassette (attR1-ccdB-attR2) into any existing mammalian, yeast or bacterial 
expression vector. (D) Entry clone in LR recombination with destination vectors containing 
the attR1 and attR2 sites. 
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3.3.2.2 PCR introduction of yeast and Gateway® sites to the DUB ORFs 
In order to transfer DUB ORFs into the pACTBE-B prey vector, primers that could amplify 
ORF out of pDONR223 and allow homologous recombination with a linearised yeast 
cloning vector in vivo were designed. Here, blue indicates bases present in the pACTBE-B 
sequence only, red in pDONR223 sequence only and green present in both sequences; 
pDONR GR F2:  5’ GAATTCACAAGTTTGTACAAAAAAGCAGGCATG 3’ 
pDONR GR R1:  5’ GTCGACCACTTTGTACAAGAAAGCTGGG 3’ 
Using this strategy, a total of 47 PCR products were successfully obtained. All of these 
products were cloned into the pACTBE-B vector simultaneously by in vivo gap repair 
cloning in Mat-α cells. 
 
3.3.2.3 In vivo homologous recombination (gap repair) 
DUB prey clones were generated in Mat-α yeast as described above. Transformation/gap 
repair reactions were then plated on SD-L, low adenine media to select positive 
transformants. Vectors containing an insert with an in-frame stop codon grow very weakly 
and accumulate red pigment containing low amounts of adenine. Red colonies were selected 
and yeast colony PCR was performed to confirm the correct ORF size. Even though all 47 
gave a number of red colonies, only 27 ORFs produced a single insert band of the predicted 
size, the rest either produced multiple bands, inaccurate band size or no detectable YC-PCR 
product.   
 
3.3.2.4 Autoactivation tests 
Each Y2H clone generated in this study was tested for autoactivation to avoid false positive 
results when performing Y2H mating. Autoactivators are haploid Mat-α clones containing 
AD-protein fusion that can activate the transcription of reporter genes HIS3, ADE2 and/or 
lacZ without the presence of an interacting bait protein (and vice versa). In principle, the 
reporter genes should only be activated upon mating the two yeast strains and forming 
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diploid cells. To assess whether any of the Y2H prey clones could induce reporter gene 
transcription within haploid Mat-α yeast, individual colonies were grown on SD-L 
(permissive), SD-LH(3-AT) and SD-LA (both non-permissive) agar plates. Haploid yeast 
which grow on SD-LH(3-AT) and/or SD-LA plates must be autoactivating the HIS3 and/or 
ADE2 reporter genes independently, therefore these were excluded from further studies.  
Autoactivation of Y2H-inducible reporter genes is a common artefact of the Y2H system. 
There are three classes of autoactivators: 
1) Genuine transcription factors that contain a bona fide AD and consequently will 
likely score as autoactivators when fused to DB, 
2) Proteins that are not transcription factors in their natural context but can behave 
as autoactivators because they contain a cryptic AD (cognate autoactivators), 
and 
3) Non-transcription factor proteins that contain one or more cryptic ADs that are 
only functional as truncated fragments and not when expressed in the context of 
full-length proteins (de novo autoactivators). 
In this experiment, four independent clones were tested for each ORF in order to select a 
representative clone that does not autoactivate either HIS3 or ADE2 reporter genes. The final 
collection of DUB preys tested in this study included 30 ORFs representing a total of 27 
unique DUBs, including duplicate clones of USP30, USP39 and USP46 (Table 3.2).  
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Table 3.2 Y2H deubiquitinating enzymes (DUBs) clone collection: The names and 
ID of the 61 human deubiquitinating proteins involved in this experiment. Some of the 
construct are only available in bait as indicated: =bait;=prey. 
 GeneID Gene Name Alternate name 
Bait () 
Prey () 
1 7345 UCHL1 PARK5; PGP95; PGP9.5; Uch-L1; PGP 9.5  
2 8314 BAP1 
UCHL2; hucep-6; FLJ35406; FLJ37180; 
HUCEP-13; KIAA0272; DKFZp686N04275 
 
3 7347 UCHL3 UCH-L3  
4 51377 UCHL5 UCH37; CGI-70; INO80R; UCH-L5  
5 7398 USP1 UBP  
6 9099 USP2a USP9; UBP41  
7 7375 USP4 UNP; Unph; MGC149848; MGC149849  
8 8078 USP5 ISOT  
9 9098 USP6 HRP1; TRE2; TRE17; Tre-2; USP6-short  
10 7874 USP7 TEF1; HAUSP  
11 9101 USP8 
UBPY; HumORF8; FLJ34456; KIAA0055; 
MGC129718 
 
12 8237 USP11 UHX1  
13 219333 USP12 UBH1; USP12L1  
14 8975 USP13 ISOT3; IsoT-3  
15 9097 USP14 TGT  
16 9958 USP15 
UNPH4; KIAA0529; MGC74854; 
MGC131982; MGC149838 
 
17 10600 USP16 MSTP039, UBP-M  
18 10869 USP19 ZMYND9  
19 10868 USP20 LSFR3A, VDU2  
20 27005 USP21 RP11-297K8.3, USP16, USP23  
21 29761 USP25 USP21  
22 83844 USP26 MGC120066; MGC120067; MGC120068  
23 57646 USP28 KIAA1515  
24 84749 USP30 FLJ40511, MGC10702  
25 84669 USP32 USP10; NY-REN-60  
26 23032 USP33 VDU1; KIAA1097; MGC16868  
27 57602 USP36 DUB1  
28 84640 USP38 FLJ35970; HP43.8KD; KIAA1891  
29 10713 USP39 
SAD1; CGI-21; HSPC332; SNRNP65; 
MGC75069 
 
30 373856 USP41   
31 84101 USP44 FLJ14528; DKFZp434D0127  
32 85015 USP45 MGC14793  
33 64854 USP46 FLJ11850; FLJ12552; FLJ14283; FLJ39393  
34 84196 USP48 
USP31; RAP1GA1; MGC14879; MGC132556; 
DKFZp762M1713 
 
35 25862 USP49 MGC20741  
36 9924 USP52 PAN2  
37 159195 USP54 
C10orf29; FLJ37318; bA137L10.3; 
bA137L10.4 
 
38 55611 OTUB1 
OTB1; OTU1; HSPC263; MGC4584; 
FLJ20113; FLJ40710; MGC111158 
 
39 78990 OTUB2 
OTB2; OTU2; MGC3102; FLJ21916; 
C14orf137 
 
40 55432 YOD1 
DUBA8; OTUD2; PRO0907; 
DKFZp451J1719; RP11-164O23.1 
 
41 54726 OTUD4 
HIN1; DUBA6; HSHIN1; KIAA1046; 
DKFZp434I0721 
 
42 55593 OTUD5 DUBA; MGC104871; DKFZp761A052  
43 139562 OTUD6A DUBA2; HSHIN6; FLJ25831  
44 51633 OTUD6B DUBA5; CGI-77  
45 56957 OTUD7B ZA20D1; CEZANNE  
46 80124 VCPIP1 DUBA3; VCIP135; FLJ23132; FLJ60694;  
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KIAA1850; DKFZp686G038 
47 7128 TNFAIP3 
A20; OTUD7C; TNFA1P2; MGC104522; 
MGC138687; MGC138688 
 
48 79184 BRCC3 C6.1A; BRCC36; CXorf53; RP11-143H17.2  
49 10987 COPS5 CSN5; JAB1; SGN5; MOV-34; MGC3149  
50 10980 COPS6 CSN6; MOV34-34KD  
51 8667 EIF3H EIF3S3; eIF3-p40; MGC102958; eIF3-gamma  
52 8665 EIF3F EIF3S5; eIF3-p47  
53 5713 PSMD7 P40; S12; Rpn8; MOV34  
54 10213 PSMD14 PAD1; POH1; RPN11  
55 10617 STAMBP AMSH; MGC126516; MGC126518  
56 57559 STAMBPL1 
AMSH-FP; AMSH-LP; ALMalpha; FLJ31524; 
KIAA1373; bA399O19.2 
 
57 92552 ATXN3L MJDL; FLJ59638; MGC168806; MGC168807  
58 9929 JOSD1 KIAA0063; dJ508I15.2  
59 126119 JOSD2 SBBI54; FLJ29018  
60  FLJ14891   
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3.3.3 Pooling and deconvolution strategy used to screen all possible E2:DUB interactions 
Pooling-deconvolution strategies are frequently used to dramatically decrease the effort 
required to perform large-scale Y2H screens. In essence, this strategy allows simultaneous 
screening of multiple prey constructs with each bait clone, thus enabling a greater number of 
possible interactions to be screened in fewer experiments to provide greater screen coverage. 
In this study, prey pools were prepared by combining up to 8 different Mat-α ORF prey 
clones (Figure 3.4). YPAD plates were set up with specific Mat-a haploid bait cells 
harbouring the bait constructs in a 96-well format. The suspension of pooled preys was then 
pipetted on top of these spots and they were allowed to mate for 24 hours. Diploid yeast 
were transferred by velvet replication onto SD-WL (for E2 bait:DUB preys) and SD-UL (for 
DUB bait:E2 preys), which were grown for 48 hours before transferred to triple selection 
SD-WLH(3-AT), SD-WLA (or SD-ULH(3-AT) or SD-ULA) plates. All screens were 
repeated twice and only positive interactions that were observed in both screens were 
recorded as true positive Y2H interactions. Pools containing positive hits were then selected 
for deconvolution where individual prey clones were tested against the observed positive bait 
partner. Following seven days of incubation on triple selection plates, images were taken and 
interactions were scored as being weak (+), medium (++), or strong (+++) activators of 
reporter gene expression as indicated by the extent of yeast colony growth on selective  
plates (Figure 3.5).  
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Figure 3.4 Pooling and deconvolution strategy: (A) Pooled mating assays were 
performed by picking yeast colonies from each vertical row and combining them together in 
one tube. Hence for the full 96-well plate, 12 pools were generated representing each 
column. Consequently, these pools were mated against a specific bait clone as shown in the 
figure. (B) Pools with positive interaction profiles were then deconvoluted and mated with 
the same bait clone which gave positive results in initial pooled screens. 
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Figure 3.5 Schematic representation of Y2H protocol: (A) PCR-amplification of DUBs in 
pDONR223 vector incorporating flanking sequences with both Gateway® and pACTBE-B 
recombination sequences. (B) In vivo homologous recombination in Mat-α cells. (C) Positive 
transformants are identified as pink colonies on SD-L, low adenine media plate. (D) 
Autoactivation tests are performed following size-verification by YC-PCR. (E) Baits and 
preys are spotted in a 96-array format on YPAD rich medium and incubated for 24h. (F) 
Diploid yeasts are transferred by velvet-replication from YPAD plates onto SD-UL or SD-
WL plates after 48h incubation. (G) Diploid yeast are replicated onto triple dropout selection 
plates (-ULH(3-AT) and -ULA or -WLH(3-AT) and –WLA) to positively select interacting 
proteins. 
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3.4 Binary Y2H screen result 
3.4.1 Reconfirmation of previously described interaction 
In this experiment, 30 DUB preys pooled into 12 separate groups were screened against 44 
E2 baits. Using this approach only 528 matings were needed to test 1 320 potential binary 
interactions. From these screens, 24 positive interactions were detected for E2 baits, 14 of 
which were observed in DUB pool 6 containing USP2a, OTUB1 and USP46n (Figure 3.6). 
Apart from these interactions, some weak interactions were seen between UBE2Q1:DUB 
pool 4, AKTIP:DUB pool 9, UBE2F:DUB pool 12 and UBE2N:DUB pool 12. DUB pool 10 
and 12 also showed weak interactions with UBE2U, UBE2DNL and TSG101. Meanwhile, 
positive interactions involving UBE2G2 were ignored as they were suspected to be false-
positive due to low level autoactivation with this clone. Also for UBE2H and UBE2K, even 
though they have no record of autoactivation in other experiments they were found to 
interact with almost all preys in this assay. As a result,  UBE2G2, UBE2H and UBE2K were 
excluded from deconvolution assay in order to avoid any false positives data. 
Following deconvolution assays, 14 E2:DUB interactions were identified, most of which 
involved OTUB1 which interacted with UBE2N and all members of the E2 D and E 
subfamilies (with the exception of UBE2E2). Besides, other positive interactions were 
observed between UBE2U, TSG101 and UBE2DNL, which share common DUB 
interactions; COPS6 and EIF3F. EIF3F also interacted with AKTIP (Figure 3.7). It should be 
noted that the construct of EIF3F generated for this experiment contained a non-coding 
C561T mutation, which may not be affecting Y2H experiment but should be addressed 
crucially when performing any further analysis. 
Y2H screens were also performed in the opposite bait/prey direction in which 38 E2 preys 
were pooled into 12 groups and mated against 72 individual DUB baits (Figure 3.8).  In this 
study 2 736 binary interactions were tested in 864 pooled matings. Five DUB preys 
constructs (USP13, USP25, OTUD6A and both STAMBP duplicates) had previously been 
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shown to exhibit autoactivation in other experiments performed in our lab hence data from 
these clones were excluded in subsequent studies. In this orientation, less positive hits were 
observed with only 10 positive interactions being identified. As expected, OTUB1 shows a 
medium-strength positive interaction with E2 pools 2, 3, 5, 8 and 9, which contain members 
of the D and E subfamilies. Beside that, some weaker positive interactions were are also 
observed between USP2a, COPS5 and TNFAIP3 with E2 pool 1 and UBE2N:pool 7. 
OTUD5, COPS6 and ATXN3L also appear to share common interactions with E2 pool 10. 
Meanwhile, COPS6 interacted with most of the E2 prey clones indicating possible non-
specific binding or low level autoactivation with this clone. Therefore, these hits were 
excluded from deconvolution assay. As very weak growth was observed (day 14) with 
EIF3F, TNFAIP3, ATXN3L, YOD1, OTUD5 and BRCC3, these interactions were recorded 
as possible positive interactions.  
Y2H deconvolution mating of selected E2 pool preys against DUB baits resulted in 12 
binary E2:DUB interactions that activated HIS3, ADE2 or both reporters. OTUB1 was again 
the major interactor for the E2s, with obvious positive interactions with UBE2D2, UBE2E1, 
UBE2E2, UBE2E3 and UBE2W. Beside that, other partnerships were observed between 
TNFAIP3:UBE2I, TNFAIP3:UBE2U and USP2a:UBE2U (Figure 3.9). 
All of these interactions with their score of either weak (+), medium (++), or strong (+++) 
activators of reporter expression are listed in Table 3.3. 
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(A) 
 
(B) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A UBE2A UBE2B UBE2C UBE2D1 UBE2D2 UBE2D3 UBE2D4 UBE2E1 UBE2E3 UBE2G1 UBE2G2 UBE2H 
B UBE2I UBE2L3 UBE2L3 UBE2L6 UBE2M UBE2N UBE2V1 UBE2V2 UBE2S UBE2R1 UBE2K UBE2R2 
C UBE2J1 UBE2J2 UBE2W UBE2E2 UEVLD UEVLD UBE2W UBE2Z AKTIP UBE2O UBE2Q1 UBE2T 
D UBE2I UBE2F BIRC6 UBE2U UBE2DNL UBE2Q2 UBE2Z TSG101     
E             
F             
G             
H             
 
Figure 3.6 E2 bait-pooled DUB prey interactions: (A) E2 baits mated against the 
DUB pooled preys on matrix format. Yeast diploids were allowed to grow for two days and 
then scored for growth on SD-ULA (stringent) and SD-ULH(3-AT) (less stringent) after 
seven days. (B) Grid positions of the E2 baits assayed in Figure 3.6(A). 
Legend:  = Strong; = Medium;  = Weak; = Auto-activated  
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(A)  
 
(B) 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
UBE2D1 
USP2a  
UBE2N 
USP2a 
UBE2D1 
OTUB1 
UBE2N 
OTUB1 
UBE2D1 
USP46n 
UBE2N 
USP46n 
UBE2Q1 
BAP1 
UBE2U 
USP16 
TSG101 
USP16 
UBE2DNL 
USP16 
  
B 
UBE2D2 
USP2a  
UBE2V1 
USP2a 
UBE2D2 
OTUB1 
UBE2V1 
OTUB1 
UBE2D2 
USP46n 
UBE2V1 
USP46n 
UBE2Q1 
USP44 
UBE2U 
COPS6 
TSG101 
COPS6 
UBE2DNL 
COPS6 
  
C 
UBE2D3 
USP2a 
UBE2E2 
USP2a 
UBE2D3 
OTUB1 
UBE2E2 
OTUB1 
UBE2D3 
USP46n 
UBE2E2 
USP46n 
UBE2Q1 
USP30n 
UBE2U 
USP30 
TSG101 
USP30 
UBE2DNL 
USP30 
UBE2F 
USP30 
 
D 
UBE2D4 
USP2a 
UEVLD 
USP2a 
UBE2D4 
OTUB1 
UEVLD 
OTUB1 
UBE2D4 
USP46n 
UEVLD 
USP46n 
UBE2Q1 
EIF3H 
UBE2U 
EIF3F 
TSG101 
EIF3F 
UBE2DNL 
EIF3F 
UBE2N 
EIF3F 
 
E 
UBE2E1 
USP2a 
UBE2W 
USP2a 
UBE2E1 
OTUB1 
UBE2W 
OTUB1 
UBE2E1 
USP46n 
UBE2W 
USP46n 
AKTIP 
USP14 
     
F 
UBE2E3 
USP2a 
UBE2U 
USP2a 
UBE2E3 
OTUB1 
UBE2U 
OTUB1 
UBE2E3 
USP46n 
UBE2U 
USP46n 
AKTIP 
COPS5 
     
G 
UBE2M 
USP2a 
UBE2Q1 
USP2a 
UBE2M 
OTUB1 
UBE2Q1 
OTUB1 
UBE2M 
USP46n 
UBE2Q1 
USP46n 
      
H           
 
 
 
Plate 1 
Figure 3.7 Pooled DUB preys deconvoluted in singe mating: (A) E2 baits mated 
against the DUB preys on matrix format. Yeast diploids were allowed to grow for two days 
at 30°C and then scored for growth on SD-WLA (stringent) and SD-WLH(3-AT) (less 
stringent) after seven days. (B) Plate 1 showing grid positions of the selected 18 E2 baits and 
30 DUB preys mated in Figure 3.7(A); red font denotes the E2s whilst blue indicates the 
DUBs. 
Legend:  = Strong; = Medium;  = Weak; = Auto-activated  
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(A) 
 
(B) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A UCHL1 UCHL3 UCHL5 BAP1 USP1 USP2a USP3 USP4 USP5 USP6 USP7 USP8 
B USP11 USP12 USP13 USP14 USP15 USP16 USP19 USP20 USP20 USP21 USP25 USP26 
C USP28 USP30 USP30 USP32 USP33 USP36 USP38 USP39 USP41B USP44 USP45 USP46 
D USP48B USP49 USP52 USP54 OTUB1 OTUB2 OTUD7A VCPIP1 OTUD4 YOD1 TNFAIP3 OTUD6B 
E OTUD6A OTUD5 BRCC3 COPS5 COPS6 EIF3H EIF3F PSMD7 PSMD14 STAMBP STAMBPL1  
F ATXN3L JOSD1 JOSD2 UBE2N FLJ14891 USP5n BAP1n USP15n STAMBP    
G             
H             
 
Figure 3.8 Pooled E2 prey-DUB bait interactions: (A) DUB baits mated against the 
E2 pooled preys. Yeast diploids were allowed to grow for two days and then scored for 
growth on SD-ULA and SD-ULH(3-AT) after seven days. (B) Grid positions of the DUB 
baits assayed in Figure 3.8(A). 
Legend:  = Strong; = Medium;  = Weak; = Auto-activated 
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(A) 
 
(B) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
 
           
B 
COPS6 
UBE2A 
EIF3F 
UBE2A 
TNFAIP3 
UBE2A 
  
USP2a 
UBE2A 
OTUB1 
UBE2B 
OTUB1 
UBE2C 
OTUB1 
UBE2D1 
OTUB1 
UBE2D2 
BRCC3 
UBE2A 
 
C 
COPS6 
UBE2I 
EIF3F 
UBE2I 
TNFAIP3 
UBE2I 
  
USP2a 
UBE2I 
OTUB1 
UBE2L3 
OTUB1 
UBE2L3 
OTUB1 
UBE2L6 
OTUB1 
UBE2M 
BRCC3 
UBE2I 
 
D 
COPS6 
UBE2J1 
EIF3F 
UBE2J1 
TNFAIP3 
UBE2J1 
  
USP2a 
UBE2J1 
OTUB1 
UBE2W 
OTUB1 
UBE2E2 
OTUB1 
UBE2W 
OTUB1 
UBE2Z 
BRCC3 
UBE2J1 
 
E 
COPS6 
UBE2G1 
EIF3F 
UBE2G1 
TNFAIP3 
UBE2G1 
  
ATXN3L 
UBE2G1 
YOD1 
UBE2G1 
OTUD5 
UBE2G1 
UBE2N 
UBE2D4 
OTUB1 
UBE2E3 
BRCC3 
UBE2G1 
 
F 
COPS6 
UBE2R1 
EIF3F 
UBE2R1 
TNFAIP3 
UBE2R1 
  
ATXN3L 
UBE2R1 
YOD1 
UBE2R1 
OTUD5 
UBE2R1 
UBE2N 
UBE2V1 
OTUB1 
UBE2S 
BRCC3 
UBE2R1 
 
G 
COPS6 
UBE2I 
EIF3F 
UBE2I 
TNFAIP3 
UBE2I 
  
ATXN3L 
UBE2I 
YOD1 
UBE2I 
OTUD5 
UBE2I 
UBE2N 
UBE2O 
OTUB1 
UBE2T 
BRCC3 
UBE2I 
 
H 
COPS6 
UBE2U 
EIF3F 
UBE2U 
TNFAIP3 
UBE2U 
  
USP2A 
UBE2U 
OTUB1 
UBE2W 
OTUB1 
UBE2E1 
OTUB1 
UBE2V2 
OTUB1 
UBE2Q1 
BRCC3 
UBE2U 
 
Plate 2 
Figure 3.9 Pooled E2 preys deconvoluted in singe mating: (A) DUB baits mated 
against the E2 preys on matrix format. Yeast diploids were allowed to grow for two days at 
30°C and then scored for growth on SD-ULA (stringent) and SD-ULH(3-AT) (less stringent) 
after seven days. (B) Plate 2 showing grid positions of the selected 10 DUB baits and 38 E2 
preys mated in Figure 3.9(A); blue font denotes the DUBs whilst red indicates the E2s. 
Legend:  = Strong; = Medium;  = Weak; = Auto-activated 
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Table 3.3 E2:DUB interaction summary: List of all interactions tested on 
deconvolution assay. Interactions are scored as being weak (+), medium (++), or strong 
(+++) activators of reporter expression evaluated by the size and intensity of the yeast colony 
growth. 
Plate / 
Well 
Bait GeneID 
Bait Gene 
Name 
Prey Gene 
Name 
Prey GeneID HIS3 ADE2 
Plate 1: E2 bait vs. DUB prey 
A1 7321 UBE2D1 USP2a 9099   
A2 7334 UBE2N USP2a 9099   
A3 7321 UBE2D1 OTUB1 55611 +++ +++ 
A4 7334 UBE2N OTUB1 55611 ++ ++ 
A5 7321 UBE2D1 USP46n 64854   
A6 7334 UBE2N USP46n 64854   
A7 55585 UBE2Q1 BAP1 8314   
A8 148581 UBE2U USP16 10600   
A9 7251 TSG101 USP16 10600   
A10 100131816 UBE2DNL USP16 10600   
B1 7322 UDE2D2 USP2a 9099   
B2 7335 UBE2V1 USP2a 9099   
B3 7322 UDE2D2 OTUB1 55611 ++ +++ 
B4 7335 UBE2V1 OTUB1 55611   
B5 7322 UDE2D2 USP46n 64854   
B6 7335 UBE2V1 USP46n 64854   
B7 55585 UBE2Q1 USP44 84101   
B8 148581 UBE2U COPS6 10980 ++ + 
B9 7251 TSG101 COPS6 10980 + +++ 
B10 100131816 UBE2DNL COPS6 10980  ++ 
C1 7323 UBE2D3 USP2a 9099   
C2 7325 UBE2E2 USP2a 9099   
C3 7323 UBE2D3 OTUB1 55611 ++ +++ 
C4 7325 UBE2E2 OTUB1 55611   
C5 7323 UBE2D3 USP46n 64854   
C6 7325 UBE2E2 USP46n 64854   
C7 55585 UBE2Q1 USP30n 84749   
C8 148581 UBE2U USP30 84749   
C9 7251 TSG101 USP30 84749   
C10 100131816 UBE2DNL USP30 84749   
C11 140379 UBE2F USP30 84749   
D1 51619 UBE2D4 USP2a 9099   
D2 55293 UEVLD USP2a 9099   
D3 51619 UBE2D4 OTUB1 55611 ++ +++ 
D4 55293 UEVLD OTUB1 55611   
D5 51619 UBE2D4 USP46n 64854   
D6 55293 UEVLD USP46n 64854   
D7 55585 UBE2Q1 EIF3F 8665   
D8 148581 UBE2U EIF3F 8665   
D9 7251 TSG101 EIF3F 8665 ++ ++ 
D10 100131816 UBE2DNL EIF3F 8665  +++ 
D11 7334 UBE2N EIF3F 8665 + +++ 
E1 7324 UBE2E1 USP2a 9099   
E2 55284 UBE2W USP2a 9099   
E3 7324 UBE2E1 OTUB1 55611 ++ ++ 
E4 55284 UBE2W OTUB1 55611   
E5 7324 UBE2E1 USP46n 64854   
E6 55284 UBE2W USP46n 64854   
E7 64400 AKTIP USP14 9097   
F1 10477 UBE2E3 USP2a 9099   
F2 148581 UBE2U USP2a 9099   
F3 10477 UBE2E3 OTUB1 55611 ++  
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F4 148581 UBE2U OTUB1 55611   
F5 10477 UBE2E3 USP46n 64854   
F6 148581 UBE2U USP46n 64854   
F7 64400 AKTIP COPS5 10987 ++  
G1 9040 UBE2M USP2a 9099   
G2 55585 UBE2Q1 USP2a 9099   
G3 9040 UBE2M OTUB1 55611   
G4 55585 UBE2Q1 OTUB1 55611   
G5 9040 UBE2M USP46n 64854   
G6 55585 UBE2Q1 USP46n 64854   
Plate 2: E2 prey vs. DUB bait 
B1 10980 COPS6 UBE2A 7319   
B2 8665 EIF3F UBE2A 7319   
B3 7128 TNFAIP3 UBE2A 7319   
B6 9099 USP2a UBE2A 7319   
B7 55611 OTUB1 UBE2B 7320   
B8 55611 OTUB1 UBE2C 11065   
B9 55611 OTUB1 UBE2D1 7321   
B10 55611 OTUB1 UBE2D2 7322 +++  
B11 79184 BRCC3 UBE2A 7319   
C1 10980 COPS6 UBE2I 7329   
C2 8665 EIF3F UBE2I 7329   
C3 7128 TNFAIP3 UBE2I 7329   
C6 9099 USP2a UBE2I 7329   
C7 55611 OTUB1 UBE2L3 7332   
C8 55611 OTUB1 UBE2L3 7332   
C9 55611 OTUB1 UBE2L6 9246   
C10 55611 OTUB1 UBE2M 9040   
C11 79184 BRCC3 UBE2I 7329   
D1 10980 COPS6 UBE2J1 51465   
D2 8665 EIF3F UBE2J1 51465   
D3 7128 TNFAIP3 UBE2J1 51465   
D6 9099 USP2a UBE2J1 51465   
D7 55611 OTUB1 UBE2W 55284   
D8 55611 OTUB1 UBE2E2 7325 +++  
D9 55611 OTUB1 UBE2W 55284   
D10 55611 OTUB1 UBE2Z 65264   
D11 79184 BRCC3 UBE2J1 51465   
E1 10980 COPS6 UBE2G1 7326   
E2 8665 EIF3F UBE2G1 7326   
E5 7128 TNFAIP3 UBE2G1 7326   
E6 92552 ATXN3L UBE2G1 7326   
E7 55432 YOD1 UBE2G1 7326   
E8 55593 OTUD5 UBE2G1 7326   
E9 7334 UBE2N UBE2D4 51619   
E10 55611 OTUB1 UBE2E3 10477 +++  
E11 79184 BRCC3 UBE2G1 7326   
F1 10980 COPS6 UBE2R1 997   
F2 8665 EIF3F UBE2R1 997   
F3 7128 TNFAIP3 UBE2R1 997   
F6 92552 ATXN3L UBE2R1 997   
F7 55432 YOD1 UBE2R1 997   
F8 55593 OTUD5 UBE2R1 997   
F9 7334 UBE2N UBE2V1 7335 +++ ++ 
F10 55611 OTUB1 UBE2S 27338   
F11 79184 BRCC3 UBE2R1 997   
G1 10980 COPS6 UBE2I 7329   
G2 8665 EIF3F UBE2I 7329   
G3 7128 TNFAIP3 UBE2I 7329 ++ + 
G6 92552 ATXN3L UBE2I 7329   
G7 55432 YOD1 UBE2I 7329   
G8 55593 OTUD5 UBE2I 7329 + ++ 
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G9 7334 UBE2N UBE2O 63893   
G10 55611 OTUB1 UBE2T 29089   
G11 79184 BRCC3 UBE2I 7329   
H1 10980 COPS6 UBE2U 148581  + 
H2 8665 EIF3F UBE2U 148581  + 
H3 7128 TNFAIP3 UBE2U 148581 ++ ++ 
H6 9099 USP2a UBE2U 148581 ++ ++ 
H7 55611 OTUB1 UBE2W 55284 ++  
H8 55611 OTUB1 UBE2E1 7324 +++  
H9 55611 OTUB1 UBE2V2 7336   
H10 55611 OTUB1 UBE2Q1 55585   
H11 79184 BRCC3 UBE2U 148581   
 
 
These results demonstrate a strong correlation with data from previous Y2H library screens 
and mass spectrometry studies (Markson et al., 2009; Sowa et al., 2009) regarding the 
interaction between OTUB1 and E2 proteins from the D and E subfamilies. 
An interesting partnership is observed between COPS6 and TSG101, as both of these 
proteins are involved in interactions with p53 (Li et al., 2001; Bech-Otschir et al., 2001). 
TSG101 is an E2 belonging to UEV (ubiquitin E2 variant) domain members which shows 
significant sequence similarity to E2 enzymes. However, they are unable to catalyse 
ubiquitin transfer as they lack the active site cysteine that forms the transient thioester bond 
with the C-terminus of ubiquitin  (Koonin and Abagyan, 1997; Ponting et al., 1997). In 
relationship with p53, TSG101 participates with E3 ligase MDM2 in an autoregulatory loop 
that modulates the cellular levels of both proteins and of p53. Meanwhile, COPS6 (also 
known as CSN6) is one of the eight subunits that make up the COP9-signalosome, a highly 
conserved protein complex that functions as an important regulator in multiple signalling 
pathways (Wei et al., 2008). Recently, another DUB component of the COP9 signalosome, 
COPS5 (or CSN5), has been shown to regulate p53 function (Zhang et al., 2008), and p53 
has also been shown to bind the native COP9 signalosome with high affinity through COPS5 
(Bech-Otschir et al., 2001). The observed interaction between COPS6 and TSG101 could 
therefore represent a mechanism by which p53 activity or stability could be regulated. In this 
experiment, COPS6 also interacted with UBE2DNL, a pseudogene with UBE2D N-terminal 
like region but very few interactions or literature reports have been recorded for UBE2DNL 
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hence the characteristic of this interaction could not be predicted. 
In the human E2:DUB known interaction network (Figure 3.10), UBE2I was interacting with 
UCHL1 (Caballero et al., 2002) but the interaction was not observed in our experiment. The 
function of UBE2I:UCHL1 interaction is unknown but UBE2I has been associated with 
protein trafficking by involvement in SUMO-modification which facilitates transport of 
modified proteins into the nucleus (Okuma et al., 1999; Hoege et al., 2002). Instead, in our 
experiment (Figure 3.9) UBE2I may has weak interaction with TNFAIP3 (also known as 
A20), functionally known as an inhibitor of cell death and chronic inflammation that 
downregulates NF-κB activation via the tumour necrosis factor receptor (TNFR)-associated 
pathway (Wertz et al., 2004). TNFAIP3 is a very interesting protein because it is the only 
known DUB that also has E3 ligase activity mediated by one of its C-terminal zinc-finger 
domains that can promote the conjugation of Lys48-linked ubiquitin chains and proteasomal 
degradation (Wertz et al., 2004). In order to disrupt interactions between E2:E3 enzymes in 
TNFR and the TLR4/IL-1R pathways, TNFAIP3 together with the regulatory molecule 
TAX1BP1 has been shown to interact with UBE2N and UBE2D3, the E2 involved in this 
pathway, thus triggering their ubiquitination and proteasome-dependent degradation 
(Shembade et al., 2010). Interestingly, TNFAIP3 shares similarity with OTUB1 as both have 
OTU domains and both are known to be immunoregulatory DUBs (Sun, 2008). In this 
experiment, TNFAIP3, as well as USP2a, also interacted with UBE2U. However, no 
interaction data for UBE2U conjugation activity have been corresponded in the literature at 
present, which may be related to its restricted expression pattern in the urogenital tract (van 
Wijk et al., 2009). 
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Figure 3.10 Known interactions between E2 ubiquitin conjugating enzymes and 
DUBs in humans: This data was extracted from our in-house database of known interactions 
mined from the MINT, HPRD, IntAct and BioGRID.  
 
Interactions observed in this study do not corresponded to known interactions found in 
human databases (Figure 3.10). Nevertheless, it offers novel candidates to be investigated in 
future interaction studies. From these studies, it appears that E2:DUB pairs are very 
uncommon in cells because from a total of 4 056 binary interaction tested, only 23 positive 
hits were identified. However, this low score of positive results may also due to the restricted 
number of DUBs tested in our Y2H screens. As our final DUB bait and prey clone sets are 
not totally comprehensive clone sets, it is possible that several potential interactions may 
have been missed. From the 23 hits, 12 are involving OTUB1 and more importantly, only 
OTUB1 gave a confident and reproducible results in both bait and prey direction while other 
interactions were only detected in one of the bait prey orientation. As a result, OTUB1 and 
its partners were selected for further investigation using complementary biophysical and 
structural methods.  
  
Edge colour: 
     In vitro|in vivo 
     Y2H 
     In vitro|Y2H 
     Non-Y2H 
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3.4.2 OTUB1 binds a subset of E2 conjugating enzymes 
OTUB1 is a DUB belong to the OTU-family and its deubiquitination activity was firstly 
detected by the ability to cleave a tetraubiquitin substrate in vitro (Balakirev et al., 2003). Its 
unexpected function was first observed when in transgenic mice transduced to express this 
gene, it promoted rather than inhibited the Lys48-linked self-ubiquitination and degradation 
of its endogenous interactor, GRAIL an E3-RING protein (Soares et al., 2004). In more 
recent studies, the atypical characteristics of OTUB1 which enable it to prevent ubiquitin 
attachment rather than mediating the cleavage or removal of bound ubiquitin has been 
revealed and will be discussed more comprehensively in Chapter 6. 
In these experiments, OTUB1 shows a clear binding preference for E2 proteins from the D 
and E subfamilies and UBE2N, Interestingly, the E2-conjugating D family is widely known 
as the most promiscuous (Brzovic and Klevit, 2006) E3-RING binding partner (Markson et 
al., 2009), which may be consistent with their role as house-keeping E2s within the ubiquitin 
system. The D family share a high level of primary sequence similarity with E family 
members; however, the latter contain an approximate 60aa N-terminal extension not found in 
D family E2 proteins. These extensions are thought to be influential in determining 
specificity as E family members are less promiscuous than UBE2D proteins. Meanwhile, in 
forming ubiquitin chains, UBE2Ds, UBE2Es and UBE2N show a diversity of preferences. D 
and E families are more promiscuous and can catalyse the formation of multiple linkage 
chain types (Kirkpatrick et al., 2006; Kim et al., 2007; Jin et al., 2008). In addition, 
promiscuous UBE2Ds preferentially promote the formation of Lys11-, Lys48- and Lys63-
linked chains in vitro with three different E3s and show evidence of mixed and branched 
chains (Kim et al., 2007). A dimeric complex composed of UBE2N and UBE2V1 was 
determined to only form a Lys63 linkage specificity (VanDemark et al., 2001; Eddins et al., 
2006).  
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During this stage of analysis, the binding interface of E2:OTUB1 was not yet revealed, 
therefore our key aim was to investigate the molecular nature of interactions between 
OTUB1 and different E2 partners based on these three hypotheses: 
1) OTUB1 binds E2 proteins at a different site from the well characterised E2-E3 
binding surface;  
2) OTUB1 and E3 compete with each other for binding to E2 partners; 
3) OTUB1, E2  and E3-RING proteins exist in a single multiprotein complex. 
As the structural model of the UBE2D2:CNOT4 complex (CNOT4 is an E3 RING ligase 
that interacts specifically with UBE2D2) had been solved by NMR and docking approaches 
(Dominguez et al., 2004), we reasoned that this information and a similar approach would 
help to distinguish between the above options. 
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3.5 Analysis of a truncated form of OTUB1 lacking the first 39 N-terminal amino 
acids  
Initial NMR analysis was performed to identify the binding interface of E2s and wild type 
(WT) OTUB1 complexes. Specific chemical shift patterns were observed in these studies 
suggesting specific points of contact between these two proteins (discussed further in 
Chapter 4). However, the full range of amino acids involved in these interactions could not 
be determined due to a very dense central region of the spectrum caused by an intrinsically 
disordered region within the OTUB1 protein. These regions (termed ‘spaghetti’ because they 
usually exist as unorganised, flexible short linear peptide motifs) do not form a well-defined 
three-dimensional structure and sometimes even appear to be totally unfolded in their native 
state. As these types of regions can affect protein solubility and crystallisability which were 
an important part of our proposed plans, the probability disorder for OTUB1 was calculated 
using RONN (Yang et al., 2005), which decides the likelihood of disorder based on 
alignments to a group of sequences of known folding state (Figure 3.11).  
 
              
Figure 3.11 Probability of disorder for OTUB1: The amino acids 1-18, 48-49, 59-
71, 116-126, 235-248 are above probability cut-off of 0.5 and considered to be unfolded. 
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RONN predicted a strong area of disorder at the N-terminus of OTUB1, which does not 
include the catalytic site. In addition, in structural studies performed on the OTUB1 protein, 
the N-terminal region was removed to produce OTUB1 (residue 40-271 only) crystal which 
successfully diffracted to 1.7Å resolution (Edelmann et al., 2009). Therefore, assuming that 
the N-terminal region would be problematic for structural studies we generated the truncated 
form of OTUB1 which lacked the N-terminal (1-39) amino acids.  
It was possible that removal of the N-terminal region of OTUB1 could make OTUB1 more 
like OTUB2, as the main difference between the two proteins is the presence of the N-
terminal extension in OTUB1 (Figure 3.12). Significantly, no interaction was observed 
between OTUB2 and any E2 proteins in our screens. In order establish if N-terminally 
truncated OTUB1 could still interact with defined E2 partners, further Y2H screens were 
performed using newly generated 
ΔN
OTUB1 bait and prey constructs.  
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Figure 3.12 Superposition of OTUB1 and OTUB2: A very similar display with 
identical folds of OTUB1 (40-271) without N-terminal (PDB ID: 2ZFY) and OTUB2 (PDB 
ID: 1TFF). Picture generated using MacPyMOL v1.3.  
OTUB1 
OTUB2 
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3.5.1 Generating 
ΔN
OTUB1 
To generate 
ΔN
OTUB1 Y2H bait and prey constructs, PCR was performed on full-length 
OTUB1 in pDONR223 using a gene-specific forward primer instead of vector-specific 
primer as used previously. The gene-specific primer was designed to contain a sequence of 
OTUB1 starting from base 118 (blue font) following the yeast/Gateway® sequence (red 
font): 
5’ GAATTCACAAGTTTGTACAAAAAAGCAGGCTGGATGGAGATTGCTGTGC 3’.  
This primer would anneal in such a way as to amplify from base 118 onwards hence 117 
bases representing the first 39 amino acids were removed. The same reverse primer 
pDONR223 GR R1 was used in conjunction with the newly designed forward primer. The 
product of this PCR is N-terminal truncated OTUB1 (aa 40-271) with overhang gap repair 
sequence at the 5’ and 3’. Consequently, gap repair transformation was performed to using 
this PCR product to generate bait clones in pGBAE-B/Mat-a cells and equivalent prey clones 
in pACTBE-B/Mat-α. Following YC-PCR analysis of gap repair colonies, verified clones 
were tested for autoactivation. 
 
3.5.2 
ΔN
OTUB1 slightly reduced interaction with E2 binding partners 
Y2H results show that removal of N-terminal did not totally abolished interactions with E2 
proteins (Figure 3.13). However, the interaction profile between 
ΔN
OTUB1 and its binding 
partners were greatly reduced especially in the 
ΔN
OTUB1 prey orientation, which might be 
due to a stearic effect. The stearic effects arise from the fact that each atom within a 
molecule occupies a certain amount of space. In some cases, if atoms are brought too close 
together, this may affect the molecule's preferred conformation and reactivity. A truncation 
is commonly disfavoured and notoriously known to cause stearic interaction with the fusion 
domain resulting in a reduced ability to bind to known interaction partners. The 
ΔN
OTUB1 
Y2H screen were analysed and the candidates for structural analysis were selected upon 
evaluating Y2H data.  
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Figure 3.13 
ΔN
OTUB1:E2 interactions: (A) 
ΔN
OTUB1 prey mated against E2 baits on 
SD-WLA and SD-WLH(3-AT) at day seven. (B) Grid positions of the E2 baits assayed in 
Figure 3.13(A). (C) 
ΔN
OTUB1 bait mated against E2 preys on SD-WLA and SD-WLH(3-
AT) at day 7. (D) Grid positions of the E2 preys assayed in Figure 3.13(C). 
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3.6 Selection of candidates for biophysical analysis 
OTUB1 in prey orientation interacts with the whole set of UBE2Ds and UBE2Es (except 
UBE2E2) and UBE2N in bait vectors, activating both HIS3 and ADE2 reporter genes. This 
observation is expected because previous experiments in our lab have shown that E2 
expressed as bait fusions always show better interaction profiles compared to when they are 
expressed as prey clones. Surprisingly, in this orientation all E2 interactions were lost with 
ΔN
OTUB1, possibly due to the stearic effects. However, when OTUB1 was expressed as a 
bait construct, interactions were only observed with UBE2D2, UBE2E1, UBE2E2 and 
UBE2E3 and only on the less stringent HIS3 reporter. Interestingly, this pattern was 
maintained in screening with 
ΔN
OTUB1 where only UBE2E3 interaction was abolished and 
the rest were preserved. The reason for OTUB1 bait selective preferences towards UBE2D2, 
UBE2E1, UBE2E2 and UBE2E3 are not well understood. Considering the Y2H data 
validation by biophysical analysis will be performed on 
ΔN
OTUB1, therefore UBE2D2, 
UBE2E1 and UBE2E2 were selected for further experimentation as these were the only E2 
proteins to maintained interaction positive interaction profiles with the truncated version of 
OTUB1. Table 3.4 on the next page shows the summary of OTUB1:E2 interaction. 
Table 3.4 OTUB1:E2 interaction summary: Interaction between OTUB1 and E2s. 
Red denotes strong interaction, orange represents medium strength and yellow shows the 
observed interaction is weak, evaluated by the size and intensity of yeast colony growth. 
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4.1 Introduction 
Although the Y2H system is a valuable tool for discovering and analysing protein 
interactions, data from these studies should only be used as a prediction to inform further 
experimental or hypothesis driven studies. Therefore, in an attempt to validate our primary 
Y2H data and provide greater insight into the molecular mechanism or biophysical 
properties of different OTUB1:E2 complexes, genes of interest (OTUB1, UBE2D2, UBE2E1 
and UBE2E2) were cloned into the pETM-11 polyhistidine-tag vector by conventional 
cloning methods in order to generate large quantities of purified proteins for use in gel 
filtration chromatography, ITC and NMR studies. 
The primary aims of this part of the project were: 
1) To express and purify sufficient quantities of recombinant OTUB1 and selected E2 
proteins in order to generate sufficient amounts of each protein to facilitate 
biophysical and structural analysis of protein complexes. 
2) To verify the observed Y2H interactions in multiple assay systems.  
3) To provide more detailed structural information relating to the molecular 
organisation of OTUB1, E2 and E3-RING proteins in different protein complexes. 
 
4.2 Producing affinity tagged proteins 
Both biophysical and structural techniques require substantial quantities of pure protein. In 
this study, an inducible bacterial expression system was used to express recombinant 
proteins containing a cleavable in-frame 6xHis affinity tag. In brief, His-tagged proteins 
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were first purified by Ni
2+
 affinity chromatography before performing Q/SP ion exchange 
chromatography to further increase the purity of target proteins. 
 
4.2.1 pETM-11 system 
Target genes were initially cloned into the PETM-11 vector under inducible control of the 
T7/lac promoter (Figure 4.1 shows the map of pETM-11). This vector was chosen as it 
generally provides high expression yields while only adding four amino acids (Gly-Ala-Met-
Ala) to the N-terminus of the target protein, with a TEV protease cleavage site prior to the 
start of the inserted protein-coding sequence.  
 
Figure 4.1 Map of pETM-11 vector: The conserved multiple cloning site (MCS) 
contains an NcoI restriction site which has an in frame methionine codon (ATG) after which 
protein coding sequences were cloned, a protein called MAD which will be excised and 
replaced with genes encoding proteins of interest, and a number of restriction sites 
downstream the MAD protein for double digestion alongside NcoI. 
EMBL Protein Expression and Purification Facility
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4.2.2 Construction of His-tag protein of interest 
4.2.2.1 Introduction of NcoI and HindIII restriction sites into the N- and C-termini of 
protein coding inserts 
Sequences for the forward and reverse primers designed for each expression construct are 
shown in Table 4.1. Target genes were PCR-amplified from the pDONR entry vector and 
PCR products were digested with NcoI and HindIII prior to ligation into pETM-11 digested 
with the same restriction enzymes. 
 
Table 4.1 NcoI and HindIII restriction site sequences incorporated in forward 
and reverse primers. Primers were designed to contain NcoI (red) and HindIII (blue) 
sequences to allow PCR of the targeted genes of interest while incorporating restriction sites 
for digestion protocol. 
 Forward primer Reverse primer 
OTUB1 
5’ CAG GGC GCC ATG GCC GCG 
GCG GAG GAA CCT CAG 3’ 
5’ CCC AAG CTT GGG CTA TTT GTA 
GAG GAT ATC GTA GTG TCC AGG 
CCG 3’ 
UBE2D2 
5’ CAG GGC GCC ATG GCC GCT 
CTG AAG AGA ATC C 3’ 
5’ CCC AAG CTT GGG CTA CAT CGC 
ATA CTT CTG AGT CCA TTC CCG 3’ 
UBE2E1 
5’ CAG GGC GCC ATG GCC TCG 
GAT GAC GAT TCG AGG 3’ 
5’ CCC AAG CTT GGG CTA TGT AGC 
GTA TCT CTT GGT CCA CTG TCT G 
3’ 
UBE2E2 
5’ CAG GGC GCC ATG GCC TCC 
ACT GAG GCA CAA AG 3’ 
5’ CCC AAG CTT GGG CTA TGT GGC 
GTA CCG CTT GGT CCA C 3’ 
ΔN
OTUB1 
5' CAG GGC GCC ATG GCC GAG 
ATT GCT GTG CAG AAC CC 3' 
5’ CCC AAG CTT GGG CTA TTT GTA 
GAG GAT ATC GTA GTG TCC AGG 
CCG 3’ 
 
 
4.2.2.2 Ligation and transformation. 
Despite the fact that the ligation step is particularly problematic, DNA fragments were 
successfully inserted into the vector by optimising insert/vector ratios, enzyme and buffer 
concentrations and also ligation time. As an alternative cloning strategy, both TOPO® 
(Invitrogen) and In-Fusion® (Clontech) cloning methods were also tried. Ligation products 
were transformed into α-select E. coli cells and PCR-verification was performed to selected 
positive colonies for insert sequencing. As pETM-11 is a low copy number plasmid, 
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maxipreps were performed to obtain clones, which were then transformed into 
Rosetta™(DE3)pLysS host strains, a BL21 derivative suitable for expression of target genes 
cloned into the pETM-11 vector (Figure 4.2). 
 
 
 
 
Figure 4.2 Generation of pETM-11 clones: (A) Target genes were amplified from 
sequence-verified templates in pDONR207 or pDONR223 vectors using forward and reverse 
primers containing NcoI and HindIII cleavage sites respectively. (B) Digestion of PCR 
products and pETM-11 plasmid using NcoI and HindIII restriction enzymes to produce 
compatible sticky ends on both PCR product and plasmid. (C) Ligation of PCR product into 
pETM-11 vector by T4 DNA ligase. (D) Transformation of ligated product into α-select 
cells. (E) Transfected clones were selected following colony growth on 2xTY agar 
containing kanamycin. (F) Growth of large-scale cultures. (G) Maxiprep to isolate the 
desired construct ready for transformation into Rosetta cells for expression studies. 
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4.3 Protein expression and purification 
4.3.1 Small-scale expression test 
Small-scale pilot experiments were performed to confirm the effectiveness of the pETM-11 
expression system. In each case, protein purification was performed using Ni-NTA agarose 
(Qiagen®) and target proteins were eluted using lysis buffer B (20 mM Na2HPO4, 500 mM 
NaCl, 500 mM imidazole). A high concentration of imidazole, a histidine competitor is 
required because in excess amount it can displace the histidines from Ni
2+
 co-ordination 
thereby freeing the His-tagged protein. The result in Figure 4.3 suggests the presence of 
recombinant proteins of sizes commensurate with all proteins of interest (predicted 
molecular weight of each construct is shown in Table 4.2). As expected, expressed proteins 
migrate slightly slower than the predicted molecular weight due to of the addition of the ~3 
kDa 6xHis-tag and a TEV cleavage site (MKHHHHHHPMSDYDIPTTENLYFQ), which 
was uncleaved in this pilot study. Very faint bands can be seen in uninduced samples 
suggesting that protein expression responded well to IPTG induction. Also, the Ni
2+
 affinity 
beads appear to clean up the sample quite appreciably. 
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Figure 4.3 Coomassie blue SDS-PAGE gels of uninduced and IPTG-induced 
samples from Ni
2+
 column elution: IPTG-induced samples (B) gave more visible bands 
compared to uninduced (A). Number 1, 2 and 3 in each protein representing the elution from 
thricely washed Ni
2+
 agarose beads with lysis buffer B (20 mM Na2HPO4, 500 mM NaCl, 
500 mM imidazole). All bands show sizes higher than the proteins’ molecular weight 
(OTUB1 31.3 kDa, UBE2E1 21.4 kDa, UBE2E2 22.3 kDa, UBE2D2 16.8 kDa) due to the 
addition of the 6xHis-tag and a TEV cleavage site. For IPTG-induced UBE2D2 the bands are 
very faint but noticeable nonetheless, indicated by the red arrow. 
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4.3.2 Large-scale protein production 
4.3.2.1 Selection of host strain and induction temperature 
Many factors can inﬂuence the expression of proteins in E. coli, including the bacterial 
strain, the vector expression system, growth medium and incubation temperature (Berrow et 
al., 2006; Gräslund et al., 2008). To optimise protein expression, each construct was 
expressed in either Rosetta or B834(DE3) cells. In each case, cells were grown until cultures 
reached an OD600 of 0.6 before being induced with 0.2 mM IPTG at either 18°C or 30°C. As 
both Rosetta and B834 cells lack an outer membrane protease which can degrade proteins 
during purification (Grodberg and Dunn, 1988), it was expected that expressed proteins 
should be more stable in these strains. In addition, Rosetta cells also contain tRNA codons 
rarely used in E.coli, which can dramatically increase expression of human proteins 
(Brinkmann et al., 1989). Analysis of lysates showed that OTUB1 expressed in Rosetta cells 
at 18°C gave the highest amount of soluble protein meanwhile E2 proteins did not show 
either host or temperature dependent changes in protein expression profiles. Therefore, all 
clones were subsequently expressed in Rosetta cells with induction of protein expression 
being performed at 18°C. 
 
4.3.2.2 Two-step purification process 
Lysates prepared from 5 L cultures of IPTG-induced Rosetta cells were subjected to a two-
step purification process. Firstly, lysates were injected through a Ni
2+
 affinity column to 
recover the His-tagged proteins, which were then eluted in lysis buffer B. Fractions 
containing eluted target proteins were pooled and incubated overnight with TEV protease to 
remove the His-tags. Following TEV digestion, samples were again injected through Ni
2+
 
column to separate the target proteins from cleaved His-tags and residual TEV protease 
(Figure 4.4). 
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Figure 4.4 Coomassie blue SDS-PAGE of large-scale protein purification before 
and after TEV protease cleavage: Lanes 2-5 show the band of target protein after 
incubation with TEV protease. TEV is visible as a 27 kDa band (arrow head) accompanying 
each protein band in the lane. All protein bands are in correct size compared to their 
respective bands before TEV protease incubation (lane 6-9), which have additional ~3 kDa 
due to the uncleaved His-tag and TEV site 
 
To remove histidine-rich contaminants, samples were also subjected to cationic or anionic 
exchange chromatography as indicated in Table 4.2. Peaks representing each protein are 
demonstrated in Figure 4.5A (Ni
2+
 affinity column) and Figure 4.5B (ion exchange column). 
 
Table 4.2 Q/SP selections for each protein: Selection of either cation or anion 
exchange columns for each protein is based on their pI and buffer pH. (MW): Molecular 
weight, (pI) Isoelectric point. 
Protein MW (Da) pI 
Buffer 
pH 
Net charge (in 
buffer) 
Column 
OTUB1 31284.0 4.85 8.0 -ve Q anion 
UBE2D2 16753.2 7.69 6.5 +ve SP cation 
UBE2E1 21404.18 8.77 6.5 +ve SP cation 
UBE2E2 22255.1 7.59 6.5 +ve SP cation 
ΔN
OTUB1 26951.35 5.14 8.0 -ve Q anion 
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(A) 
  
                    (i)                                        (ii) 
 
  
                    (iii)                                      (iv) 
(B) 
 
                   (i)                                        (ii) 
 
 
                   (iii)                                      (iv) 
     
Figure 4.5(A) and (B) Typical column peaks for (i) OTUB1, (ii) UBE2D2, (iii) UBE2E1 and (iv) UBE2E2: Ni
2+
 affinity column (A) and ion exchange 
column (B) show very prominent protein peaks measured by UV Absorbance at 280 nm (blue lines). The red lines represent the absorbance by nucleic acids at 
260 nm while the rest green and brown lines denote the gradient of increasing imidazole and salt concentrations.  
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4.3.3 Correct protein folding was analysed by 1D 
1
H NMR 
All purified protein samples were analysed by solution state NMR to ensure the expressed 
recombinant proteins are not misfolded in solution. The NMR spectrum was collected at 
25°C using a Bruker 600 MHz Avance solution-state spectrometer. Samples were analysed 
at a concentration of 0.2 mM in Tris buffer pH 7.4, mimicking the optimal human 
physiological pH. Figure 4.6 suggested that all the proteins are folded properly. In general, 
folded proteins exhibit a range of chemical shifts due to the anisotropic magnetic fields of 
proximal aromatic or carbonyl groups compared to the applied magnetic field. Thus, if very 
little chemical shift dispersion is observed, the protein may be unfolded, or may have an 
unstable structure. However, as all protein spectrums show a wide range of ppm, it can be 
assumed that they are all appropriately folded. The term ‘ppm’ refers to the unit of ‘parts per 
million’ or one part per 1 000 000 parts, which is used to measure a small increments in 
magnetic field range in NMR spectroscopy. The magnetic field range displayed in the 
common NMR diagram is very small compared with the actual field strength hence it is 
customary to describe this small value using a pseudo units like ‘ppm’. 
Sharp peaks observed in the spectrum also suggest that all proteins are well-behaved in 
solution. In general, aggregation causes peaks to be broadened and in extreme cases, 
formation of protein aggregates can result in no peaks being observed as peaks tend to merge 
into the baseline. Sometimes low molecular weight impurities (such as imidazole) can also 
be observed in 1D spectrums as sharp peaks amid the broader envelope of protein resonance. 
As seen in Figure 4.6, all of the tested spectra have these sharp peaks at 2.6-2.7 ppm, 
suggesting that sample purity or buffer exchange should be improved.  In this 1D NMR 
experiment, most of the signal overlapped heavily due to the large size of the protein. 
However, all proteins appeared to be folded properly and therefore suitable for use in 
subsequent biophysical and structural studies. 
 
 
Chapter Four | BIOPHYSICAL EVIDENCE OF BINARY E2:OTUB1 COMPLEXES FORMATION   
 
Page | 110  
 
 
 
 
 
Figure 4.6 1D-NMR spectrum: One-dimensional spectra of proteins were acquired at 
25°C in a Bruker 600 MHz Avance solution-state spectrometer. 
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4.4 Preliminary analysis of OTUB1 in complex with UBE2D2, UBE2E1 and 
UBE2E2 
4.4.1 Identification of an OTUB1:UBE2E1 complex by gel filtration chromatography 
As an initial approach to validate Y2H data, gel filtration (GF) chromatography was used to 
observe formation of complexes between predicted protein interaction partners. GF is a 
simple and reliable chromatographic method which can be used to separate proteins or 
complexes according to their size. In principle, proteins with higher molecular weights travel 
faster through the column as they will interact less with the matrix (Sun et al., 2004). In 
contrast, smaller proteins tend to diffuse into the matrix hence retarding their movement 
through the column. Thus, proteins are eluted in order of decreasing size. Superdex™ 75 GF 
column (GE Healthcare) is a composite of dextran and cross-linked agarose, and has the 
ability to size-fractionate multiprotein complexes of molecular weight in the range of 3-70 
kDa. Unlike ion exchange or affinity chromatography, molecules do not bind to the 
chromatography medium so buffer composition does not directly influence the resolution in 
GF. Tris-buffer pH 7.4 was used to mimic physiological pH and 0.15 M NaCl was included 
to avoid non-ionic interactions between the sample and the matrix. To observe interaction 
between proteins, each GF experiment involved injection of a quantified amount of each 
protein, both individually and in mixtures with their partner in pre-determined concentration 
ratios. 
In this experiment, quantified amounts of OTUB1 and E2 proteins were injected separately 
into the column followed by premixed samples consisting two protein partners in a 3:1 
E2:OTUB1 ratio. Differences in elution profiles for mixtures of protein with respect to their 
individual control samples are indicative of complex formation (Buechler et al., 1993). GF 
analysis demonstrated the presence of potential complex formation between OTUB1 and 
UBE2E1 but no clear complexes were observed with the other E2s. As shown in Figure 
4.7A, there is no significant shift in OTUB1:UBE2D2 mixture as the resolved peak from the 
mixture was clearly representing individual OTUB1 and UBE2D2 instead of one peak 
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indicating formation of a protein complex. It should be noted that the final concentration of 
mixed and single protein samples were set to be similar hence a decreased peak intensity 
observed in mixed samples was expected due to the presence of less single protein. 
Interestingly, mixtures of OTUB1:UBE2E1 gave rise to three unresolved peaks (Figure 
4.7B); one may represents a complex as it is the first to eluted suggesting a complex bigger 
than OTUB1 and UBE2E1, while the other two appear to represent individual proteins, as 
they elute at the same time when compared with each of the corresponding single sample. 
Because single sample analysis shows only one resolved peak for both OTUB1 and 
UBE2E1, it is unlikely that the first elution peak represents a dimer of either OTUB1 or 
UBE2E1. Theoretically, when 31 kDa OTUB1 and 21 kDa UBE2E1 form a complex, it is 
estimated to be 52 kDa in size but the first peak was eluted very close to the single OTUB1 
peak suggesting the size is not far from ~31 kDa. This may be explained by the fact that GF 
is fractionating the molecules based solely on their size, which in some cases can be biased 
by the protein conformation rather than simple molecular weight. In Figure 4.7C, 
OTUB1:UBE2E2 also does not give convincing evidence of complex formation because the 
peak pattern observed in the mixed sample does not show any significant shift. 
The absence of complex formation especially in the case of OTUB1:UBE2D2 mixture was 
surprising because in Y2H experiments OTUB1 shows the strongest interaction with 
UBE2D2.  However, considering that Y2H is binary system, possibly no other factors were 
needed for protein interaction meanwhile in vitro experiment may requires other participants 
apart from the two proteins to establish an interaction. 
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(B) 
                      
                                                    (C) 
 
Figure 4.7 Typical gel filtration column peaks: (A) OTUB1:UBE2D2 (B) 
OTUB1:UBE2E1 (C) OTUB1:UBE2E2 in Tris buffer pH 7.4. The dotted brown peaks 
represent OTUB1 protein alone, grey lines denote distribution of E2 proteins alone and blue 
peaks correspond to the mixture of OTUB1 and its E2 partner. 
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        E2 
        Complex 
       Legend: 
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4.4.2 ITC analysis of potential OTUB1:E2 complexes 
Initial ITC and NMR experiments were performed on the OTUB1:UBE2E1 complex, as this 
complex showed promising complex formation in GF analysis. ITC was performed to define 
the binding affinity, mechanism and stoichiometry of proteins within complexes. Obtaining 
an ITC profile for the OTUB1:UBE2E1 complex proved to be challenging. Since the Kd for 
this complex is unknown, the concentration of component proteins may require optimisation. 
An initial binding curve was observed when 0.73 mM UBE2E1 (in syringe) was titrated into 
75 μM OTUB1 (in cell) in 40 injections of 2 μl each. The ITC heat dilution curve, after 
subtracting background (established by titrating UBE2E1 into buffer without OTUB1) 
produced a final binding curve with a Kd = 0.15 mM, which generally indicates very weak 
binding (Figure 4.8). However, the curve was not considered satisfactory as the heat release 
was still detected when samples reached saturation, which is often a sign of buffer mismatch. 
The signal to noise ratio was very small suggesting a higher protein concentration was 
required to produce more significant peaks. Also, the small (near zero) ΔH value could 
suggest the reactions are unmeasurable or that a higher protein concentration is needed to 
increase ΔH values and enable prediction of the mechanisms of interaction. The data was 
fitted to a one-site binding model and although the n value of 0.00372 would not suggest a 
1:1 stoichiometry, this can be adjusted by reducing the amount of injection, seeing that 
saturation was reached at less than 40 injections.  
To generate a more reliable ITC binding curve, higher concentrations of protein were 
required to detect a significant heat release. However, when the concentration of UBE2E1 
was increased to 0.15 mM, it produce a curve which implies that double binding activities 
were happening (Figure 4.9). The most likely explanation for this result is the possibility that 
UBE2E1 might form dimers in high concentration. 
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 (A) 
 
 
 
 
Figure 4.8 ITC titration of UBE2E1 with OTUB1: (A) Experiment was performed in 
phosphate buffer pH 7.4 at 25°C. The concentrations of reactants are 0.73 mM UBE2E1 (in 
syringe) and 75 μM OTUB1 (in cell). The solid line corresponds to theoretical curves with n 
= 0.00372, Ka = 6.6x10
-3
 M
-1
 and ΔH = 1.1x10-6 cal/mol. (B) Dissociation constant = 1/Ka, 
lower Kd values indicate tighter binding and therefore a greater affinity and vice versa. 
 
 
 
 
 
 
Figure 4.9 UBE2E1 may form dimers at high concentration: Beside the heat release 
from OTUB1:UBE2E1 binding interaction, at higher concentrations of UBE2E1 (0.15 mM) 
there is evidence of a different binding mode. 
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When catalysing polyubiquitination, there is a high possibility for some E2 enzymes to act as 
dimers because at least one of the E2 monomers could remain associated with the substrate 
while maintaining continuous additions of ubiquitin monomers as an intramolecular reaction. 
The sequential addition of ubiquitin will probably require multiple cycles of E2-E3 binding 
and release. Also, the presence of a stable E2 dimer in the E2-E3 complex might circumvent 
the need for complete dissociation of the E3 from the E2 (David et al., 2010). 
To avoid any possibility of dimerisation, injection parameters were set in such a way that the 
protein concentration could not be increased. However, at this stage of the study, a decision 
was made to generate a truncated version of OTUB1 upon looking at the 2D-NMR spectrum 
of 
15
N-OTUB1 (discussed below). Hence it was decided that subsequent ITC experiments 
should be performed using the N-terminal truncated version of OTUB1. 
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4.4.3 (
1
H
15
N)-HSQC NMR experiment 
4.4.3.1 
15
N-labelled protein 
Isotopic-labelled proteins were produced by expression of target proteins in bacteria grown 
on minimal medium supplemented with 
15
NH4Cl as the sole nitrogen source and common 
glucose (McIntosh and Dahlquist, 1990). Basically, the minimal media contained all salts 
and trace elements required by the bacteria except for a carbon or nitrogen source. The 
15
N-
label is the simplest and cheapest form of label, which is mainly used to record the standard 
solution NMR HSQC spectrum. The HSQC spectrum is like a fingerprint of the protein 
because each peak corresponds to an NH of each amino acid residue. Highly purified 
15
N-
labelled protein can be prepared for 
15
N-HSQC in which the folding of protein could be 
checked and the quality of the spectrum could be assessed to determine whether it is worth 
recording other spectra and proceeding on to more expensive labelling schemes such as 
13
C 
labelling. 
15
N-labelled protein can also be useful for titrations with other proteins with which 
it forms a complex. Double-labelled proteins, or 
15
N
13
C-labelling on the other hand were 
produced by growing bacteria in minimal media supplemented with 
15
NH4Cl and 
13
C glucose 
(McIntosh and Dahlquist, 1990). This form of labelling enables straightforward assignment 
of both the backbone and side-chain 
1
H, 
13
C and 
15
N atoms using triple-resonance spectra. A 
high proportion of these assignments are required to precisely calculate the protein structure 
(McIntosh and Dahlquist, 1990). 
Initially, 
15
N-labelled OTUB1 protein was successfully produced and HSQC titration 
analysis performed on this protein with unlabelled UBE2E1 shows a distinct chemical shift 
indicating direct protein interaction. Double 
15
N
13
C-labelled protein was produced once but 
gave rather a weak signal. We therefore resorted to production of 
15
N-labelled protein to 
optimise OTUB1 expression. 
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4.4.3.2 Investigating the  OTUB1:UBE2E1 complex  
(
1
H
15
N)-HSQC spectra were recorded on 
15
N-OTUB1 in the absence and presence of 
unlabelled UBE2E1. From the 271 residues that make up OTUB1 protein, about 220 peaks 
are visible, suggesting that the protein was in a folded form since the spectra showed signs of 
dispersion. However, the rest of the peaks were observed as disordered and dispersed signals 
which overlapped with each other and therefore could not be counted. As seen in Figure 
4.10, a very dense spectrum was obvious in the region between 7.6 and 8.5 ppm on the 
proton chemical shift scale. Peaks in this region usually arise from residues that are in 
unstructured and flexible regions resulting in their brisk tumble movement. In contrast, 
residues held rigid by the structure tend to have very broad peaks indistinguishable from the 
background. This observation led to the decision to generate the truncated OTUB1 without 
the N-terminal region, which had previously been identified as an unstructured region 
(discussed in Chapter 3) in order to get a cleaner spectrum to evaluate the chemical shifts. 
Chemical shifts, or the changes in a peak position and intensity in an NMR HSQC spectrum 
indicate a change in the environment of the corresponding residue due to the protein being in 
a contrasting free or bound form. The proximity of the unlabelled partner in the complex will 
have the effect of modifying the environment of residues at the interface of the complex. As 
a result, residues involved in or affected by binding will have a different chemical shift than 
observed in the unbound form. To observe the chemical shifts upon formation of the 
OTUB1:UBE2E1 complex, a 2D-HSQC spectrum was acquired for uniformly deuterated 
15
N-OTUB1 with a titration of UBE2E1 in 1:1 ratio (Figure 4.10) 
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Figure 4.10 NMR titration 
15
N-OTUB1:UBE2E1: (
1
H
15
N)-HSQC spectra of 
15
N-
OTUB1:UBE2E1 (0.2 mM each at pH 7.4) recorded at 25°C using Bruker 800 MHz Avance 
spectrometer. Red peaks were coming from the free
15
N-OTUB1 while the complex of 
15
N-
OTUB1:UBE2E1 was represented by blue peaks. The black boxes emphasizing the area with 
the most noticeable chemical shifts.  
 
Comparison of the spectra acquired for free 
15
N-OTUB1 with the 
15
N-OTUB1:UBE2E1 
complex revealed a series of clear chemical shift perturbations induced by UBE2E1 binding. 
The perturbations of signals, ranged from differences in chemical shifts, increased line 
width, decreased peak intensity, through to complete loss of signal (Figure 4.10) suggesting 
specific points of contact between OTUB1 and bound UBE2E1. As yet, the perturbations 
could not be mapped and the exact amino acids involved in the interactions could not be 
determined due to the fact that amino acids within the OTUB1 spectrum have not yet been 
assigned and the disordered region within OTUB1 induced a dense central cluster of 
ambiguous peaks. As a result, a N-terminal truncated OTUB1 was generated as discussed in 
Chapter 3. 
Free
15
N-OTUB1 Complex of
15
N-OTUB1:UBE2E1 
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4.5 Analysis of the 
ΔN
OTUB1:E2 complex 
4.5.1 
ΔN
OTUB1 expression and purification 
The 
ΔN
OTUB1 protein was expressed and purified in the same manner as wild type OTUB1. 
For ion exchange chromatography, although the pI of 
ΔN
OTUB1 was slightly increased to 
5.14 compared to 4.85 for wild type OTUB1, the Q column and Tris-buffer pH 8.0 were still 
capable of retaining the protein in the column. Removal of the N-terminal gives a clearer 
NMR spectrum due to the elimination of the dense central part from disordered N-terminal 
(Figure 4.11). 
 
 
      
Figure 4.11 NMR spectrum of 
ΔN
OTUB1: The elimination of the dense spectrum 
region caused by the unstructured N-terminal region of OTUB1 makes the NMR spectrum 
easier to evaluate. 
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4.5.2 Improved gel filtration chromatography data 
Gel filtration chromatography experiments were repeated using 
ΔN
OTUB1 in combination 
with either UBE2D2 or UBE2E1 proteins. Both showed evidence of complex formation 
when mixed in a 1:1 ratio (Figure 4.12). Premixing of 
ΔN
OTUB1 and UBE2D2 in a 1:1 ratio 
gave rise to a significantly shifted peak, which elutes earlier than 
ΔN
OTUB1 suggesting the 
formation of a 
ΔN
OTUB1:UBE2D2 complex. A prominent small peak eluted just before the 
complex peak reached baseline indicating an excess of unbound UBE2D2. The same model 
can be seen in 
ΔN
OTUB1:UBE2E1 interaction, where a significantly shifted peak 
corresponding to a protein complex was observed. Surprisingly, when both single proteins 
were run independently, 
ΔN
OTUB1 (26.951 kDa) was eluted later than UBE2E1 (21.404 
kDa) even though it is bigger than UBE2E1 in size. This may be an example of how gel 
filtration chromatography patterns are dependent on both size and shape. To get information 
about the stoichiometry of complexes observed in GF studies and estimate the absolute mass 
of complexes, results obtained by gel filtration chromatography could be further explored 
using the SEC MALLS (Size Exclusion Chromatography–Multi-Angle Laser Light 
Scattering) method, where a gel filtration column is attached to light scattering equipment 
(Oliva et al., 2004). Unfortunately, this step could not be taken due to the limited amount of 
samples. 
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(A)        (B) 
 
Figure 4.12 Typical gel filtration column peak: (A) 
ΔN
OTUB1:UBE2D2, green line 
represents the single UBE2D2 protein, brown line represents 
ΔN
OTUB1 while the blue peak 
represents the complex of both proteins. (B) 
ΔN
OTUB1:UBE2E1, brown peak is 
ΔN
OTUB1, 
the grey one is single UBE2E1 and the blue peak corresponds to the complex of both 
proteins. All samples were run in Superdex™ 75 GF column and eluted in Tris buffer pH 
7.4.  
  
        
ΔN
OTUB1            E2                Complex 
 
         
 
       Legend: 
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4.5.3 Analysis of 
ΔN
OTUB1:UBE2D2 and 
ΔN
OTUB1:UBE2E1 thermodynamic profiles by 
ITC 
As stated in Section 4.4.2, preliminary analysis of UBE2E1 implied the formation of dimers 
at higher protein concentrations. This observation was supported by the fact that titration of 
0.5 mM UBE2E1 into buffer also produced a detectable heat release. For this reason, 
UBE2E1’s role as the ‘ligand’ in the syringe was replaced by ΔNOTUB1. In this experiment, 
2.1 mM 
ΔN
OTUB1 (in syringe) was titrated into 0.1 mM UBE2E1 (in cell) at 25°C cell 
temperature. The total injection was reduced from 40 to 15, in order to achieve 1:1 
stoichiometry. As can be seen in Figure 4.13, both 
ΔN
OTUB1:UBE2D2 and 
ΔN
OTUB1:UBE2E1 complexes appear to have affinity interaction with Kd = 3.89 μM and 
16.5 μM, respectively. The smaller unit of concentration for ΔNOTUB1:UBE2D2 implies that 
UBE2D2 binds to 
ΔN
OTUB1 with a slightly greater affinity than UBE2E1. Interestingly, 
these results are consistent with data from our initial Y2H studies where UBE2D2 always 
showed the strongest interaction profile. Negative heat flow and decrease in enthalpy 
(ΔH<0) in ITC measurements denotes that both complexes have exothermic reactions in 
which the heat is lost to the surroundings upon protein interaction. The one-site models and 
the value of n≈1 for both complexes clearly suggest that ΔNOTUB1:UBE2D2 and 
ΔN
OTUB1:UBE2E1 both adopted a 1:1 stoichiometry. Even though the ITC profiles were 
greatly improved compared to the experiment with full-length OTUB1, we cannot conclude 
that 
ΔN
OTUB1 has stronger affinity for E2s than FL OTUB1 because ITC experiments were 
performed using different parameters. Unfortunately, it was not possible to repeat the 
experiment with both versions of OTUB1 in comparison due to time restrictions and 
subsequent problems with protein production. 
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(A) 
  
   
(B) 
  
    
Figure 4.13 ITC titration of UBE2E1 and UBE2D2 with 
ΔN
OTUB1: Experiments 
were performed in phosphate buffer pH 7.4 at 25°C using 2.1 mM ΔNOTUB1 (in syringe) 
and 0.1 mM UBE2E1 or UBE2D2 (in cell). (A) The solid line corresponds to the 
ΔN
OTUB1:UBE2E1 binding curve with n = 1.16, Ka = 6.04x10
-4
 M
-1
 and ΔH = -0.576 
kcal/mol. (B) The solid line corresponds to the 
ΔN
OTUB1:UBE2D2 binding curve with n = 
0.961, Ka = 2.57x10
-5
 M
-1
 and ΔH = -2.604 kcal/mol.  
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4.5.4 Identification of possible points of contact in 
ΔN
OTUB1:UBE2D2 and 
ΔN
OTUB1:UBE2E1 complexes observed by shifts in (
1
H
15
N)-HSQC NMR spectra 
As discussed above (Section 4.4.3.2), during titration, the chemical environment of amino 
acid residues can change due to the protein being in the free or bound form, or a mixture of 
both. Figure 4.14 shows the peaks from 
ΔN
OTUB1:UBE2D2 titration in free form, 1:1 ratio 
and 1:2 (excess of unlabelled partner) ratio. Many of the signals from the complex (green 
and red) were shifted and even completely disappeared when compared to the black (free 
forms) signals, indicating residues which may be involved in binding. The same pattern was 
observed in Figure 4.15 where red and blue signals show some chemical shifts suggesting 
points of contact in the 
ΔN
OTUB1:UBE2E1 complex. To identify which amino acids 
correspond to shifted residues, NMR assignment on 
15
N
13
C-labelled protein should be 
performed. Also, because both complexes were large there were some overlapping signals in 
the 
15
N spectrum which could only be resolved by a three-dimensional spectrum. For the 
ΔN
OTUB1:UBE2D2 complex, comparison of the green signal (spectrum of 1:1 titration 
recorded for 1 hour) with the red signal (spectrum of 1:2 ratio recorded for 15 hours), it can 
be suggested that binding is not transient because the red signal did not return to the free 
form (black signal) over time. 
The exchange rates, as monitored by the NMR resonance characteristics, can be classified as 
slow, intermediate and fast on the chemical shift timescale. At substoichiometric quantities 
of the unlabelled partner, the NMR signals resonate at a position between those from the free 
and fully complexed states, which reflects the mole fraction of both the free and bound form. 
If the two different states are interchanging rapidly, the effect on the spectra will be to 
produce a single peak at a position reflecting the average populations of each state; this is 
fast exchange. If the spin are in slow exchange each state will give rise to separate peaks. In 
intermediate exchange a broad peak will arise between positions representative of either 
state. Analysis of the exchange rates for both complexes show that the shifted and loss of 
signal occur as early as 1:0.25 titration. Supposedly, with further additions of the unlabelled 
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partner, the resonance position should move closer to that in the bound state. However, in 
this experiment the signals stay shifted/lost for the full duration of the titration, suggesting 
slow exchange and tight binding. 
 
4.5.4.1 Are 
ΔN
OTUB1 not fully active? 
The conversion from free form to bound form appears to occur very early in titration (ratio 
1:0.25), which is far from a 1:1 ratio. The ITC experiment suggested that the OTUB1 was 
not fully active because up to 2.1 mM OTUB1 was used to titrate 0.1 mM E2s (a 21-fold 
excess of OTUB1) in order to achieve a 1:1 stoichiometry. This is twice the concentration 
suggested for ITC where usually for a complex with a micromolar Kd, a ten-fold 
concentration of sample in the syringe compared to the cell is recommended. For this reason, 
the unbalanced ratio in 
ΔN
OTUB1:E2 complexes maybe be due to less 
ΔN
OTUB1 in an 
‘active form’ being available for binding. In addition, the 15N-E2s titrated with ΔNOTUB1 
also gave a signal shifted/lost at 1:0.25 which remained throughout the titration, strongly 
supporting the hypothesis of 
ΔN
OTUB1 is only partly active. 
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(A) 
 
(B) 
 
Figure 4.14 2D NMR titration of 
ΔN
OTUB1:UBE2D2: (A) (
1
H
15
N)-HSQC spectra of 
15
N-
ΔN
OTUB1:UBE2D2, and (B) (
1
H
15
N)-HSQC spectra of 
15
N-UBE2D2:
ΔN
OTUB1 
recorded at 25°C using a Bruker 800 MHz Avance spectrometer. Black signals represent 0.2 
mM free
 
proteins, green are from the complex at 1:1 ratio recorded for 1 hour and red signals 
represent the complex at 1:2 ratio (excess of unlabelled partner) incubated in the 
spectrometer for 15 hours.  
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(A) 
 
(B) 
 
Figure 4.15 2D NMR titration 
ΔN
OTUB1:UBE2E1: (A) (
1
H
15
N)-HSQC spectra of 
15
N-
ΔN
OTUB1:UBE2E1, and (B) (
1
H
15
N)-HSQC spectra of 
15
N-UBE2E1:
ΔN
OTUB1 recorded at 
25°C using a Bruker 800 MHz Avance spectrometer. Red signals are derived from the 0.2 
mM free
 
proteins while blue signals represent signals from the complex at 1:1 ratio incubated 
in the spectrometer for 1 hour.  
Single protein Complex at 1:1 
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4.5.4.2 UBE2D2 and UBE2E1 share a similar interface in binding with 
ΔN
OTUB1 
(
1
H
15
N)-HSQC spectral superposition of the single 
15
N-
ΔN
OTUB1, 
15
N-
ΔN
OTUB1:UBE2D2 
and 
15
N-
ΔN
OTUB1:UBE2E1 complexes show that 
ΔN
OTUB1 is bound in a very similar 
position and orientation relative to both UBE2D2 and UBE2E1. In Figure 4.16, signals 
representing free 
ΔN
OTUB1 (blue) were either shifted or lost when in complex with UBE2D2 
(green) and UBE2E1 (red). Interestingly, the occurrence of chemical shifts at the same 
residues suggests that 
ΔN
OTUB1 uses the same surface to bind with both E2s. However, 
approximately 3-4 peaks have only blue (free) and red (
ΔN
OTUB1:UBE2E1) signals while 
green (
ΔN
OTUB1:UBE2D2) was lost, and in one peak only blue (free) and green 
(
ΔN
OTUB1:UBE2D2) were observed. This suggests that  although both E2s bind to the same 
surface, there are selective amino acids in 
ΔN
OTUB1 that only bind to either UBE2D2 or 
UBE2E1. The similarity of 
ΔN
OTUB1 binding surface with both E2s are not surprising 
because both E2s are very closely related in sequence and tend to also have common E3-
RING binding protein partners (Markson et al., 2009). 
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Figure 4.16 Superposition of free 
15
N-
ΔN
OTUB1, 
15
N-
ΔN
OTUB1:UBE2D2 and 
15
N-
ΔN
OTUB1:UBE2E1 2D NMR spectrum: Chemical shifts observed 
in all three spectrum suggested that a similar binding interface may be used by 
ΔN
OTUB1 to bind with UBE2D2 and UBE2E1. 
       free 
ΔN
OTUB1 
       complex 
ΔN
OTUB1:UBE2D2 
       complex 
ΔN
OTUB1:UBE2E1 
Legend: 
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4.5.4.3 Prediction of amino acids involved in 
ΔN
OTUB1:UBE2D2 interaction 
To further investigate the residues in UBE2D2 that interact with 
ΔN
OTUB1, we wished to 
compare the spectrum of our 
15
N-UBE2D2:
ΔN
OTUB1 complex with the spectrum of the 
qualitative UBE2D2 profile that is available in the PDB (Houben et al., 2004) (*BRMB 
accession number: 6277). However, this UBE2D2 assignment data was collected at a 
difference temperature, pH and salt concentration (26.85°C, pH 7.0, 150 mM KCl) compared 
to our experiments (25°C, pH 7.4, 50 mM Tris). Therefore, all the signals may not appear at 
the exactly same location. However, by overlaying the spectrum of 
15
N-UBE2D2:
ΔN
OTUB1 
with the known UBE2D2 NMR assignment, chemical shifts caused by binding interaction 
can be predicted. This is illustrated in Figure 4.17, in which the residues of  
15
N-UBE2D2 
making contact with 
ΔN
OTUB1 are represented by red peaks while green peaks correspond to 
the known UBE2D2 assignment. All red peaks that show distinct chemical shifts compared 
to the respective green peaks were considered to be the predicted points of contact. The 
prediction of UBE2D2 residues that are key in the binding interaction with 
ΔN
OTUB1 
allowed us to perform targeted mutagenesis studies (Chapter 5) to test the requirement for 
particular predicted contact points within OTUB1:E2 complexes. However, related residues 
in 
ΔN
OTUB1 could not be predicted due to the absence of data for OTUB1 in the PDB.  
Predicted 
15
N-UBE2D2:
ΔN
OTUB1 binding points were mapped onto the UBE2D2 3D 
structure and rendered using pyMol v1.3 to define the binding surface. As can be seen in 
Figure 4.18, the data suggests that the 1
st
 α-helix, L1 loop of 3rd and 4th β-sheet and the area 
around L2 loop connecting the 4
th
 β-strand and H2 α-helix are potentially the binding 
interface for UBE2D2. When compared to the structural model of UBE2D2:CNOT4 
complex (Dominguez et al., 2004), this suggests that 
ΔN
OTUB1 and CNOT4 (an E3 RING 
ligase) may utilise some of the same residues to interact with UBE2D2 (Table 4.3). At this 
stage of the project, the OTUB1:UBE2D2 structure was still unknown, therefore a 
hypothesis was made suggesting that OTUB1 and E3-RINGs may compete with each other 
to bind to UBE2D2. However, there are some differences in UBE2D2 binding residues 
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especially in the L2 loop connecting 4
th
 β-strand and H2 α-helix, which could also suggest 
that DUB and E3 may bind to similar residues but in a slightly different manner, which 
raises the possibility that in some cases it may be possible to form DUB:E3:UBE2D2 
complexes.  
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Figure 4.17 Superposition of 15N-UBE2D2:ΔNOTUB1 and known UBE2D2 profile: UBE2D2 surfaces that bind with ΔNOTUB1 were predicted by 
overlaying the spectrum of 15N-UBE2D2:ΔNOTUB1 (red) and known UBE2D2 NMR analysis (green). 
Our 
15
N-UBE2D2:
ΔN
OTUB1 Known UBE2D2 assignment 
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                  α1                 β1         β2              β3                  loop 1             β4   
N- |MALKRIHKELNDLAR|DPPAQ|CSAGPVGD|DM|FHWQATIM|GPNDSPYQGG|VFFLTIHF|PTDYPFKP|PKVA|FTTRIY 
                            loop 2              α2      α3     α4 
HP*NINSNGSI*CLDILRS|QWSPALTI|SKVLLSICSLLC|DPNPDDPLV|PEIARIYK|TD|REKYNRIAREWTQK|YAM -C 
                                                    
Figure 4.18 Predicted  UBE2D2 binding interface with 
ΔN
OTUB1: Structure of UBE2D2 and the predicted binding interface with  
ΔN
OTUB1 were 
depicted by the area labelled green (1
st
 α-helix), blue (L1 loop of 3rd and 4th β-sheet) and yellow (around L2 loop connecting 4th β-strand and H2 α-helix). The 
active site Asn77 and Cys85 are indicated by the asterisks (*). Picture generated using MacPyMOL v1.3. 
N- 
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Table 4.3 Comparison of 
ΔN
OTUB1 and CNOT4 binding sites on UBE2D2: 
Predicted UBE2D2 amino acids involved in 
ΔN
OTUB1 binding in comparison with CNOT4 
binding site from Dominguez et al. (2004).  
1
st
 α-helix 
L1 loop of 3
rd
 and 4
th
 β-
sheet 
L2 loop of 4
th
 β-strand 
and H2 α-helix 
ΔN
OTUB1 CNOT4 
ΔN
OTUB1 CNOT4 ΔNOTUB1 CNOT4 
Ala2 Ala2 His55  Leu86  
 Leu3 Thr58 Thr58 Asp87  
Arg5 Arg5 Asp59 Asp59 Ile88  
Ile6 Ile6 Tyr60 Tyr60 Leu89  
His7  Phe62  Trp93 Trp93 
Lys8   Lys63  Ser94 
Glu9 Glu9    Ala96 
Leu10 Leu10    Thr98 
 Asn11    Ile99 
Asp12 Asp12   Lys101 Lys101 
Leu13    Leu104 Leu104 
Ala14      
Arg15      
Asp16      
 
 
 
4.5.5 Co-crystallisation trial 
To verify that the interactions observed in solution-state NMR are also observed in solid-
state, a crystallisation trial was performed as a complementary approach to NMR 
experiments. Moreover, it is widely known that proteins greater than 30 kDa can be 
problematic in NMR structural studies. A protein of 30 kDa like OTUB1 will have around 
270 cross-peaks, which are difficult to identify via overcrowded 2D spectra. Although 
acquiring the spectra in a higher field or using a 3D, selective or segmental labelling strategy 
can alleviate these problems, the cost and technical difficulties made this an unattractive 
option. In addition, the most significant problem of large protein NMR studies is that of 
tumbling, although this can be surmounted Transverse Relaxation Optimised Spectroscopy 
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(TROSY) (Fernández and Wider, 2003). In contrast, crystallisation trials are not limited so 
much by size but by the search for exact condition for crystal growth. Unfortunately, in 
protein crystallisation, there are no empirical rules for finding the exact chemical condition 
that can crystallise a protein (Hosfield et al., 2003). The highly effective approach to identify 
optimal crystallisation conditions is to systematically explore chemicals or conditions that 
have been shown to deliver crystals. A strategy known as ‘sparse matrix’ randomly maps a 
wide sector of the crystallisation conditions using many different precipitants, salts and pH. 
Conditions are based on successful crystallisation experiments found in databases, the most 
famous being the PCCD (Protein-Complex Crystallization Database), established by Radaev 
et al. (2006). Sparse matrix strategies were chosen in this experiment because they usually 
provide an excellent starting point to begin the search for a successful crystallisation 
condition (Jancarik and Kim, 1991). 
In this experiment, co-crystallisation screens of the ~43.7 kDa complex of 
ΔN
OTUB1:UBE2D2 were performed using four commercially available sparse matrix initial 
condition kits, each having 96 unique mixtures of precipitants, salts and pH. Complexes 
were prepared at 10 mg/ml and 20 mg/ml concentrations and they were incubated at RT and 
4°C, which means that 1 536 initial conditions were screened for the ΔNOTUB1:UBE2D2 
complex. Crystal growth was observed under several conditions, however, most examples 
were probably due to the formation of UBE2D2 crystals as the individual UBE2D2 (positive 
control) also generated crystals in these particular conditions (Fig. 4.19A). These UBE2D2 
crystals were not brought forward for X-ray diffraction analysis because the structure had 
already been solved. Meanwhile, two positive hits that did not show any crystal growth in 
positive UBE2D2 controls were also observed, suggesting that these may be complex 
specific crystals. Unfortunately, these crystals did not achieve a diffraction-quality thought to 
be suitable for X-ray diffraction analysis. 
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The first hit of 20 mg/ml 
ΔN
OTUB1:UBE2D2 complex was observed as 2D needles 
(whiskers-like) growing from a single nucleation center in initial condition 15% (w/v) PEG 
20K,100 mM HEPES and pH 7.0 (Fig. 4.19B). Nucleation is the initial process that occurs in 
the formation of a crystal where a few molecules join together and become solute molecules 
(like an aggregate) but their combined attraction forces are stronger than other forces in the 
solution which usually can disrupt the formation of these aggregates. They are also called 
‘protocrystals’ or ‘pre-crystals’ that become nucleation sites upon which crystals will begin 
to grow. To encourage the crystal formation from the conditions giving this nucleation, an 
optimisation of the conditions was performed where 96 conditions were prepared with a 
range of 13%-24% (w/v) PEG 20K, 100 mM HEPES and a pH range from 6.5-7.8, arranged 
in a 96-well sitting drop-vapour diffusion crystallisation plate. 
The second hit was also observed in the 20 mg/ml complex conditions, in 20% (w/v) PEG 
8K,100 mM HEPES pH 7.5. These crystals appeared more promising than the first because 
they were observed in thin-plates shape and could be grow more in third dimension form 
(Fig. 4.19C). In this case, there may be a need for condition optimisation to get good 
diffraction crystals. The conditions were optimised with a range of new condition consisting 
PEG 8K 15%-25% (w/v), 100 mM HEPES and pH 7.2-8.4. Unfortunately, at this stage we 
started to experience problems with 
ΔN
OTUB1 homogeneity, which appeared to inhibit 
crystal formation in subsequent crystallisation trials.  
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(A) 
 
(B) 
 
(C) 
 
 
Figure 4.19 Crystal growth from initial trials: (A) Example of a very good crystal 
growth of UBE2D2 (10 mg/ml) in 0.1 M Tris pH 8.0. (B) 2D needles obtained from 
ΔN
OTUB1:UBE2D2 complex (20 mg/ml) in the condition 15% (w/v) PEG 20K, 100 mM 
HEPES pH 7.0 and (C) 3D needles obtained from 
ΔN
OTUB1:UBE2D2 complex (20 mg/ml) 
in 20% (w/v) PEG 8K, 100 mM HEPES pH 7.5. 
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4.6 Progress limitation 
Although the initial objectives of this chapter to express the recombinant proteins and 
validate the Y2H data were achieved, only limited insight could be provided into the 
structural information relating to the molecular organisation of OTUB1 and E2 protein 
complexes, which is important for understanding how DUB and E2 proteins aid the 
specificity and architecture of substrate ubiquitination on a systematic level. The main 
hindrance in this project was the failure to reproducibly produce pure 
ΔN
OTUB1 protein. 
During the later stages of this project, purification of 
ΔN
OTUB1 was routinely producing low 
yields of protein which appeared to exist in more than one species when analysed in 2D 
NMR spectra. However, no noticeable differences could be detected on SDS-PAGE gels, or 
by ion exchange chromatography, suggesting that both forms have the same molecular 
weight and pI. Much effort was invested to obtain the perfect form, however, this issue 
remained unresolved through to the end of the project. 
Usually the reason for low protein expression relates to vector selection or host growth 
conditions. However, the vector and host cells were carefully chosen and validated in the 
initial stages of this study. Therefore, only the expression and purification protocol were re-
evaluated. To begin with, the protease inhibitor PMSF was replaced by leupeptin, pepstatin 
and a protease inhibitor cocktail in order to see if there were any noticeable increases in the 
yield of purified proteins. When purifying an expressed protein, the first step is to rupture the 
cells resulting in the release of the total proteins, some of which might be proteases. These 
proteases may potentially digest proteins, including the expressed one, resulting in lower 
yield. PMSF as a serine protease inhibitor was chosen to inhibit targeted protein digestion 
considering that 
ΔN
OTUB1 itself is a cysteine protease hence the use of protease inhibitor 
cocktail might inactivate 
ΔN
OTUB1. However, other proteases may also act to reduce protein 
yield hence purifications were also performed with leupeptin (serine and thiol protease 
inhibitor), pepstatin (aspartic protease inhibitor) and protease inhibitor cocktail. 
Unfortunately, this had not effect on the 
ΔN
OTUB1 2D NMR spectrum. 
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Secondly, the protein purification was performed at both RT and 4°C (constantly on ice). In 
our previous procedure, some of the steps for example during the incubation with TEV 
protease (to remove the His-tag) were carried out overnight at RT. In both temperatures, the 
spectra still consisted of two forms of 
ΔN
OTUB1, which means that the aberrant form does 
not come about because of high temperature. 2D NMR screens were also performed on 
freshly purified protein and after being flash frozen in liquid nitrogen to confirm the 
formation of a second species was not simply caused by freezing. 
Other unsuccessful attempts to recover 
ΔNOTUB1 into a single ‘good’ form include 
modifying growth conditions. Proteins were expressed at higher ODs to ensure sufficient 
cells to express target protein and by shortening the induction time to avoid expression of 
toxic proteins. Also, addition of glucose was tested as a way of suppressing leaky expression. 
Unfortunately, none of the modifications in growth conditions or purification steps solved 
the problem. Moreover, the problem was only shown by the 
ΔN
OTUB1 protein as all E2s 
proteins continued to behave well throughout this project. For this reason, the vector as well 
as expression were also re-evaluated. 
To rule out the possibility of any contamination of the 
ΔN
OTUB1-pETM11 stock, the initial 
glycerol stock was revived and clones were isolated by maxiprep and sent for sequencing. 
They were then transformed into four different expression hosts namely: BL21 Star, B834 
pLysS, Arctic express and Rosetta cells to re-evaluate the expression host (Figure 4.20 
shows the SDS PAGE evaluation of these four hosts). Sadly, none of the hosts successfully 
restored the initial good spectrum of 
ΔN
OTUB1. 
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Figure 4.20 Coomassie blue 1D SDS-PAGE of newly purified 
ΔN
OTUB1: Purification 
ΔN
OTUB1 grown in four different expression host cells. Lanes 2,5,8,11 show the lysates after 
French press. Lanes 3,6,9,12 were the 
ΔN
OTUB1 after Ni
2+
 purification before incubation 
with TEV protease and lanes 4,7,10,13 show the 
ΔN
OTUB1 after TEV treatment and a 
second purification with ion exchange chromatography. 
 
Re-cloning the 
ΔN
OTUB1 ORF into pET151/D TOPO® His-tag vector (TOPO® Cloning 
were described comprehensively in Chapter 5) as an alternative to pETM-11 vector also does 
not give any fruitful outcome. The expression and purification of 
ΔN
OTUB1 consistently 
gave an extra signals on 2D NMR spectrum and the population ranged from being in the 
minority to the majority. Figure 4.21A shows the best spectrum that was achieved where the 
ΔN
OTUB1 spectrum is predominantly seen in the good form while Figure 4.21B shows a 
ΔN
OTUB1 preparation dominated by the ‘bad’ form of the protein. 
At this point, further expression studies were halted to focus on the generation and testing of 
NMR informed mutagenesis studies (Chapter 5).  
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(A) 
 
(B) 
 
 
Figure 4.21 2D NMR spectrum of double species
 ΔN
OTUB1: (A) and (B) Both are the 
(
1
H
15
N)-HSQC spectra of 
15
N-
ΔN
OTUB1. Black signals were from the good sample and pink 
were from suspected double species spectrum recorded at 25°C using a Bruker 800 MHz 
Avance spectrometer. Purification and expression of 
ΔN
OTUB1 continuously produced a 
second form in a variety of percentages, ranging from (A) the minority to (B) the majority. 
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5.1 Introduction 
In the previous chapter, our initial goal of getting detailed structural information about 
OTUB1:E2 complexes could not be achieved within the time scale of this project due to 
repeated problems in getting pure 
ΔN
OTUB1 expressed in a good conformation. 
Nevertheless, some useful information relating to the molecular requirements for OTUB1:E2 
complex formation were obtained from NMR studies. Therefore, a decision was made to 
investigate the role that these predicted contact points may play in mediating OTUB1:E2 or 
E2:E3-RING binary interactions. When studying the molecular requirements for specific 
protein-protein interactions, generation of targeted binding site mutants can be a powerful 
method of identifying residues required for interaction or partner specificity. Indeed, similar 
mutagenesis approaches have been used successfully to study interactions between OTUB1 
and other interaction partners (Edelmann et al., 2009; Juang et al., 2012). 
In this chapter, the targeted E2 proteins; UBE2D2, UBE2E1 and UBE2N; were studied with 
either full-length OTUB1 or
 ΔN
OTUB1. In addition, a panel of point mutations were 
introduced into UBE2D2 and the effects on interaction patterns with OTUB1, 
ΔN
OTUB1 or a 
broad collection of human E3-RING proteins were analysed by Y2H and in vivo 
immunofluorescence techniques in order to develop a better understanding of the molecular 
basis of OTUB1:E2 or E2:E3-RING interactions. Y2H analysis of mutant UBE2D2s and 
fluorescent co-localisation tests were done in collaboration with Amy Ponsford, who was a 
final year undergraduate student working in the Sanderson lab partially under my 
supervision. 
 
Chapter Five: 
TARGETED ANALYSIS OF E2:OTUB1 
COMPLEXES 
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The aims of this part of the project were: 
1) To generate a series of binding site-impaired UBE2D2 mutants based on predictions 
made from our previous NMR studies. 
2) To assess the relative effects of targeted mutations on the binding of OTUB1 and 
E3-RING proteins. 
3) To generate a model which predicts the mechanism of action of human E2:OTUB1 
complexes.  
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5.2 Generation of E2-binding site mutants  
5.2.1 Potential amino acids to be mutated 
In the previous chapter, a series of key residues in UBE2D2 were identified as being 
potentially important for interaction with OTUB1. These residues were identified by 
overlaying spectrum of the 
15
N-UBE2D2:
ΔN
OTUB1 complex and an available qualitative 
UBE2D2 NMR spectrum (Houben et al., 2004). However, predicted binding points may not 
be exact due to the parameter differences used to record both spectra. Also, observed shifts 
may be the consequence of binding rather than actual physical points of contact.  
Targeted mutagenesis was performed to generate forms of UBE2D2 with amino acid point 
mutations in order to determine if  amino acid substitution is sufficient to disrupt interaction 
with OTUB1, 
ΔN
OTUB1 or E3-RING proteins. If this is the case then it would implicate 
these particular amino acids as being necessary for binding to OTUB1, thereby validating 
our UBE2D2 binding interface predictions. Therefore, Lys8, Glu9 and Asp12 within the 1
st
 
α-helix and Lys101 at the L2 loop of 4th β-strand and H2 α-helix were chosen to be mutated 
as they are all polar, and polar amino acid side chains tend to gather on the outside of the 
protein where they have the potential to interact with the aqueous environment. Meanwhile, 
the non-polar amino acid side chains are buried on the inside to form a tightly packed 
hydrophobic core of atoms that are hidden from the aqueous environment (Alberts et al., 
2002). For this reason, we avoided mutating non-polar amino acids in order to avoid 
imposing unwanted conformational changes. Also, polar amino acids are more likely to be 
accessible on partner binding surfaces.  
Acidic side chain amino acids Glu9 and Asp12 were mutated to alanine or arginine 
respectively. As the simplest and smallest amino acid, mutation to alanine could ensure that 
the mutations will not disrupt the secondary structure due to stearic hindrance (Alberts et al., 
2002). It was also thought to be a good idea to mutate them into basic side chain amino acids 
such as lysine, arginine or histidine in order to swap the acidity/basicity in order to see if the 
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binding interaction could be abolished rather than substituting them into another acidic 
amino acids, which may also mediate interactions. Therefore, Glu9 was substituted to Ala 
(
E9A
UBE2D2) and Asp12 was changed to Arg (
D12R
UBE2D2). Meanwhile, both Lys8 and 
Lys101 were mutated to alanine (
K8A
UBE2D2 and
 K101A
UBE2D2). All these residues were 
mutated following QuikChange® site-directed mutagenesis protocol.  
 
5.2.2 Mutagenesis strategy 
QuikChange® mutagenesis was carried out as described in Chapter 2 and point mutations 
were made in such a way that encoded amino acids were converted to either alanine or 
arginine. Two complementary forward and reverse primers were designed carrying base 
substitutions in the centre of the primers as tabulated below: 
 
Table 5.1 Forward and reverse UBE2D2 mutagenesis primers: The mutation 
conferred by these primers is described in the “Mutation” column. Bases that are mutated 
compared to the wild-type sequence are highlighted in maroon and pink.  
 Mutation Forward primer Reverse primer 
1 K8A 
5’ G AAG AGA ATC CAC GCC 
GAA TTG AAT GAT CTG 3’ 
5’ CAG ATC ATT CAA TTC GGC 
GTG GAT TCT CTT C 3’ 
2 E9A 
5’ GA ATC CAC AAG GCC TTG 
AAT GAT CTG G 3’ 
5’ C CAG ATC ATT CAA GGC 
CTT GTG GAT TC 3’ 
3 D12R 
5’ G GAA TTG AAT CGC CTG 
GCA CGG G 3’ 
5’ C CCG TGC CAG GCG ATT 
CAA TTC C 3’ 
4 K101A 
5’ GCA CTA ACT ATT TCA 
GCC GTA CTC TTG TCC 
ATC 3’ 
5’ GAT GGA CAA GAG TAC GGC 
TGA AAT AGT 
TAG TGC 3’ 
5 K8A,E9A 
5’ GA ATC CAC GCC GCC TTG 
AAT GAT CTG G 3’ 
5’ C CAG ATC ATT CAA GGC 
GGC GTG GAT TC 3’ 
6 K8A,D12R 
5’ G AAG AGA ATC CAC GCC 
GAA TTG AAT CGC CTG 3’ 
5’ CAG GCG ATT CAA TTC GGC 
GTG GAT TCT CTT C 3’ 
7 E9A,D12R 
5’ GA ATC CAC AAG GCC TTG 
AAT CGC CTG G 3’ 
5’ C CAG GCG ATT CAA GGC 
GGC GTG GAT TC 3’ 
8 
K8A,E9A, 
D12R 
5’ C GCC TTG AAT CGC CTG 
GCA CGG G 3’ 
5’ C CCG TGC CAG GCG ATT 
CAA GGC G 3’ 
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The mutation strategy was to perform PCR-amplification firstly using primers 1, 2, 3 and 4 
on UBE2D2 in pDONR207 in order to generate a series of point UBE2D2 mutants: 
K8A
UBE2D2, 
E9A
UBE2D2, 
D12R
UBE2D2 and 
K101A
UBE2D2. PCR for double point mutations 
could then be performed in these single mutants using the appropriate primers. The PCR 
products were treated with DpnI before transforming them into chemically competent cells 
for positive transformants selection. DpnI is a restriction endonuclease that recognises a 
short DNA sequence (GATC), but only when the DNA is methylated. DNA replicated within 
bacteria, like the template used in the reactions, will be methylated and therefore recognised 
by DpnI which will subsequently cleaved it. However, products synthesised in vitro will not 
be methylated and will not serve a substrate. They will be safely transformed into bacterial 
cells as an intact vector containing the UBE2D2 mutants ORF. 
This experiment aimed to generate UBE2D2 as single, double, triple and quadruple mutants, 
however only 8 mutants were successfully generated. These included all the single mutants 
K8A
UBE2D2, 
E9A
UBE2D2, 
D12R
UBE2D2 and 
K101A
UBE2D2, and the double mutants 
K8A,K101A
UBE2D2, 
K8A,E9A
UBE2D2, 
K8A,D12R
UBE2D2 and 
E9A,D12R
UBE2D2. Generation of the 
mutants proved to be quite problematic and involved many failed attempts to produce 
positive transformants. This might be due to various factors for instance, an older 
mutagenesis kit was initially being used so there is a possibility that the enzymes may have 
denatured or not had their full activity. In addition, other solutions such as the reaction buffer 
or dNTPs may also not be as active due to numerous freeze-thaw cycles. Mutagenesis was 
therefore repeated using a new kit. The transformation was originally performed into XL 10-
Gold Ultracompetent cells and then changed to XL 1-Blue Supercompetent cells in an 
attempt to increase the transformation efficiency. Optimisations were also made to the 
volume of DpnI-treated DNA transformed into cells and also the transformation solution that 
was plated to increase the probability of bacterial colony growth. The generation of other 
double, triple and quadruple mutants was undertaken, however due to time constraints were 
not produced. Nevertheless, it would be interesting if all the remaining double mutants and 
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the triple and quadruple mutants could be produced in order to analyse further the 
importance of the binding sites. 
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5.3 Y2H evaluation of predicted UBE2D2 binding site 
Y2H screening was performed to assess the relative effects of mutations on protein 
interactions between mutant forms of UBE2D2 and OTUB1, 
ΔN
OTUB1 or E3-RING 
proteins. Yeast clones of UBE2D2 mutants were prepared as described in Chapter 3. Wild 
type and mutant forms of UBE2D2 protein expressed as Y2H bait fusions were then mated 
with a OTUB1 prey clone to observe colony growth. Mutant UBE2D2 clones which no 
longer show interactions with OTUB1 indicate amino acid residues which in some way 
facilitate OTUB1:UBE2D2 interaction. However, it should be noted that mutations that 
disrupt interaction between UBE2D2s and OTUB1s may exert effects by changing the 
conformation of UBE2D2 hence making it a non-functional protein. To ensure that 
mutations which disrupt UBE2D2:OTUB1 interaction do not induce unwanted 
conformational changes, mutant forms of UBE2D2 were also screened against a series of 
known interaction partners. Therefore, a complementary Y2H assay was also performed to 
screen UBE2D2 WT and mutants against a selection of E3-RING ligases. In a study 
performed previously in this laboratory, RNF5 and RNF185 were found to interact with WT 
UBE2D2, whereas RNF144B did not, hence these clones acted as positive and negative 
controls for the Y2H screening between UBE2D2s and OTUB1s. 
 
5.3.1 Y2H screen results 
5.3.1.1 UBE2D2 WT and mutants versus OTUB1 full-length and truncated 
Analysis of UBE2D2 mutants demonstrated a variety of effects on OTUB1 binding in which, 
some mutants do not influence the interactions while others abolished the interaction. The 
E9A mutation both as a single and double mutation with K8A and D12R, abolishes 
interaction with OTUB1 on both -WLA and -WLH(3-AT) plates (Figure 5.1A). Meanwhile, 
the K101A mutation appears to cause a reduction in the binding affinity between UBE2D2 
and OTUB1 as the yeast growth only appears on the less stringent -WLH(3-AT) selection 
plate. In contrast, K8A and D12R mutants do not abolish protein interaction when present as 
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single mutants, however when combined as double mutants binding was clearly impaired as 
no growth was observed on -WLA selection. Interestingly, the K8A+K101A mutation 
actually induced interaction with OTUB1 even though the K101A single mutation showed 
less growth on the -WLH(3-AT) plate and no growth on the -WLA plate. Growth of the 
double mutant also appeared to be weaker on the -WLA plate. The K8A and D12R mutants 
alone still allowed protein interaction; however when E9A is combined with either K8A or 
D12R the interaction is completely abolished. This experiment shows that K8A mutant 
interacts with 
ΔN
OTUB1 even though the wild type does not show any growth suggesting a 
decrease in the binding affinity as discussed in Chapter 3. 
Overall, it can be seen that Glu9 of UBE2D2 is required for interaction with OTUB1. This is 
supported by the lack of yeast growth by the double mutants K8A+E9A and E9A+D12R 
even though K8A and D12R mutations do not abolish interaction by themselves, suggesting 
that the E9A mutation has a dominant negative effect over other mutations. Data from this 
study also suggests that Lys101 may also be involved in forming the interaction surface, but 
may not be absolutely vital for OTUB1 binding as some degree of interaction is still 
observed on the less stringent plate. The lack of growth caused by the K8A+D12R double 
mutant suggests that mutation of just one residue is not enough to abolish the interaction but 
with both substituted binding is no longer feasible. These amino acid residues may therefore 
still form part of the interaction surface. The growth seen in the presence of the double 
K8A+K101A mutation suggests that the K8A mutation exerts a dominant effect over the 
K101A mutation, so even though the K101A mutation causes a reduction in binding affinity, 
the presence of the K8A mutation is enough to maintain binding. 
The importance of the N-terminus of OTUB1 was also demonstrated in this experiment by 
the lack of interaction observed between 
ΔN
OTUB1 and WT UBE2D2 or all UBE2D2 
mutants except K8A. Loss of yeast growth suggests that the ubiquitin-binding domain 
contained at the N-terminus of OTUB1 increases the binding affinity of OTUB1 for 
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UBE2D2. Previous studies have suggested that E2 enzymes charged with ubiquitin produced 
higher affinity binding for OTUB1 so it is possible that when OTUB1 cannot bind to 
ubiquitin attached to the E2, the proteins cannot interact or have lower affinity. Meanwhile, 
there is the possibility that the K8A mutation is causing a structural change to UBE2D2 that 
could open up, for example, a new binding site, or reveal a different residue or conformation 
which allows a weaker interaction with OTUB1 even though it is missing the N-terminus. 
 
5.3.1.2   Analysis of interactions between WT and mutants forms of UBE2D2 with known 
E3-RING interaction partners 
A complementary Y2H assay was performed to screen WT UBE2D2 and UBE2D2 mutants 
against three E3 RING ligases; RNF5, RNF185 and RNF144B. In previous Y2H screens 
performed in the Sanderson laboratory, RNF5 and RNF185 were shown to interact with WT 
UBE2D2, while RNF144B did not interact with WT UBE2D2. Results presented in Figure 
5.1B show that the UBE2D2 mutant E9A abolished interaction with OTUB1, however there 
is still interaction with RNF185 shown on both the -WLA and -WLH(3-AT) plates. The 
K101A mutant also abolished interaction with OTUB1 but still interacts with RNF185, again 
on both plates. The double mutation K8A+D12R causes a decrease in the binding affinity to 
OTUB1, however with RNF185, high affinity binding is detected on both plates. The  
E9A+D12R double mutant also shows interaction with RNF185 however they completely 
abolished interaction with OTUB1. The K8A+E9A double mutation however abolishes 
interaction with both RNF185 and OTUB1. Interestingly, the K8A+D12R double mutant, 
but not WT UBE2D2, interacts with RNF144B. Only WT UBE2D2 and the D12R mutant 
maintains binding to RNF5. All other single and double mutations abolished this interaction. 
The results from this Y2H study suggest that the mutations are not causing gross 
conformational changes in UBE2D2 that could inactivate the protein. Therefore, it would 
appear that these mutations specifically block interaction with OTUB1. The K8A+E9A 
double mutant shows no growth on both -WLA and -WLH(3-AT), suggesting that this 
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double mutation may cause a structural change in UBE2D2 that make it non-functional as 
this mutation also inhibits OTUB1 binding. However it is also possible that these two amino 
acids are required for the binding of both OTUB1 and E3-RINGs. Surprisingly, the 
K8A+D12R double mutation interacts with RNF144B, suggesting that these two mutations 
together may reveal or create a new binding site or residue that increases affinity of UBE2D2 
binding to E3-RINGs. The binding of some but not all E3-RING proteins to UBE2D2 was 
inhibited by some of the same UBE2D2 mutations that inhibited OTUB1 binding, suggesting 
that in many cases OTUB1 and E3-RING binding to E2 proteins may be a competitive 
process. 
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Figure 5.1 Mutant UBE2D2 interactions in Y2H: (A) OTUB1 FL and 
ΔN
OTUB1 prey 
mated against mutant UBE2D2 baits on SD-WLA and SD-WLH(3-AT) at day seven. (B) E3 
RING ligases prey mated against mutant UBE2D2 baits on SD-WLA and SD-WLH(3-AT) 
at day seven. (C) Grid positions of the UBE2D2 mutant baits assayed in Figure (A) and (B).  
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5.3.2 Competitive and non-competitive OTUB1:E3 RING:UBE2D2 binding models 
Results in this experiment support both the competitive inhibition and non-competitive 
binding model presented in Figure 5.2. The data from Y2H assays show that some mutants 
do and others do not inhibit E3-RING binding. Figure 5.2A shows that when OTUB1 is 
bound to UBE2D2, this prevents E3-RING binding. Moreover, data from this experiment 
show that the interaction between RNF5 and UBE2D2 is inhibited by K8A, E9A and K101A 
mutations, and E9A+K101A also prevents OTUB1 binding. This suggests that RNF5 and 
OTUB1 use some of the same residues to bind to UBE2D2, and this supports a competitive 
mechanism for some E3-RING proteins. On the other hand, mutations that do not allow 
OTUB1 to bind but do not disrupt E3-RING RNF185 binding could suggest that RNF185 
may bind in a slightly different way, which supports the non-competitive inhibition model as 
RNF185 interacts with all but one mutant analysed in this study, so could therefore be 
binding to UBE2D2 at a different site other than OTUB1. 
However, it is also interesting to consider that mutations of UBE2D2 might change its 
specificity towards E3-RINGs. Based on their evolutionary comparison of the UBC fold in 
E2 proteins, it has been proposed to adopt ‘three shells’ of amino acids; the solvent 
accessible first shell which is directly involved in Ub/UBL conjugation, the second shell (or 
the inner core structures) partially covering the first shell and finally the third shell, the 
actual surface residues which mediate direct interactions with other partners like E1 and E3 
proteins (Figure 5.3). If these properties are true then it should be possible to synthesise for 
example a UBE2N mutant that resembles UBE2D2 by mutating surface (third shell) 
residues. In addition, mutation of second shell residues also lead to changes in E3 
interactions, as they support the correct organisation of third shell residues (van Wijk and 
Timmers, 2010). 
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Figure 5.2 Binding model of UBE2D2, OTUB1 and E3 RINGs: (A) Competitive 
binding model. Y2H results support the competitive model that suggests OTUB1 and E3-
RINGs compete for the same or similar binding site on UBE2D2. (B) Non-competitive 
binding model. This model suggests that E3 RINGs bind to residues that are not involved in 
OTUB1 binding. OTUB1 inhibits ubiquitination of targets through a non-competitive 
mechanism. Figure adapted from Nakada et al. (2010).  
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Figure 5.3 E2 shell-like model proposed to be important for selectivity of key 
enzymes (E1, E3, Ub/UBL) in directing Ub/UBL-conjugation pathways: (A) and (B) 
Evolutionary-diverged, mutational distances of amino acids in E2 enzymes concentrate at 
one side of protein according to the colour key. (C) Schematic representations of the shell-
model for E2 enzymes. The first shell contains the catalytic cysteine, connected through the 
second shell with the third shell that contains structural elements that mediate selectivity 
towards Ub/UBL, E1s and E3s. Figure from van Wijk and Timmers (2010). 
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5.4 Expression and purification of UBE2D2 mutant proteins 
The work in this part was done concurrently with experiments performed in Chapter 4 to sort 
out 
ΔN
OTUB1 expression and purification problems. The UBE2D2 mutants which showed an 
interesting Y2H result were cloned into the pET151/D vector that fuses a His-tag to the 
protein and purified for NMR titration experiment with 
ΔN
OTUB1, in case problems with 
production of 
ΔN
OTUB1 could ever be resolved. Moreover, as an alternative to the pETM-11 
vector, 
ΔN
OTUB1 was also cloned into this vector to ensure that the problem of 
ΔN
OTUB1 
heterogeneity is not caused by pETM-11. 
 
5.4.1 Directional TOPO® Cloning 
The chosen method for cloning UBE2D2 mutants into suitable expression vector was to use 
the Champion TOPO® cloning kit from Invitrogen. The vector pET151/D contains the T7 
bacteriophage promoter for a high inducible expression similar to pETM-11, and also has an 
N-terminal His-tag and TEV cleavage site (Figure 5.4A). TOPO® cloning does not require 
any DNA ligases to clone the targeted genes into specific vectors. This system merely relies 
on Taq polymerase to amplify the gene with primers containing TOPO® sites (CACC). The 
vital feature of this system is the pre-linearised vector containing topoisomerase at the 5’ and 
3’ ends of the vector which functions as both restriction enzyme and ligase. Directional 
TOPO® cloning enables cloning of the blunt-ended PCR products in a 5´ to 3´ orientation 
directly into the vector in 5 minutes ligation reaction, thereby eliminating subcloning steps 
and saving a lot of time. The vectors contain a single-strand GTGG overhang on the 5´ end 
and a blunt end on the 3´ end. The four-nucleotide overhang invades the double-strand DNA 
of the PCR product and anneals to the CACC sequence at 5´ end and topoisomerase will then 
ligate the PCR product in the correct orientation, similar to the method described in Shuman 
(1994). 
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Figure 5.4 Map of pET151/D-TOPO® vector: Visible prior to the topoisomerase site 
are His-tag and TEV site, which function in producing the expressed protein with a cleavable 
N-terminal 6xHis-tag. Ampicillin resistance serves as a selectable marker for this vector. 
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5.4.1.1 Primer design and the TOPO® cloning principle 
All forward primers have the CACC sequence at the 5’ end of the primer; this was to ensure 
the topoisomerase reaction worked. The remainder of the primer was designed to provide a 
suitable annealing length complementary to the two strands of the target DNA, with a 
melting temperature (Tm) between 50°C-58°C and the Tm difference between the forward and 
reverse primers should be no more than 2°C to allow efficient PCR reaction. 
 
Table 5.2 TOPO® forward and reverse primers: ORF Primer 5’ to 3’ (first base 
position indicated at 5’ end) with CACC addition denoted by the green font. 
 Forward primer Reverse primer 
OTUB1 
5' CAC CAT GGC GGC GGA 
GGA AC 3' 
5' CTA TTT GTA GAG GAT ATC GTA 
GTG TCC 3' 
ΔN
OTUB1 
5' CAC CGA GAT TGC TGT 
GCA GAA CC 3' 
5' CTA TTT GTA GAG GAT ATC GTA 
GTG TCC 3' 
UBE2D2 
5' CAC CAT GGC TCT GAA 
GAG AAT CCA C 3' 
5' TTA CAT CGC ATA CTT CTG AGT CC 
3' 
UBE2E1 
5' CAC CAT GTC GGA TGA 
CGA TTC G 3' 
5' TTATGTAGCGTATCTCTTGGTCC 3' 
UBE2N 
5' CAC CAT GGC CGG GCT G 
3' 
5' TTA AAT ATT ATT CAT GGC ATA 
TAG CCT CGT CCA TG 3' 
 
 
The PCR products were then incubated with the linear vector that already has the 
topoisomerase enzyme covalently attached to both of its strands' free 3' ends. When the free 
5' ends of the PCR product strands attack the topoisomerase (or 3' end) of each vector strand, 
the strands are covalently linked by the already bound topoisomerase. This reaction proceeds 
efficiently when this solution is incubated at room temperature with required salt to prevent 
re-cutting by the topoisomerase. Reaction products were transformed into chemically 
competent cells and positive transformants were selected from ampicillin selection plate. 
Overall, TOPO® cloning proved to be a more convenient protocol compared to conventional 
cloning with the pETM-11 vector.  
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5.4.1.2 Purification of UBE2D2 mutant proteins 
Following cloning of the UBE2D2 mutants into the His-tag pET151/D TOPO® vector, they 
were transformed into Rosetta expression cells for large-scale protein purification. Protein 
expression and purification were performed in the same manner as for wild type UBE2D2. 
Although some modifications in ion exchange chromatography were required due to the pI 
being either increased or decreased upon amino acids substitution, all mutants were purified 
in satisfying yield and were found to be correctly folded by analysis of 1D NMR spectra. 
However, no binding experiments could be done on them until the end of this project since 
the problem with 
ΔN
OTUB1 could not be solved. 
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5.5 Immunofluorescence study of OTUB1 and E2 conjugase proteins 
To determine the subcellular distribution of the enzymes, co-localisation experiments were 
performed by co-expressing the OTUB1 and the E2 conjugases in mammalian cells. For this 
study, OTUB1 and the selected E2 proteins were transferred from pDONR223 (or 
pDONR207) entry vectors into fluorescent-tagged mammalian expression constructs. 
Although in terms of validation, it has already been shown that OTUB1 interacts with these 
E2s, the location in which they interact has not yet been established. As individual enzyme, 
OTUB1 possesses a putative nuclear localisation signal and resides in the nucleus of porcine 
kidney cells (Balakirev et al., 2003; Shan et al., 2009). However, recent work revealed that 
OTUB1 regulates p53 in the cytoplasm (Sun et al., 2012). On the other hand, analysis of the 
localisation of UBE2A/B, UBE2D1, UBE2D2, UBE2D3, UBE2E1, UBE2E2, UBE2N and 
UBE2R1 shows that the Ubc4/5 family proteins (UBE2D1, UBE2D2, and UBE2D3) 
specifically co-localised with c-Cbl in endosomes (Umebayashi et al., 2008). UBE2D2 was 
also found to co-localised with Nedd4 in the cytoplasmic periphery (Anan et al., 1998) and 
UBE2N has been shown to regulate p53 also in the cytoplasmic compartment (Laine et al., 
2006). While UBE2D2 and UBE2N seem to be cytoplasmic proteins, UBE2E1 co-
immunoprecipitates and co-localises with Ataxin-1 protein in the nucleus (Hong et al., 
2008).  
In this experiment, the main objective was to evaluate whether co-expression causes a 
change in the distribution that could suggest a particular localisation for interaction. OTUB1 
and 
ΔN
OTUB1 were transferred into pEGFP-N2 vector that fuses an N-terminal green 
fluorescent-tagged to the protein. It should be noted that OTUB1 in pDONR223 does not 
have any stop codon (Rual et al., 2004), therefore only N-terminal tags will be suitable to 
OTUB1. Meanwhile, all the E2 enzymes were transferred into pG-cherry-mGR (kindly 
contributed by Sheila Ryan, University of Liverpool). ORF cloned in this vector will be 
expressed in mammalian cells as a tagged protein with C-terminal red fluorescent-tag. All 
clones were sequence-verified before transfecting into HeLa cells for immunofluorescence 
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studies. Vectors containing gene of interests were then singly transfected or co-transfected 
into HeLa cells to observe any overlap in their distribution, or changes when co-expressed to 
suggest the potential for interaction.  
 
5.5.1 Localisation of OTUB1, 
ΔN
OTUB1, UBE2D2, UBE2E1 and UBE2N 
Immunofluorescence studies showed that OTUB1 localised to the same cellular 
compartments as the E2 enzymes, which shows that they have a potential for interaction in 
vivo. This experiment demonstrates that OTUB1, UBE2D2 and UBE2N are localised 
throughout the cell while UBE2E1 is predominantly nuclear.  
In Figure 5.5, OTUB1 and 
ΔN
OTUB1 prove to have a diffuse localisation throughout the cell. 
Meanwhile in Figure 5.6, UBE2E1 appears to have a predominantly nuclear localisation, 
consistent with literature reports. Also, it can be confirmed that similar to OTUB1 and 
ΔN
OTUB1, UBE2D2 demonstrates a diffuse localisation throughout the cell, as does UBE2N, 
although it does appear to have a stronger localisation in the nucleus which would be 
consistent with its reported role in DNA repair (Nakada et al., 2010).  
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Figure 5.5 Localisation of (A) OTUB1 and (B) 
ΔN
OTUB1 singly transfected into HeLa 
cells. Both transfections show a wide distribution throughout the cell. The DAPI blue stain 
shows cell nuclei while OTUB1 and
 ΔN
OTUB1 are observed in green.  
 
 
 
 
(A) 
 
 
 
(B) 
 
 
 
 
(C) 
   
Figure 5.6 Localisation of (A) UBE2N, (B) UBE2E1 and (C) UBE2D2 in HeLa 
cells: UBE2N and UBE2D2 show a diffuse distribution throughout the cell while UBE2E1 
shows a nuclear distribution. The DAPI blue stain shows cell nuclei while the E2s are 
observed in red.  
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DAPI Merge OTUB1-GFP 
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5.5.2 Co-localisation study of OTUB1 and 
ΔN
OTUB1, with E2 proteins 
Co-localisation studies were performed to determine whether OTUB1 co-expressed with the 
E2s could cause any recruitment of either protein to a particular subcellular localisation, thus 
implying a physical interaction. As seen in Figure 5.7, when OTUB1 is co-expressed with 
UBE2D2 and UBE2N, there does not appear to be any change in the subcellular distribution 
of any of the proteins. However, when OTUB1 is co-expressed with UBE2E1, there does 
appear to be some recruitment of OTUB1 to the nucleus compared to when OTUB1 is singly 
transfected; however it is still localised throughout the cell. There is no change in the 
subcellular distribution of UBE2E1 compared to its single transfections where it still shows 
localisation predominantly to the nucleus and small punctuate structures in the cytoplasm. 
In Figure 5.8, there do not appear to be any changes in the subcellular distribution of any of 
the proteins when co-expressed in which, 
ΔN
OTUB1 and UBE2D2 still show a wide 
distribution as when singly transfected and UBE2N still appears to have a stronger 
expression in the nucleus. In conclusion, co-expression of the E2 enzymes UBE2D2, 
UBE2E1 and UB2N with both OTUB1 and 
ΔN
OTUB1 did not alter the distribution of any of 
the proteins; however they still have the potential to co-localise as they are expressed within 
the same cellular compartments. 
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Figure 5.7 Co-localisation of (A) UBE2D2, (B) UBE2E1 and (C) UBE2N with 
OTUB1 in HeLa cells: When compared to single transfections the subcellular distribution 
of OTUB1 does not change when co-expressed with UBE2D2 and UBE2N, suggesting that 
one does not recruit the other to certain organelles when co-expressed. However OTUB1 
seems to be slightly more nuclear when co-expressed with UBE2E1. The DAPI stain shows 
cell nuclei. 
 
 
 
 
(A) 
 
 
 
(B) 
    
Figure 5.8 Co-localisation of (A) UBE2D2 and (B) UBE2N with 
ΔN
OTUB1 in HeLa 
cells: There appears to be no change in subcellular distribution even though OTUB1 is 
missing its N-terminus. The DAPI stain shows cell nuclei. 
 
DAPI Merge UBE2D2-mCherry 
DAPI Merge UBE2E1-mCherry 
UBE2N-mCherry DAPI Merge 
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ΔNOTUB1-GFP 
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6.1 Solved structures of OTUB1:UBE2D2 and OTUB1:UBE2N complexes 
Two comprehensive papers addressing the structural information of OTUB1:UBE2D2 and 
OTUB1:UBE2N complexes were published separately on February 10
th
 and February 22
nd
 
2012 (Juang et al., 2012; Wiener et al., 2012) while we were in the process of preparing this 
thesis. Juang et al. (2012) demonstrated that ubiquitin-charged UBE2D2 is recognised by 
OTUB1 through contacts with both donor ubiquitin and the E2 enzyme. By mimicking the 
Lys48-linked ubiquitin recognition, the free ubiquitin interacts with the N-terminal ubiquitin-
binding site on OTUB1 to promote binding with the ubiquitin charged UBE2D2 protein 
(Juang et al., 2012; Wiener et al., 2012). 
OTUB1 has been proven to have specificity towards K48-linked ubiquitin chains (Edelmann 
et al., 2009). The interaction of the two ubiquitin molecules with OTUB1 puts the K48 of the 
donor ubiquitin in immediate proximity to the C-terminus of the distally bound ubiquitin, 
therefore this binding configuration might reflect how OTUB1 recognises its preferred 
substrate, K48-linked ubiquitin chains. In addition, the active site cysteine is well positioned 
to attack the K48-linked isopeptide bond. The interactions of OTUB1, UBE2D2 and two 
ubiquitin molecules (donor ubiquitin and free ubiquitin) are demonstrated in Figure 6.1. The 
specific surface residues involved in the interactions are defined in Table 6.1, which also 
revealed that the UBE2D2 surface obviously overlaps with E3 binding surface suggesting 
that OTUB1 and E3 would compete with each other to bind to E2 proteins (as summarised in 
Table 6.2). 
  
 
Chapter Six: 
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Figure 6.1 Schematic and ribbon representation of Ub~UBE2D2-OTUB1-Ub 
complex: (1) and (2) OTUB1:UBE2D2 binding surfaces consist of a larger surface in the 
center of OTUB1 (red) and UBE2D2 (blue) and a smaller contact at the catalytic cleft region 
of UBE2D2. (3) and (4) Two regions of OTUB1:donor Ub (brown) binding surfaces. (5) 
OTUB1:free Ub (yellow) binding interface. (6) UBE2D2:donor Ub binding surface involves 
little contact between C-terminus (Gly76) of the donor Ub and the catalytic cysteine of 
UBE2D2. Figure generated using MacPyMOL v1.3. 
*Details on specific surface 1-5 residues are elaborated in Table 6.1. Meanwhile, surface 6 
only involves Gly76 of ubiquitin and Cys85 of UBE2D2 hence no elaboration needed.  
  
Donor (proximal) 
ubiquitin 
Free (distal) 
ubiquitin 
5 
2 
1 
3 
4 
6 
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Table 6.1 Specific residues that mediate interactions in Ub~UBE2D2-OTUB1-Ub 
complex: (A) Binding interface between OTUB1 and UBE2D2. (B) OTUB1 and donor 
ubiquitin. (C) OTUB1 and distal (free) ubiquitin. 
(A) Surface 1  Surface 2 
OTUB1 UBE2D2 OTUB1 UBE2D2 
helices α5, α7, 
and α9-α10 linker 
helix α1, the α2- 
α3 linker, and the 
β3-β4 linker 
helix αA 
catalytic cleft 
region 
Phe130 Met1 Asp27 Lys63 
Thr131 Arg5 Glu28 Lys66 
Phe133 Lys8 Met31 Ser83 
Thr134 Asp12 Asp35 Arg90 
Ile135 Pro61  Ser91 
Asp137 Phe62   
Phe138 Lys63   
Asp169 Gln92   
Tyr170 Ser94   
Val173 Pro95   
Leu177 Ala96   
Gln206 Thr98   
Glu209 Lys101   
Pro210    
Met211    
Lys213    
 
(B) Surface 3  Surface 4 
OTUB1 Donor Ubq OTUB1 Donor Ubq 
loop regions (α1-
α2, b2-α3, β4-β5) 
β3 to β5 
N-terminal helix 
αA 
β1, β3, β4, and 
intervening 
linkers 
Tyr61 Lys48 Tyr26 Lys48 
Ala62 Arg54 Ile30 Arg54 
Asp65 Ser57 Gln33 Ser57 
Tyr68 Asp58 Gln34 Asp58 
Pro87 Tyr59 Arg36 Tyr59 
Asp237 Asn60 Ile37 Asn60 
Pro263 Gln62 Gln38 Gln62 
His265  Ile41  
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(C) Surface 5 
OTUB1 Distal Ubq 
helix α10; strands β3, β3’, and β4; and 
irregular loop region connecting helices 
α7 and α9 
β1, β3, β4 and flanking loop regions 
Phe189 Gln225 Leu8 Gly47 
His192 Tyr235 Thr9 His68 
Phe193 Asp237 Ile36 Val70 
Glu195 Asn245 Pro39 Leu71 
Glu214 His247 Asp39 Leu73 
Ser215 Phe249 Gln40 Gly75 
Asp216 Glu251 Arg42 Gly76 
His217 Tyr261 Ile44  
Ile218 Tyr266   
Ile221    
 
 
Table 6.2 Comparison of OTUB1 (DUB) and CNOT4 (E3) binding sites on 
UBE2D2 (E2): UBE2D2 amino acids involved in OTUB1 binding (Juang et al., 20120) in 
comparison with CNOT4 binding site (Dominguez et al., 2004).  
 
1
st
 α-helix 
L1 loop of 3
rd
 and 4
th
 β-
sheet 
L2 loop of 4
th
 β-strand 
and H2 α-helix 
OTUB1 CNOT4 OTUB1 CNOT4 OTUB1 CNOT4 
Met1   Thr58 Ser83  
 Ala2  Asp59 Arg90  
 Leu3  Tyr60 Ser91  
Arg5 Arg5 Pro61  Gln92  
 Ile6 Phe62   Trp93 
Lys8  Lys63 Lys63 Ser94 Ser94 
 Glu9 Lys66  Pro95  
 Leu10   Ala96 Ala96 
 Asn11   Thr98 Thr98 
Asp12 Asp12    Ile99 
    Lys101 Lys101 
     Leu104 
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6.1.1 Comparison of methodologies 
The structure of OTUB1:UBE2D2 complex was solved by crystallisation. As in our studies 
their initial crystal trials yielded numerous crystals corresponding to UBE2D2~Ub alone. 
However, they successfully crystallised the complex which was expressed from a single 
ORF containing a fusion of UBE2D2(ΔC85S):OTUB1(with a deletion of residues 1-24) 
(Juang et al., 2012). The fused UBE2D2:OTUB1 protein was then charged by ubiquitin in 
vitro and the excess free ubiquitin was removed by gel filtration chromatography. Their 
approach in producing crystals was quite intriguing, it suggests that they also had problems 
purifying OTUB1 and solving the structure via NMR. Moreover, the 2D NMR experiment to 
verify the interaction observed in their crystal structure were performed with 
15
N-labelled 
UBE2D3 (not UBE2D2) and UBE2N, while the OTUB1 was unlabelled and the reasons for 
this are unexplained. 
An indirect approach was also observed in crystallisation of OTUB1:UBE2N complex in the 
work by Wiener et al. (2012) where the C. elegans (worm) OTUB1 was used instead of 
human. Worm OTUB1 only shares 34% sequence identity and 56% similarity with human 
OTUB1 and the N-terminal part is particularly poorly conserved. Because of this, crystal 
structures were also determined from hybrid OTUB1 containing the N-terminal 45 residues 
of human OTUB1 and the OTU domain of worm OTUB1 in quaternary complex with UbaI 
(ubiquitin aldehyde) and UBE2N
DCA
~Ub. In contrast with the crystal production of the 
OTUB1:UBE2D2 as a protein fusion, the crystal of the worm OTUB1 and human UBE2N 
complex were grown from a 1:1 mix of the proteins. 
 
6.1.2 The importance of OTUB1 N-terminal region 
The N-terminal region of OTUB1 was truncated in our studies because it forms an 
unstructured region that proved to be problematic in protein structure determination through 
NMR and crystallisation (Edelmann et al., 2009). Although removal of this domain 
advanced our studies, it would appear that this decision was unfortunate because the deleted 
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N-terminal region (aa1-39) contains a ubiquitin binding domain, which we now know 
increases binding affinity towards charged E2s (Nakada et al., 2010). Indeed, certain DUBs 
require ubiquitin binding to obtain their active conformations and to prevent uncontrolled 
proteolytic activity and some DUBs have additional binding sites with affinity for the target 
protein that is ubiquitinated (Ventii and Wilkinson, 2008). 
There is now growing evidence that intrinsically disordered proteins or protein regions may 
have an important role in many fundamental biological processes. In many cases, the 
disordered region undergoes from disordered to ordered transition upon binding with 
substrates or partners. For example, Ski interaction protein (SKIP) has a highly flexible 
region (residues 59-129) which is intrinsically unstructured but become ordered upon 
binding with peptidylprolyl isomerase-like protein 1 (PPIL1) (Wang et al., 2010). In the 
experiment to test the ability of human OTUB1 to inhibit K63 polyubiquitin synthesis by 
UBE2N-UBE2V1, only deletion of aa residues 1-15 has no effect on inhibition of K63 
ubiquitin synthesis whereas larger deletions exhibit defects (Wiener et al., 2012), indicating 
that N-terminal residues from 16-39 that were truncated in our study are actually vital for 
activity. 
 
6.1.3 Agreement with Y2H analysis of UBE2D2 binding site mutants 
Lys8, Asp12 and Lys101 of UBE2D2 were mutated in our study (Chapter 5) to verify that 
they are indeed key residues in the formation of UBE2D2:OTUB1 complexes.  These three 
residues were acknowledged to be involved in UBE2D2:OTUB1 interaction (Juang et al., 
2012) hence supporting the Y2H mutagenesis data. However, Glu9 which were also included 
in our mutagenesis studies appears not to be directly involved at the binding interface (Juang 
et al., 2012). 
Figure 6.2 clearly shows the side chain of Lys8, Asp12 and Lys101 facing towards the 
direction of OTUB1 binding surface and making direct contact with OTUB1 residues. Glu9 
side chain is however not in a favorable position to interact with OTUB1 although this 
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mutation clearly inhibits complex formation in our Y2H studies. This discrepancy may be 
explained by subtle enforced changes in local conformation which reduce binding efficiency, 
even though this residue is not in direct physical contact with OTUB1. 
 
 
Figure 6.2 Stereo view of the OTUB1:UBE2D2 binding interface: Lys8, Asp12 and 
Lys101 side chains of UBE2D2 facing towards OTUB1 binding surface while Glu9 side 
chain extending away from OTUB1:UBE2D2 binding interface. OTUB1 is coloured cyan 
and UBE2D2 in green. 
  
Lys8 
Glu9 
Asp12 
Lys101 
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6.2 Insight into OTUB1 physiological function 
Otubain-1 (OTUB1), a cysteine protease initially found in ovarian tumours is a DUB that 
contains a conserved OTU (ovarian tumour) domain which is present in all OTUB proteins 
(Edelmann et al., 2009). Its N-terminus contains a ubiquitin-binding domain which is 
thought to interact with ubiquitin to increase its binding affinity to E2 enzymes. OTUB1 was 
initially proposed to provide an editing function for polyubiquitin chain growth by cleaving 
tetraubiquitin substrate (Balakirev et al., 2003). Surprisingly, it was later revealed that 
OTUB1 promotes rather than inhibits the K48-linked self-ubiquitination and proteolysis of 
E3 RING ligase RNF128 (GRAIL) (Soares et al., 2004). In the proteomic study by 
Edelmann et al. (2010), two more OTUB1 interactors were identified: FUS/TLS and Rack1, 
both of which are involved in RNA splicing. However, the significance of these interactions 
and whether FUS/TLS and Rack1 are deubiquitinated by OTUB1 remains unknown. 
With a growing body of evidence that DUBs have non-canonical activity (Hanna et al., 
2006), OTUB1 proves this principle by its ability to regulate protein ubiquitination reactions. 
This is achieved by suppressing RNF168-dependent polyubiquitination by a mechanism that 
is independent of its catalytic activity, by simply binding to and blocking ubiquitin transfer 
and E3-RING docking to UBE2N. In other words they prevent ubiquitin attachment rather 
than detaching bound ubiquitin, thereby inhibiting DNA repair (Nakada et al., 2010; Sun et 
al., 2012) and presumably many other cellular processes as well. The fact that OTUB1 
inhibits DNA repair could have therapeutic relevance. Nakada et al., (2010) found that 
reducing the level of OTUB1 expression restores the process of homologous recombination 
in cells in which ATM (Ataxia telangiectasia mutated) kinase is inhibited. Thus, OTUB1 
depletion can, in principle, mitigate DNA-repair effects. This observation makes the 
interaction between OTUB1 and UBE2N an attractive target for therapeutic intervention 
with particular relevance for disorders affecting DNA repair and possibly for use in 
combination with radiation therapy. 
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6.3 OTUB1 protein interaction network 
The interaction of OTUB1 with UBE2D2 (and UBE2N) could be manipulated to inhibit the 
ubiquitination cascade in order to establish a new therapeutic drug targets. Being able to 
block OTUB1 would allow downstream cellular signalling pathways to occur. The 
involvement of UBE2D2 in the DNA damage response could be the target to allow the repair 
of DSBs and prevent chromosomal rearrangements that may lead to tumourigenesis and 
cancer. Although the downregulation of UBE2D2 by suppressing OTUB1 may seem 
promising, in our analysis OTUB1 interacts with a wider range of proteins. Therefore, we 
should consider whether the inhibition of OTUB1 will disrupt other physiologically 
important processes. Figure 6.3 shows the known OTUB1 interaction network which 
contains a broad range of binding partners, suggesting it has other functions other than DNA 
damage response. Interestingly, several binding partners are known to have roles in the cell 
cycle, which may represent an interesting area of future research.  
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Edge legend:           Node legend: 
        BioGRID    Cytoplasmic   
 BioGRID|Human   Nuclear 
 BioGRID|Human|MS   Cytoplasmic|Nuclear 
 BioGRID|Ilog    Unknown 
 BioGRID|MS 
 Human 
 Ilog 
 MS 
 MS|Human 
 
Figure 6.3 OTUB1 interaction network: Figure shows OTUB1 and its interactors. 
The colour of the sphere containing the protein indicates the data source of type of 
experiment performed in order to get the interaction data. The colour of the node indicates 
the localisation of each protein. Figure generated using Cytoscape ver2.8.2. 
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6.4 Future directions 
Work performed in this study has provided insight into the molecular mechanisms of the 
OTUB1:E2 protein interaction. In addition, we have generated a large collection of 
molecular reagents which can be used to further explore the nature and function of 
OTUB1:E2 and E2:E3-RING complexes in live cells. Preliminary work in this area is 
looking very promising. Using mutants and constructs generated in this project, other 
members of the Sanderson lab have successfully used fluorescence cross correlation 
spectroscopy (FCCS) methods to investigate the nature of OTUB1:E2 complexes in different 
cellular compartments in live cells. These studies confirmed many of predictions made in 
this thesis and allow the size, distribution and conditional nature of OTUB1:E2 protein 
interactions to be monitored in real time in vivo. Such methods may also provide a 
mechanism of screening for compounds which selectively disrupt different OTUB1:E2 or 
E2:E3-RING complexes, which in turn may offer new therapeutic opportunities. 
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